

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 14/47, C12N 5/10, 5/16, 15/63, 15/64</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/61625</b> <b>(43) International Publication Date:</b> 19 October 2000 (19.10.00)
<b>(21) International Application Number:</b> PCT/US00/08981 <b>(22) International Filing Date:</b> 6 April 2000 (06.04.00)  <b>(30) Priority Data:</b> 60/128,701 9 April 1999 (09.04.99) US 60/177,166 20 January 2000 (20.01.00) US  <b>(71) Applicant (for all designated States except US):</b> HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).  <b>(71)(72) Applicant and Inventor:</b> ROSEN, Craig, A. [US/US]; 22400 Rolling Hill Road, Laytonsville, MD 20882 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> RUBEN, Steven, M. [US/US]; 18528 Heritage Hills Drive, Laytonsville, MD 20882 (US). KOMATSOUKIS, George [US/US]; 9518 Garwood Street, Silver Spring, MD 20901 (US).  <b>(74) Agents:</b> HOOVER, Kenley, K. et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> 48 HUMAN SECRETED PROTEINS  <b>(57) Abstract</b>  The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



## **48 Human Secreted Proteins**

### ***Field of the Invention***

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

### ***Background of the Invention***

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly,

proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a "linker" holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins  
5 include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent  
10 medical diseases, disorders, and/or conditions by using secreted proteins or the genes that encode them.

### ***Summary of the Invention***

The present invention relates to novel polynucleotides and the encoded  
15 polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The  
20 invention further relates to screening methods for identifying binding partners of the polypeptides.

### ***Detailed Description***

#### **Definitions**

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as

disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain  
5 the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the  
10 nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the  
15 polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As  
20 shown in Table 1, each clone is identified by a cDNA Clone ID (Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

25 A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to

sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x

5 Denhardt's solution, 10% dextran sulfate, and 20  $\mu$ g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions.

Changes in the stringency of hybridization and signal detection are primarily  
10 accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M  $\text{NaH}_2\text{PO}_4$ ; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100  $\mu$ g/ml  
15 salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the  
20 inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above,  
25 due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more

detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does  
5 exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to  
10 the polypeptide of the present invention.)

Many proteins (and translated DNA sequences) contain regions where the amino acid composition is highly biased toward a small subset of the available residues. For example, membrane spanning domains and signal peptides (which are also membrane spanning) typically contain long stretches where Leucine (L), Valine  
15 (V), Alanine (A), and Isoleucine (I) predominate. Poly-Adenosine tracts (polyA) at the end of cDNAs appear in forward translations as poly-Lysine (poly-K) and poly-Phenylalanine (poly-F) when the reverse complement is translated. These regions are often referred to as "low complexity" regions.

Such regions can cause database similarity search programs such as BLAST to  
20 find high-scoring sequence matches that do not imply true homology. The problem is exacerbated by the fact that most weight matrices (used to score the alignments generated by BLAST) give a match between any of a group of hydrophobic amino acids (L,V and I) that are commonly found in certain low complexity regions almost as high a score as for exact matches.

25 In order to compensate for this, BLASTX.2 (version 2.0a5MP-WashU) employs two filters ("seg" and "xnu") which "mask" the low complexity regions in a



particular sequence. These filters parse the sequence for such regions, and create a new sequence in which the amino acids in the low complexity region have been replaced with the character "X". This is then used as the input sequence (sometimes referred to herein as "Query" and/or "Q") to the BLASTX program. While this regime helps to ensure that high-scoring matches represent true homology, there is a negative consequence in that the BLASTX program uses the query sequence that has been masked by the filters to draw alignments.

Thus, a stretch of "X"s in an alignment shown in the following application does not necessarily indicate that either the underlying DNA sequence or the translated protein sequence is unknown or uncertain. Nor is the presence of such stretches meant to indicate that the sequence is identical or not identical to the sequence disclosed in the alignment of the present invention. Such stretches may simply indicate that the BLASTX program masked amino acids in that region due to the detection of a low complexity region, as defined above. In all cases, the reference sequence(s) (sometimes referred to herein as "Subject", "Sbjct", and/or "S") indicated in the specification, sequence table (Table 1), and/or the deposited clone is (are) the definitive embodiment(s) of the present invention, and should not be construed as limiting the present invention to the partial sequence shown in an alignment, unless specifically noted otherwise herein.

### **Polynucleotides and Polypeptides of the Invention**

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 1**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Stratagene pancreas (#937208); and Adipocytes, re-excision.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 59 as residues: Arg-46 to Arg-53.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 965 of SEQ ID NO:11, b is an integer of 15 to 979, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 2

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_pregnant\_uterus\_NbHPU and to a lesser extent in Soares retina N2b4HR; stomach cancer (human); Soares\_multiple\_sclerosis\_2NbHMSP; Nine Week Old Early Stage Human; Soares ovary tumor NbHOT; Adipocytes, re-excision; Human Stomach; Stratagene HeLa cell s3 937216; Glioblastoma; Jurkat T-cell G1 phase; Human Adult Small Intestine; KMH2; CD34 depleted Buffy Coat (Cord Blood); T-Cell PHA 16 hrs; L428; 12 Week Old Early Stage Human, II; Human Pancreas Tumor; Human umbilical vein endothelial cells, IL-4 induced; Human Adrenal Gland Tumor; Human Whole Six Week Old Embryo; Spleen, Chronic lymphocytic leukemia; T cell helper II; Human 8 Week Whole Embryo and Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2938 of SEQ ID NO:12, b is an integer of 15 to 2952, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

### **FEATURES OF PROTEIN ENCODED BY GENE NO: 3**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares placenta Nb2HP and to a lesser extent in Soares adult brain N2b5HB55Y; Soares fetal liver spleen 1NFLS; Soares infant brain 1NIB; Soares melanocyte 2NbHM; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_fetal\_heart\_NbHH19W; Soares breast 3NbHBst; Spleen/normal; Morton Fetal Cochlea; Soares\_pregnant\_uterus\_NbHPU; Soares\_parathyroid\_tumor\_NbHPA; Soares\_senescent\_fibroblasts\_NbHSF; Human Bone Marrow, treated; Human Adult Retina; H. Atrophic Endometrium; Adipocytes, re-excision; Soares retina N2b4HR; Human Synovium; H Female Bladder, Adult; Synovial hypoxia-RSF subtracted; Synovial hypoxia; Human Chronic Synovitis; Stratagene endothelial cell 937223; Smooth muscle, serum induced, re-exc; Human Gall Bladder; Soares\_fetal\_lung\_NbHL19W; Soares\_multiple\_sclerosis\_2NbHMSP; Resting T-Cell Library, II; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Bone marrow; Human

Fetal Heart; Human Adult Pulmonary, re-excision; Human Microvascular Endothelial Cells, fract. A and Soares\_total\_fetus\_Nb2HF8\_9w.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1103 of SEQ ID NO:13, b is an integer of 15 to 1117, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

#### 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 4**

It has been discovered that this gene is expressed primarily in Anergic T-cell.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:14 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1059 of SEQ ID NO:14, b is an integer of 15 to 1073, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO: 14, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 5

- 5           The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil493055 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "putative protein kinase C inhibitor [Rattus norvegicus]." A partial alignment demonstrating the
- 10           observed homology is shown immediately below.

```

>gi|493055 putative protein kinase C inhibitor [Rattus norvegicus]
>pir|A35350|A35350 protein kinase C inhibitor - bovine {SUB 2-
15 126}
      Length = 126

      Plus Strand HSPs:

20      Score = 423 (148.9 bits), Expect = 5.3e-39, P = 5.3e-39
      Identities = 77/126 (61%), Positives = 98/126 (77%), Frame = +2

      Q:   467 NEVAKAQQATPGGAAPTIFSRILDKSLPADILYEDQQCLVFRDVAPQAPVHFLVIPKKPI 646
            +E+AKAQ A PGG TIF +I+ K +PA I+YED QCL F D++PQAP HFLVIPKK I
25      S:   3 DEIAKAQVARPGG--DTIFGKIIRKEIPAKIYEDDQCLAFHDISPQAPTHFLVIPKKYI 60

      Q:   647 PRISQAEEEDQQLLGHLLLVAKQTAKAEGLDGYRLVINDGKLGAQSVYHLHIHVLGGRQ 826
            +IS AE++D+ LLGHL++V K+ A GL GYR+V+N+G G QSVYH+H+HVLGGRQ
30      S:   61 SQISAAEDDDSLGHLMIVGKKCAADLGLKKGYRMVNVNEGSDGGQSVYHVHLHVLGGRQ 120

      Q:   827 LQWPPG 844
            + WPPG
      S:   121 MNWPPG 126

```

- 35           The segment of gil493055 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 107. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities

are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 108 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Soares\_fetal\_lung\_NbHL19W; Soares\_fetal\_heart\_NbHH19W; Colon Normal III; Soares placenta Nb2HP; Human Kidney Tumor; Human OB HOS control fraction I; stomach cancer (human); Amniotic Cells - Primary Culture; Jurkat T-Cell, S phase; Human Jurkat Membrane Bound Polysomes; Soares\_pregnant\_uterus\_NbHPU; Human umbilical vein endothelial cells, IL-4 induced; Macrophage (GM-CSF treated); Hepatocellular Tumor, re-excision; Neutrophils control, re-excision; Human Placenta; Bone Marrow Cell Line (RS4,11) and Keratinocyte.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 63 as residues: Lys-25 to Ser-30.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1016 of SEQ ID NO:15, b

is an integer of 15 to 1030, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 6

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Activated T-cells, 24 hrs, re-excision; Soares infant brain 1NIB; Soares melanocyte 2NbHM; Human Microvascular Endothelial Cells, fract. A; Keratinocyte; Human Cerebellum; Soares\_senescent\_fibroblasts\_NbHSF; Stratagene colon (#937204); Soares placenta Nb2HP; HL-60, PMA 4H, re-excision; Human Adult Pulmonary, re-excision; Endothelial-induced; Human Endometrial Tumor; Human Synovial Sarcoma; Activated T-Cell (12hs)/Thiouridine labelled Eco; Activated T-cell(12h)/Thiouridine-re-excision; Primary Dendritic Cells, lib 1; Early Stage Human Lung, subtracted; Human Jurkat Membrane Bound Polysomes; Human Testes Tumor, re-excision; Human Testes Tumor; Stratagene pancreas (#937208); Neutrophils control, re-excision; Hodgkin's Lymphoma II; Stratagene NT2 neuronal precursor 937230; Breast Cancer cell line, MDA 36; Human Primary Breast Cancer Reexcision; Human Pancreas Tumor; Human Adult Testes, Large Inserts, Reexcision; Epithelial-TNF $\alpha$  and INF induced; Human B Cell Lymphoma; Human 8 Week Whole Embryo; Human Infant Brain; Stratagene fetal spleen (#937205); Human Thymus Stromal Cells; Soares\_testis\_NHT; NTERA2, control; Resting T-Cell Library, II; H Macrophage (GM-CSF treated), re-excision; Human Fetal Lung III; Human Neutrophil, Activated; Endothelial cells-control; Smooth muscle, control; Bone Marrow Cell Line (RS4,11); Nine Week Old Early Stage Human; Human Whole 6 Week Old Embryo (II), sub; LNCAP + 30nM R1881; Morton Fetal Cochlea; Smooth

Muscle Serum Treated, Norm; Supt Cells, cyclohexamide treated; H. Epididymus,  
 cauda; HSA 172 Cells; Soares retina N2b4HR; NTERA2 teratocarcinoma cell  
 line+retinoic acid (14 days); Soares\_fetal\_heart\_NbHH19W; Smooth muscle, IL1b  
 induced; human corpus colosum; NTERA2 + retinoic acid, 14 days; Jurkat T-Cell, S  
 5 phase; Soares\_fetal\_lung\_NbHL19W; H. Kidney Medulla, re-excision; Breast Cancer  
 Cell line, angiogenic; L428; Human Hippocampus; Human Substantia Nigra; Human  
 Placenta; human tonsils; Monocyte activated; Osteoblasts; Soares ovary tumor  
 NbHOT; Activated T-Cells, 24 hrs.; Human Gastrocnemius; Human Uterus, normal;  
 Weizmann Olfactory Epithelium; Human Cerebellum, subtracted; Human Umbilical  
 10 Vein Endothelial Cells, fract. A; Human Neutrophils, Activated, re-excision; Smooth  
 muscle, control, re-excision; Human Fetal Bone; H. Epididymus, caput & corpus; H.  
 cerebellum, Enzyme subtracted; Activated T-Cells, 12 hrs, re-excision; Human Pineal  
 Gland; Messangial cell, frac 2; Stromal-Osteoclastoma; Human Synovium; Synovial  
 IL-1/TNF stimulated; pBMC stimulated w/ poly I/C; Alzheimers, spongy change;  
 15 Human Umbilical Vein, Endo. remake; Healing groin wound, 7.5 hours post incision;  
 Salivary Gland, Lib 2; Soares\_pregnant\_uterus\_NbHPU; Stratagene neuroepithelium  
 (#937231); Synovial hypoxia; Human Ovary; Synovial Fibroblasts (IL1/TNF), subt;  
 wilm's tumor; Brain Frontal Cortex, re-excision; Human Neutrophil; Human Chronic  
 Synovitis; Human Thymus; Human Brain, Striatum; Human Activated T-Cells;  
 20 Stromal cell TF274; Human Hypothalmus, Schizophrenia; Human umbilical vein  
 endothelial cells, IL-4 induced; NCI\_CGAP\_Co9; Human Activated Monocytes;  
 Human Activated T-Cells, re-excision; Stratagene endothelial cell 937223; Stratagene  
 NT2 neuronal precursor 937230; Bone Marrow Stromal Cell, untreated; Human Fetal  
 Brain; Human Adrenal Gland Tumor; Rejected Kidney, lib 4; Human Whole Six  
 25 Week Old Embryo; Colon Normal II; Adipocytes; Bone marrow; Human Fetal Heart;  
 NCI\_CGAP\_GCB1; Human Amygdala; Soares\_fetal\_liver\_spleen\_1NFLS\_S1;



Stratagene HeLa cell s3 937216; Stratagene lung carcinoma 937218; H. Adipose, subtracted; Human Brain, striatum, re-excision; Human Osteoarthritic Cartilage Fraction IV; Larynx normal #10 261-273; CD34+cells, II; Namalwa Cells; Colon Normal; Osteoclastoma-normalized A; Human Adult Heart, subtracted; CD34+ cell, I; Bone marrow stroma,treated; Larynx Normal; Human Adult Heart; Human Umbilical Vein Endothelial cells, frac B, re-excision; H. hypothalamus, frac A; Human Microvascular Endothelial Cells, fract. B; CD34+ cell, I, frac II; Activated T-Cells, 8 hrs., ligation 2; Testes; Human osteoarthritis,fraction I; Human Hippocampus, subtracted; H. Adipose Tissue; H Umbilical Vein Endothelial Cells, frac A, re-excision; Human Kidney; H. Normalized Fetal Liver, II; Human OB HOS treated (1 nM E2) fraction I; Human OB MG63 control fraction I; Soares\_pineal\_gland\_N3HPG; HL-60, PMA 4H; prostate-edited; Human Fetal Brain; Human OB MG63 treated (10 nM E2) fraction I; Human Colon; Human Adult Pulmonary; HSC172 cells; Human Fetal Spleen; Healing Abdomen wound,70&90 min post incision; Human Thyroid; Human Liver; Amniotic Cells - TNF induced; Human Lung; Human Quadriceps; Human Soleus; Human Adult Heart,re-excision; Smooth Muscle- HASTE normalized; H. Whole Brain #2, re-excision; Apoptotic T-cell, re-excision; B Cell lymphoma; HEL cell line; Human Epididymus; Human Amygdala,re-excision; Pancreas Tumor PCA4 Tu; Morton Fetal; Human Hypothalamus,schizophrenia, re-excision; Hepatocellular Tumor; H Female Bladder, Adult; Human Osteoclastoma Stromal Cells - unamplified; Amniotic Cells - Primary Culture; Glioblastoma; LNCAP prostate cell line; Human Whole Brain #2 - Oligo dT > 1.5Kb; Human Adipose Tissue, re-excision; Human endometrial stromal cells; Jurkat T-cell G1 phase; Myeloid Progenitor Cell Line; Soares\_parathyroid\_tumor\_NbHPA; H. Meningima, M1; H. Lymph node breast Cancer; Fetal Liver, subtraction II; Human Fetal Kidney; Apoptotic T-cell; 12 Week

Old Early Stage Human, II; Human Fetal Dura Mater; T-Cell PHA 24 hrs; Human Adipose; NCI\_CGAP\_Co3; NCI\_CGAP\_GC4; NCI\_CGAP\_Pr2; NCI\_CGAP\_Co12; Stratagene hNT neuron (#937233); Human Rhabdomyosarcoma; Soares\_NhHMPu\_S1; Human Chondrosarcoma; Synovial Fibroblasts (control);

5 Stratagene neuroepithelium NT2RAMI 937234; Stratagene lung (#937210); Human Liver, normal; Smooth muscle, serum induced, re-exc; Pancreas Islet Cell Tumor; Human Gall Bladder; PC3 Prostate cell line; Colon Tumor; 12 Week Old Early Stage Human; H. Frontal cortex, epileptic, re-excision; Human T-Cell Lymphoma; Brain frontal cortex; Soares breast 3NbHBst; Early Stage Human Brain; Dendritic cells,  
10 pooled; Normal colon; Soares\_multiple\_sclerosis\_2NbHMSP; Soares\_placenta\_8to9weeks\_2NbHP8to9W; 12 Week Early Stage Human II, Reexcision; Colon Normal III; Human Bone Marrow, treated; Spleen, Chronic lymphocytic leukemia; Neutrophils IL-1 and LPS induced; Human Testes; and T cell helper II.

15 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
20 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1150 of SEQ ID NO:16, b is an integer of 15 to 1164, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a  
25 + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 7**

It has been discovered that this gene is expressed primarily in Healing groin wound, 7.5 hours post incision.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 857 of SEQ ID NO:17, b is an integer of 15 to 871, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 8**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Dendritic cells, pooled; and Anergic T-cell.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1483 of SEQ ID NO:18, b

is an integer of 15 to 1497, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

## 5 FEATURES OF PROTEIN ENCODED BY GENE NO: 9

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Fetal Lung III; Human Bone Marrow, treated; Human Cerebellum; and Soares fetal liver spleen INFLS.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.

10 67 as residues: Pro-2 to His-8.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
15 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1147 of SEQ ID NO:19, b is an integer of 15 to 1161, where both a and b correspond to the positions of  
20 nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 10

It has been discovered that this gene is expressed primarily in the following  
25 tissues/cDNA libraries: Primary Dendritic cells,frac 2; and Human Bone Marrow, treated.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 68 as residues: Leu-19 to Ala-50.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1448 of SEQ ID NO:20, b is an integer of 15 to 1462, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

## 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 11**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Osteoblasts II; and Soares fetal liver spleen 1NFLS.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 69 as residues: Pro-16 to Lys-23.

20 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
25 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 1565 of SEQ ID NO:21, b is an integer of 15 to 1579, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

5

## FEATURES OF PROTEIN ENCODED BY GENE NO: 12

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

10 gi|2854153 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "No definition line found [Caenorhabditis elegans]." A partial alignment demonstrating the observed homology is shown immediately below.

```

15 >gi|2854153 (AF045640) No definition line found [Caenorhabditis elegans]
    >sp|O45069|O45069 C11D2.4 PROTEIN.
    Length = 543

    Plus Strand HSPs:

20 Score = 366 (128.8 bits), Expect = 2.1e-55, Sum P(2) = 2.1e-55
    Identities = 66/89 (74%), Positives = 80/89 (89%), Frame = +2

25 Q: 668 FILPHQQVDKGAIKFVLSGANIMCPGLTSPGAKLYPAAV-DTIVAIMAEGKQHALCVGVM 844
    FILPHQQVDKGAIKF+L+G++IMCPGLTSPGAKL P D++VA+MAEGKQHAL +G+M
    S: 449 FILPHQQVDKGAIKFILNGSSIMCPGLTSPGAKLTPLVPKDSVVAVMAEGKQHALAIGLM 508

    Q: 845 KMSAEDIEKVNKGIGIENIHLYNDGLWHM 931
    MS+E+I+ VNKG GIEN+HYLNDGLWH+

30 S: 509 SMSSEEIQSVNKGNGIENLHYLNDGLWHL 537

```

The segment of gi|2854153 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 109.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 110 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

5 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares placenta Nb2HP; Soares fetal liver spleen 1NFLS and to a lesser extent in Human Fetal Lung; Messangial cell, frac 2; Human Epididymus; Stratagene fetal spleen (#937205); Soares\_fetal\_heart\_NbHH19W; Soares\_pregnant\_uterus\_NbHPU; Soares\_parathyroid\_tumor\_NbHPA; Stratagene  
10 colon (#937204); Stratagene fibroblast (#937212); Human Umbilical Vein Endothelial Cells, uninduced; Hemangiopericytoma; Rejected Kidney, lib 4; Human Whole Six Week Old Embryo; Macrophage-oxLDL, re-excision; Colon Tumor II; Soares melanocyte 2NbHM; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Bone marrow; Endothelial cells-control; Colon Normal III; Human Osteoclastoma; Human  
15 Microvascular Endothelial Cells, fract. A; Smooth muscle, control; Human Testes; Osteoblasts; Soares\_total\_fetus\_Nb2HF8\_9w; Stratagene endothelial cell 937223 and T cell helper II.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
20 related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
25 general formula of a-b, where a is any integer between 1 to 1121 of SEQ ID NO:22, b is an integer of 15 to 1135, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

### FEATURES OF PROTEIN ENCODED BY GENE NO: 13

5           The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|e1344293 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "similar to Yeast  
10   hypothetical protein YEY6 like." A partial alignment demonstrating the observed homology is shown immediately below.

```

>gnl|PID|e1344293 similar to Yeast hypothetical protein YEY6 like; cDNA
EST
15           yk206h5.3 comes from this gene; cDNA EST yk206h5.5 comes from
this
              gene; cDNA EST yk303h1.3 comes from this gene; cDNA EST
yk303h1.5
              comes from this gene; cDNA EST yk367e12.3 comes from>
20           >gnl|PID|e1354517 similar to Yeast hypothetical protein YEY6
like;
              cDNA EST yk206h5.3 comes from this gene; cDNA EST yk206h5.5
comes
              from this gene; cDNA EST yk303h1.3 comes from this gene; cDNA
25           EST
              yk303h1.5 comes from this gene; cDNA EST yk367e12.3 comes
from>
              >sp|O17606|O17606 K08H10.8 PROTEIN.
              Length = 340
30           Plus Strand HSPs:

              Score = 855 (301.0 bits), Expect = 8.6e-85, P = 8.6e-85
              Identities = 155/321 (48%), Positives = 224/321 (69%), Frame = +2
35           Q:   185 IGTHNGTFHCDEALACALLRLLPEYRDAEIVTRDPEKLASCDIVVDVGGEYDPRRHRYD 364
                  IGTH+G FHCDEA AC +L+ LP+++D I+RTRD +L CDI+VDVGG +D + RYD
              S:   5 IGTHSGKPHCDEAFACFMLKQLPQPKDHSILRTRDAAQLEKCDIIVDVGGIFDHSKQRYD 64

40           Q:   365 HHQRSFTETMSSLSPGKPWQTKLSSAGLIYLFHGHKLLAQLLGTSEEDSMVGTLYDKMYE 544
                  HHQR FT+TM +L       + TKLSSAGL+Y H+G +++ Q+LG + SM+ Y ++YE
              S:   65 HHQRGFTDTMRTLEKLN-FDTKLSSAGLVYAHYGREVINQILGGNVSSSMIDLPHYRLYE 123

```



5 Q: 545 NFVEEVDVNDNGISQWAEQEPYALTTTLSARVARLNPTWNHPDQDTEAGFKRAMDLVQE 724  
     FVE +DA+DNGISQ+ +G PRY + LS+R + N WN P+ D + F++AM + E  
 S: 124 QFVESIDAIDNGISQY-DGVPRYHSSGNLSSRTGQFNHWNENPENDADERFQQAMQFIGE 182  
  
 Q: 725 EFLQRLDFYQHSWLPARALVEEALAQRFQVDPGSEIVELAKGACPWKEHLYHLESGLSPP 904  
     EF + + + + W PAR ++E A+ +RF++D SG I+ + G CPWKEH + +E +  
 S: 183 EFSRSVKYLANVWWPAREIIEAAVDKRFEIDASGRILIENGCGCPWKEHFFDIE--VEKN 240  
  
 10 Q: 905 VA---IFFVIYTDQAG-QWRIQCVKPEP-HSFQSRPLPEPWRLRDEALDQVSGIPGCI 1069  
     +A I +++++D WR+Q +P + SF++R+PLP WRGLRD+ L + SGIPG +  
 S: 241 IADDNITYILFSDSTNASWRVQAIPVDMSSFENRMPLPAAWRGLRDDLSKESGIPGGV 300  
  
 15 Q: 1070 FVHASGFIGGHRREGALSMARATL 1144  
     FVH SGFIGG+ TREGA++MAR L  
 S: 301 FVHISGFIGGNLTREGAIAMARKAL 325

The segment of gnllPIDle1344293 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 111.

20 Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 112 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

25 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human adult testis, large inserts; Activated T-cell(12h)/Thiouridine-re-excision; Soares fetal liver spleen 1NFLS and to a lesser extent in Soares adult brain N2b5HB55Y; CD34 positive cells (Cord Blood); Human Testes; Soares infant brain 1NIB; Human Cerebellum, subtracted; Human Primary Breast Cancer Reexcision; Soares\_fetal\_heart\_NbHH19W; Human Thymus; Human  
 30 Fetal Brain; Human Gall Bladder; Human 8 Week Whole Embryo; Stratagene hNT neuron (#937233); Human Gastrocnemius; H. Striatum Depression, subt; Human Primary Breast Cancer, re-excision; Smooth muscle, control, re-excision; Pancreas Tumor PCA4 Tu; Human endometrial stromal cells-treated with progesterone; Human Brain, Striatum; Human Fetal Dura Mater; Macrophage-oxLDL;

Hemangiopericytoma; Soares breast 2NbHBst; Rejected Kidney, lib 4; Resting T-Cell Library, II; Human T-Cell Lymphoma; Smooth muscle, serum treated; Human Testes Tumor; H Macrophage (GM-CSF treated), re-excision; Normal colon; Human Synovial Sarcoma; Activated T-Cell (12hs)/Thiouridine labelled Eco; Neutrophils IL-1 and LPS induced; Human Cerebellum and Primary Dendritic Cells, lib 1.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 71 as residues: Gly-60 to Pro-65.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1211 of SEQ ID NO:23, b is an integer of 15 to 1225, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 14

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Rejected Kidney, lib 4.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 72 as residues: Gln-30 to Tyr-36, Thr-47 to Glu-56, Asn-58 to Thr-63.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1310 of SEQ ID NO:24, b is an integer of 15 to 1324, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

10

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 15

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

15 gi1890108 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "lysyl oxidase-related protein [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

20 >gi|1890108 lysyl oxidase-related protein [Homo sapiens]  
>sp|G1890108|G1890108  
LYSYL OXIDASE-RELATED PROTEIN.  
Length = 774

25 Plus Strand HSPs:

Score = 1117 (393.2 bits), Expect = 2.7e-151, Sum P(2) = 2.7e-151  
Identities = 222/408 (54%), Positives = 281/408 (68%), Frame = +1

30 Q: 544 KPILASAKQHSPVTEGAVEVKYEGHWRQVCDQGWTMNNRSRVVCGMLGFPSEVPVDSHYR 723  
+ IL++ ++ +PV EG VEVK W+Q+CD+ WT NSRVVCGM GFP E Y  
S: 189 RAILSTYRKRTFVMEGYVEVKEGKTWKQICDKHWTAKNSRVVCGMFGFPGE----RTYNT 244  
Q: 724 KVDLKMRRDPKSRLLKSLTNKNSFWIHQVTCLGTEPHMANC-----QVQVAPARGKLRPACP 891

KV+ KM SR K +W + C GTE H+++C QV + P + C  
 S: 245 KVV--KMF--ASR-----RKQRYWPFSDCTGTEAHISSCKLGPQVSLDPMKNV---TCE 292  
 5 Q: 892 GGMHAVVSCVAGPHFRPPKTKPQRKGSWAEPRVRLRSGAQVGEGRVEVLMNRQWGTVCD 1071  
 G+ AVVSCV G F P RK E+P VRLR GA +GEGRVEVL N +WGTVCD  
 S: 293 NGLPAVVSCVPGQVFS PDGSPRFRKAYKPEQPLVRLRGGAYIGEGRVEVLKNGEWGTVCD 352  
 10 Q: 1072 HRWNLISASVVCRLGFGSAREALFGARLGQGLGPIHLSEVRCRGYERTLSDCPALEGSQ 1251  
 +W+L+SASVVCRLGFGSA+EA+ G+RLGQG+GPIHL+E++C G E+++ DC SQ  
 S: 353 DKWDLVSASVVCRELGFGSAKEAVTGSRLGQIGIGIHLNEIQCTGNEKSIIDCKFNAESQ 412  
 15 Q: 1252 NGCQHENDAAVRCNVPNMGFQNVRLAGGRIPEEGLLEVQVEVNGVPRWGSVCSENWGLT 1431  
 GC HE DA VRCN P MG Q ++RL GGR P EG +EV VE NG WG VC +NWG+  
 S: 413 -GCNHEEDAGVRCNTPAMGLQKKLRLNGGRNPYEGRVEVLVERNGSLVWGMVCGQNWGIV 471  
 Q: 1432 EAMVACRQLGLGFALHAYKETWFWSGTPRAQEVVMSGVRCSGTELALQQCQRHGP-VHCS 1608  
 EAMV CRQLGLGFA +A++ETW+W G + +VMSGV+CSGTEL+L C+ G V C  
 S: 472 EAMVVCRLGLGFASNAFQETWYWHGDVNSNKVMSGVKCSGTELSLAHCRHDGEDVACP 531  
 20 Q: 1609 HGGGRFLAGVSCMDSAPDLVMNAQLVQETAYLEDRLPSQLYCAHEENCLSKSA 1767  
 GG ++ AGV+C ++APDLV+NA++VQ+T YLEDRP+ L CA EENCLS SA  
 S: 532 QGGVQYGAGVACSETAPDLVLNAEMVQQTYYLEDRLPMFLQCAMENCLSASA 584

The segment of gil1890108 that is shown as "S" above is set out in the  
 25 sequence listing as SEQ ID NO. 113. Based on the structural similarity these  
 homologous polypeptides are expected to share at least some biological activities.  
 Such activities are known in the art, some of which are described elsewhere herein.  
 Assays for determining such activities are also known in the art, some of which have  
 been described elsewhere herein.

30 Preferred polypeptides of the invention comprise a polypeptide having the  
 amino acid sequence set out in the sequence listing as SEQ ID NO. 114 which  
 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a  
 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following  
 35 tissues/cDNA libraries: Human Osteoblasts II; Neutrophils IL-1 and LPS induced and  
 to a lesser extent in Healing groin wound, 6.5 hours post incision; Human  
 Osteoclastoma, re-excision and Pancreas Islet Cell Tumor.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 73 as residues: Pro-19 to Ser-26, Pro-37 to Gly-44, Lys-87 to Gly-93, Gln-111 to Trp-117, Asp-121 to Glu-126, Pro-134 to Gly-139, Ala-153 to Gln-161.

Many polynucleotide sequences, such as EST sequences, are publicly  
5 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention  
10 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1768 of SEQ ID NO:25, b is an integer of 15 to 1782, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

15

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 16

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.  
20 gil1710216 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "unknown [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

25 >gi|1710216 unknown [Homo sapiens] >sp|Q99770|Q99770 HYPOTHETICAL 15.4 KD  
PROTEIN.  
Length = 139

• Minus Strand HSPs:

Score = 142 (50.0 bits), Expect = 8.2e-15, Sum P(2) = 8.2e-15  
Identities = 27/30 (90%), Positives = 28/30 (93%), Frame = -3

5 Q: 760 RLECSGTISAHCKLCLPGSGHSPASASRVA 671  
RLECSGTISAHC LCLPGS +SPASASRVA  
S: 62 RLECSGTISAHCNLCPLGSSNSPASASRVA 91

10 Score = 66 (23.2 bits), Expect = 8.2e-15, Sum P(2) = 8.2e-15  
Identities = 12/18 (66%), Positives = 14/18 (77%), Frame = -1

Q: 645 FVFLVETGFHRVSQDGLN 592  
FVFL E GFP V +DGL+  
S: 104 FVFLAEMGFHHVGRDGLD 121

15

The segments of gil1710216 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 115 and SEQ ID NO. 117.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 116 and/or SEQ  
20 ID NO. 118 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Stratagene colon (#937204); Stratagene ovarian cancer (#937219); and Rejected Kidney, lib 4.

25 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 74 as residues: Arg-7 to Arg-14, Tyr-38 to Glu-43.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of  
30 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 835 of SEQ ID NO:26, b is an integer of 15 to 849, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 17

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

10 gi2809383 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "translation initiation factor 6 [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

```

15  >gi|2809383 (AF022229) translation initiation factor 6 [Homo sapiens]
      >gnl|PID|e304603 b4 integrin interactor [Homo sapiens]
      >gnl|PID|e304603 b4 integrin interactor [Homo sapiens]
      Length = 245

20      Plus Strand HSPs:

      Score = 1254 (441.4 bits), Expect = 4.0e-127, P = 4.0e-127
      Identities = 245/245 (100%), Positives = 245/245 (100%), Frame = +3

25      Q:   108 MAVRASFENNCEIGCFAKLTNTYCLVAIGGSENFYSVFEGELSDTIPVVHASIAGCRIIG 287
          MAVRASFENNCEIGCFAKLTNTYCLVAIGGSENFYSVFEGELSDTIPVVHASIAGCRIIG
      S:     1 MAVRASFENNCEIGCFAKLTNTYCLVAIGGSENFYSVFEGELSDTIPVVHASIAGCRIIG 60

30      Q:   288 RMCVGNRHGLLVPNNTTDQELQHIRNSLPDTVQIRRVEERLSALGNVTTTCNDYVALVHPD 467
          RMCVGNRHGLLVPNNTTDQELQHIRNSLPDTVQIRRVEERLSALGNVTTTCNDYVALVHPD
      S:     61 RMCVGNRHGLLVPNNTTDQELQHIRNSLPDTVQIRRVEERLSALGNVTTTCNDYVALVHPD 120

      Q:   468 LDRETEEILADV LKVEVFRQTVADQVLVGSYCVFSNQGGLVHPKTSIEDQDELSSLLQVP 647
          LDRETEEILADV LKVEVFRQTVADQVLVGSYCVFSNQGGLVHPKTSIEDQDELSSLLQVP
35      S:   121 LDRETEEILADV LKVEVFRQTVADQVLVGSYCVFSNQGGLVHPKTSIEDQDELSSLLQVP 180

      Q:   648 LVAGTVNRGSEVIAAGMVVNDWCAFCGLDTTSTELSVVESVFKLNEAQPSTIATSMRDSL 827
          LVAGTVNRGSEVIAAGMVVNDWCAFCGLDTTSTELSVVESVFKLNEAQPSTIATSMRDSL
40      S:   181 LVAGTVNRGSEVIAAGMVVNDWCAFCGLDTTSTELSVVESVFKLNEAQPSTIATSMRDSL 240

```

Q: 828 IDSLT 842  
 IDSLT  
 S: 241 IDSLT 245

5 The segment of gil2809383 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 119. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have  
 10 been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 120 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

15 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Activated T-Cell (12hs)/Thiouridine labelledEco and to a lesser extent in Human adult testis, large inserts; Stratagene colon (#937204); Human Fetal Kidney; Bone Marrow Stromal Cell, untreated; Soares melanocyte 2NbHM; Amniotic Cells - Primary Culture; Human Pancreas Tumor; Spleen, Chronic  
 20 lymphocytic leukemia; Keratinocyte; Breast Cancer cell line, MDA 36; Human Adult Testes, Large Inserts, Reexcision; Soares breast 2NbHBst; Macrophage-oxLDL, re-excision; Human Testes Tumor; Soares\_multiple\_sclerosis\_2NbHMSP; Primary Dendritic cells,frac 2; Soares\_fetal\_heart\_NbHH19W; Tongue carcinoma; Amniotic Cells - TNF induced; Cem cells cyclohexamide treated; NTERA2 teratocarcinoma  
 25 cell line+retinoic acid (14 days); Human Amygdala,re-excision; Human Fetal Epithelium (Skin); Stratagene pancreas (#937208); Stratagene fetal retina 937202; Human endometrial stromal cells-treated with progesterone; Healing groin wound,



6.5 hours post incision; Breast Cancer Cell line, angiogenic; Human Rhabdomyosarcoma; Human Fetal Brain; Human Whole Six Week Old Embryo; Pancreas Islet Cell Tumor; Adipocytes; Dendritic cells, pooled; Human Synovial Sarcoma; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Human Microvascular Endothelial

5 Cells, fract. A; CD34 positive cells (Cord Blood); Bone Marrow Cell Line (RS4,11); Human Endometrial Tumor; T cell helper II; Soares\_pregnant\_uterus\_NbHPU; Stratagene neuroepithelium (#937231); Human Cerebellum; Soares placenta Nb2HP; Soares fetal liver spleen 1NFLS; CD34 positive cells (Cord Blood); Soares ovary tumor NbHOT; Soares\_total\_fetus\_Nb2HF8\_9w; Activated T-Cells, 8 hrs.; Human B

10 Cell 8866; Human 7 Weeks Old Embryo, subtracted; L1 Cell line; Human OB MG63 treated (10 nM E2) fraction I; Human OB HOS treated (10 nM E2) fraction I; Human colon carcinoma (HCC) cell line, remake; Human Adult Pulmonary; Healing Abdomen wound, 70&90 min post incision; Human Pituitary, subtracted; Human Neutrophils, Activated, re-excision; human colon cancer; Human Primary Breast

15 Cancer; Human Thyroid; Breast Lymph node cDNA library; Soares retina N2b4HR; Smooth Muscle- HASTE normalized; Human Pineal Gland; Raji Cells, cyclohexamide treated; Messangial cell, frac 2; Human Tonsils, Lib 2; HEL cell line; Stratagene endothelial cell 937223; Salivary Gland, Lib 2; Ovarian Tumor 10-3-95; HL-60, PMA 4H, re-excision; Jurkat T-cell G1 phase; Jurkat T-Cell, S phase; wilm's

20 tumor; Prostate BPH; CHME Cell Line, treated 5 hrs; Human Osteoblasts II; Soares\_fetal\_lung\_NbHL19W; Human Umbilical Vein Endothelial Cells, uninduced; Human Activated T-Cells; Human Primary Breast Cancer Reexcision; Stromal cell TF274; Macrophage-oxLDL; Spinal cord; Ulcerative Colitis; Human Thymus Stromal Cells; Macrophage (GM-CSF treated); Stratagene lung (#937210); Smooth

25 muscle, serum induced, re-exc; 12 Week Old Early Stage Human; H. Frontal cortex, epileptic, re-excision; Human T-Cell Lymphoma; Colon Carcinoma; Smooth

muscle, serum treated; H Macrophage (GM-CSF treated), re-excision;

Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human Fetal Lung III; Human Testes, Reexcision; Endothelial-induced; Endothelial cells-control; Colon Normal III; Human Amygdala; Smooth muscle,control; Monocyte activated; Human B Cell Lymphoma;

5 Stratagene endothelial cell 937223; Human Testes; Pancreatic Islet;

Soares\_senescent\_fibroblasts\_NbHSF; Stratagene corneal stroma (#937222); Human 8 Week Whole Embryo and Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:27 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
15 general formula of a-b, where a is any integer between 1 to 1133 of SEQ ID NO:27, b is an integer of 15 to 1147, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 18

It has been discovered that this gene is expressed primarily in Healing Abdomen wound,70&90 min post incision.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 76 as residues: Pro-17 to Ser-24.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:28 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 767 of SEQ ID NO:28, b is an integer of 15 to 781, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 19

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

gnl|PID|e27332 HCMVUL126 [Human cytomegalovirus] (all information available through the recited accession number is incorporated herein by reference) which is described therein as "HCMVUL126 [Human cytomegalovirus]." A partial alignment demonstrating the observed homology is shown immediately below.

```
>gnl|PID|e27332 HCMVUL126 [Human cytomegalovirus] >pir|S09875|S09875
    hypothetical protein UL126 - human cytomegalovirus (strain
AD169)
    >sp|P16836|ULC6_HCMVA HYPOTHETICAL PROTEIN UL126.
    Length = 134
```

Minus Strand HSPs:

```
Score = 192 (67.6 bits), Expect = 1.2e-14, P = 1.2e-14
Identities = 35/37 (94%), Positives = 36/37 (97%), Frame = -3
```

```
Q:  547 SAPLTQMGGRRVRWKVYISRAXLVNRQIAWRRHPRCF 437
    SAPLTQMGGRRVRW+VYISRA LVNRQIAWRRHPRCF
S:   35 SAPLTQMGGRRVRWEVYISRARLVNRQIAWRRHPRCF 71
```

The segment of gnlIPIDle27332 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 121.

Preferred polypeptides of the invention comprise a polypeptide having the  
5 amino acid sequence set out in the sequence listing as SEQ ID NO. 122 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in Primary Dendritic cells,frac 2.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
15 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 538 of SEQ ID NO:29, b is an integer of 15 to 552, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a  
20 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 20

It has been discovered that this gene is expressed primarily in L1 Cell line.

Many polynucleotide sequences, such as EST sequences, are publicly  
25 available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 437 of SEQ ID NO:30, b is an integer of 15 to 451, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

10

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 21

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

15 gil2804436 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Similar to mitochondrial carrier protein [*Caenorhabditis elegans*]." A partial alignment demonstrating the observed homology is shown immediately below.

20

```
>gi|2804436 (AF043695) Similar to mitochondrial carrier protein
[Caenorhabditis
  elegans] >sp|O44967|O44967 C42C1.10 PROTEIN.
  Length = 650
```

25

Plus Strand HSPs:

```
Score = 557 (196.1 bits), Expect = 3.5e-53, P = 3.5e-53
Identities = 138/335 (41%), Positives = 188/335 (56%), Frame = +2
```

30

```
Q: 95 MVGYDPKPDGRNNTKFPQVAVAGSVSGLVTRALISPPDVIKIRFQLQHERLXRSDPSAKYH 274
    MVGY P+      T  + + AG SG+VTR +I P DV+KIRFQLQ E + R S KY
S: 1  MVGYHPEAINEPLTSAEYSEAGLASGIVTRMI IQPLDVLKIRFQLQEPI-RGKKSGKYK 59

Q: 275 GILQASRQILQEEGPTAFWKGHVPAQILSIGYAVQFLSFEMLTENVHRGSVYDAREFSV 454
```

5  
 10  
 15  
 20  
 25  
 30  
 35

```

      G++Q+   I +EEG  AFWKGH+PAQ LS  YG VQF SFE L++      V  A   SV
S:   60  GVMQSIFLITREEGAHAFWKGHIPAQGLSATYGLVQFSSFEWLSQ--QAAKVIPADNQSV 117

Q:   455 H----FVCGGLAACMATLTVHPVDVLRTRFAAQ-GEPKVYNTLRHAVGTMYSRSEGPOQVY 619
      F CG L+ C+A      P+DV+RTR AQ      VY      HAV ++ EG  ++
S:   118 RSTSDFACGALSGCLAMTAAMPLDVIRTRLVAQKAGHAVYTGTMHAVKHIWEKEGIAGYF 177

Q:   620 KGLAPTLIAIFPYAGLQFSCYSSSLKHLYKWAIPAEGKKNNENLQNLGSGAGVISKTLTY 799
      +G P+++ I P+ G+QF+ Y+      L W P G   E+      L G+ AG ++KT+ Y
S:   178 RGWVPSVVQIAPFTGMQFALYNCFMDL--W--PFNGY--ESAGALFSGAMAGTVAKTVLY 231

Q:   800 PLDLFKKRLQVGGFEHARAFAFGQVRRY-KGLMDCAKQVLQKEGALGFFKGLSPSLLKAAL 976
      PLD+ + RLQ+ GFE  RA FG+   Y +GL      V++ E   G FKGL PS +KAA
S:   232 PLDMVRHRLQMNGFE--RAGFGKTSNYSQGLFKTIGMVVKNESWYGLFKGLWPSQIKAAA 289

Q:   977 STGFMFFSYEFFC-NVFHCMNRTASQR*AQEGPQVFPGGSL 1099
      ++G+   S      V   + TA+ R      ++ GG LL
S:   290 NSGWRIVSIHASAFTVSKLVFGTAADR--TSNSRLLIGGILL 329
  
```

The segment of gil2804436 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 123.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 124 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: NCI\_CGAP\_GCB1 and to a lesser extent in Human Pituitary, subt IX; Soares\_testis\_NHT; Human Rhabdomyosarcoma; NCI\_CGAP\_Co3; Soares infant brain 1NIB; normalized infant brain cDNA; Soares\_total\_fetus\_Nb2HF8\_9w; Human Adult Small Intestine; Human Fetal Heart; Activated T-Cell (12hs)/Thiouridine labelledEco; Human 8 Week Whole Embryo; H. Umbilical Vein Endothelial Cells, IL4 induced; Gessler Wilms tumor; Jia bone marrow stroma; Soares ovary tumor NbHOT; Stratagene hNT neuron (#937233); Human Membrane Bound Polysomes- Enzyme Subtraction; Human Placenta; Human Pituitary, subtracted; Aorta endothelial cells + TNF-a; Human Quadriceps; Human Pineal

Gland; Human Amygdala, re-excision; Human Brain, Striatum; Human Jurkat Membrane Bound Polysomes; Human adult testis, large inserts; Pancreas Islet Cell Tumor; Macrophage-oxLDL, re-excision; Colon Carcinoma; Soares melanocyte 2NbHM; Human Adult Pulmonary, re-excision; Human Microvascular Endothelial Cells, fract. A; Soares\_pregnant\_uterus\_NbHPU; Stratagene colon (#937204); Smooth muscle, control; Human B Cell Lymphoma; Activated T-cell(12h)/Thiouridine-re-excision; Soares fetal liver spleen 1NFLS; NCI\_CGAP\_GC3; NCI\_CGAP\_GC4; NCI\_CGAP\_Kid3 and Primary Dendritic Cells, lib 1.

10 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 79 as residues: Pro-11 to Gln-16.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1544 of SEQ ID NO:31, b is an integer of 15 to 1558, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 22

25 The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting

example, the sequence accessible through the following database accession no. gil1710216 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "unknown [Homo sapiens]." A partial alignment demonstrating the observed homology is shown

5 immediately below.

```

>gi|1710216 unknown [Homo sapiens] >sp|Q99770|Q99770 HYPOTHETICAL 15.4 KD
      PROTEIN.
      Length = 139

10      Plus Strand HSPs:

      Score = 190 (66.9 bits), Expect = 1.6e-13, P = 1.6e-13
      Identities = 39/71 (54%), Positives = 42/71 (59%), Frame = +1

15      Q:   526 NFFFXXXXXXXXXXXXXXECSGMIQAHNRLRLPGSSNSHASASRVAGITGACXHGWLFPVF 705
              +F F                      ECSG I AH NL LPGSSNS ASASRVAG  G C    L+FVF
      S:   47  SFLFFFFETQSHSVTRLECSGTISAHCNLCPLPGSSNSPASASRVAGTAGTCRRAQLIFVF 106

20      Q:   706 XVETGFHHVQ 738
              E GFHHVG+
      S:   107 LAEMGFHHVGR 117

```

The segment of gil1710216 that is shown as "S" above is set out in the

25 sequence listing as SEQ ID NO. 125.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 126 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

30 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in L428; NCI\_CGAP\_Alv1; Jurkat T-Cell, S phase; Human Ovary; NCI\_CGAP\_Lei2; Stratagene neuroepithelium (#937231); Bone Marrow Cell Line (RS4,11); Human B Cell 8866; Human Fetal Lung; Human (HCC) cell line liver (mouse) metastasis,



remake; Human Colon Carcinoma (HCC) cell line; Hepatocellular Tumor; Smooth muscle, IL1b induced; Healing groin wound, 7.5 hours post incision; Stratagene HeLa cell s3 937216; Stratagene NT2 neuronal precursor 937230; Spinal Cord, re-excision; 12 Week Old Early Stage Human, II; Human Jurkat Membrane Bound Polysomes; T-  
 5 Cell PHA 24 hrs; Stromal cell TF274; NCI\_CGAP\_AA1; NCI\_CGAP\_Co9; NCI\_CGAP\_GC4; NCI\_CGAP\_Pr3; NCI\_CGAP\_Pr7; NCI\_CGAP\_GCB1; NCI\_CGAP\_Pr12; NTERA2, control; Soares\_pregnant\_uterus\_NbHPU; Stratagene neuroepithelium (#937231); Smooth muscle, serum induced, re-exc; Pancreas Islet Cell Tumor; Human Substantia Nigra; Dendritic cells, pooled; Human Placenta;  
 10 Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human Amygdala; Activated T-cell(12h)/Thiouridine-re-excision; Nine Week Old Early Stage Human; Human Cerebellum and Soares infant brain 1NIB.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
 15 related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
 20 general formula of a-b, where a is any integer between 1 to 1487 of SEQ ID NO:32, b is an integer of 15 to 1501, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

25 **FEATURES OF PROTEIN ENCODED BY GENE NO: 23**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil972176 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "ATPase inhibitor, mitochondrial precursor [Sus scrofa]." A partial alignment demonstrating the observed homology is shown immediately below.

```

10  >gi|972176 ATPase inhibitor, mitochondrial precursor [Sus scrofa]
    >sp|Q29307|IATP_PIG ATPASE INHIBITOR, MITOCHONDRIAL PRECURSOR.
    Length = 108

    Plus Strand HSPs:

15  Score = 174 (61.3 bits), Expect = 3.6e-21, Sum P(2) = 3.6e-21
    Identities = 32/49 (65%), Positives = 38/49 (77%), Frame = +1

    Q:   70 LGVWGVRTMQARGFGSDQSENVDRGAGSIREAGGAFGKREQAEERYFR 216
        +G W V  MQ+RGF SD  E V  GAG++R AGGAFGK+EQA+EERYFR
20  S:   12 IGAWSVWAMQSRGFSSDTPEGVRSGAGAVRXAGGAFGKKEQADEERYFR 60

    Score = 113 (39.8 bits), Expect = 3.6e-21, Sum P(2) = 3.6e-21
    Identities = 26/47 (55%), Positives = 29/47 (61%), Frame = +3

25  Q:  1599 RAQSREQLAALXXXXXXXXXXXXXXXXXRLQKEIERHKQIKMLKHDD 1739
        RA++REQLAAL                      RLQKEIERHKQ IK LK+DD
    S:   60 RARAREQLAALKKHENXISHHVKEIERLQKEIERHKQSIKKLNDD 106

```

The segments of gil972176 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 127 and SEQ ID NO. 129. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 128 and/or SEQ

ID NO. 130 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human 8 Week Whole Embryo; Human Cerebellum and to a  
 5 lesser extent in Human Pineal Gland; Hepatocellular Tumor; Soares\_senescent\_fibroblasts\_NbHSF; Human Jurkat Membrane Bound Polysomes; Soares\_parathyroid\_tumor\_NbHPA; Stratagene lung carcinoma 937218; Soares fetal liver spleen 1NFLS; FGF enriched mixed library; Bone Cancer; LNCAP + o.3nM R1881; Human Prostate Cancer, Stage B2 fraction; Human Pituitary, subtracted;  
 10 Human Quadriceps; Human Soleus; Soares adult brain N2b4HB55Y; Pancreas Tumor PCA4 Tu; Healing groin wound, 6.5 hours post incision; HL-60, PMA 4H, re-excision; wilm's tumor; Human Manic Depression Tissue; Prostate BPH; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Stratagene pancreas (#937208); Breast Cancer Cell line, angiogenic; Human Fetal Dura Mater; T-Cell PHA 24 hrs; Stromal cell  
 15 TF274; Liver, Hepatoma; Human cerebral cortex; Human pancreatic islet; NCI\_CGAP\_Pr9; NCI\_CGAP\_Pr22; Human umbilical vein endothelial cells, IL-4 induced; Human Adrenal Gland Tumor; Stratagene liver (#937224); Pancreas Islet Cell Tumor; Human colorectal cancer; Liver HepG2 cell line.; Soares\_testis\_NHT; Soares\_total\_fetus\_Nb2HF8\_9w; Fetal Heart; 12 Week Old Early Stage Human; H  
 20 Macrophage (GM-CSF treated), re-excision; Human Fetal Lung III; Neutrophils control, re-excision; Endothelial-induced; Human Amygdala; Smooth muscle, control and Human Testes.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 81 as residues: Gly-24 to Gly-36, Gly-48 to Arg-60.

25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:33 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1866 of SEQ ID NO:33, b is an integer of 15 to 1880, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a + 14.

10

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 24**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares fetal liver spleen 1NFLS and to a lesser extent in Soares melanocyte 2NbHM; Soares placenta Nb2HP; Soares retina N2b5HR; Soares

15 retina N2b4HR; Human Cerebellum; Human Prostate; NCI\_CGAP\_GCB1; Weizmann Olfactory Epithelium; Soares\_pregnant\_uterus\_NbHPU; Stratagene HeLa cell s3 937216; Soares breast 2NbHBst; Human Gall Bladder; Colon Carcinoma; Primary Dendritic cells,frac 2; Soares\_pregnant\_uterus\_NbHPU; T cell helper II; Soares infant brain 1NIB; Osteoclastoma-normalized A; Human Fetal Heart,

20 Differential (Fetal-Specific); Resting T-Cell; Human Adult Spleen; Human Adult Retina; Human T-cell lymphoma,re-excision; Stratagene fibroblast (#937212); Hepatocellular Tumor; Alzheimers, spongy change; Ovarian Tumor 10-3-95; Synovial hypoxia; Synovial Fibroblasts (II1/TNF), subt; T-Cell PHA 16 hrs; Human Uterine Cancer; Human Pancreas Tumor; Macrophage-oxLDL; Merkel Cells;

25 Synovial Fibroblasts (control); NTERA2, control; Human Liver, normal; Pancreas Islet Cell Tumor; Resting T-Cell Library,II; H. Frontal cortex,epileptic,re-excision;

Human T-Cell Lymphoma; Human adult (K.Okubo); Human aorta polyA+  
(TFujiwara); Human fetal heart, Lambda ZAP Express; NCI\_CGAP\_Co8;  
NCI\_CGAP\_GC4; Human Testes Tumor; NCI\_CGAP\_Lu5; NCI\_CGAP\_Kid5;  
Colon Normal III; Human Osteoclastoma; Human Amygdala; T Cell helper I; Human  
5 Testes; Hodgkin's Lymphoma II and Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:34 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
10 excluded from the scope of the present invention. To list every related sequence  
would be cumbersome. Accordingly, preferably excluded from the present invention  
are one or more polynucleotides comprising a nucleotide sequence described by the  
general formula of a-b, where a is any integer between 1 to 2890 of SEQ ID NO:34, b  
is an integer of 15 to 2904, where both a and b correspond to the positions of  
15 nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a  
+ 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 25**

It has been discovered that this gene is expressed primarily in the following  
20 tissues/cDNA libraries: Human 8 Week Whole Embryo and to a lesser extent in  
HSC172 cells; Endothelial-induced; Soares\_fetal\_heart\_NbHH19W; Fetal Heart;  
Stratagene HeLa cell s3 937216; Human Fetal Dura Mater; Stratagene lung  
(#937210); Smooth muscle, serum induced, re-exc; Human Fetal Lung III; Soares  
placenta Nb2HP; Stratagene endothelial cell 937223; Stratagene HeLa cell s3 937216;  
25 Stratagene HeLa cell s3 937216; Human Rhabdomyosarcoma; Hemangiopericytoma;  
Soares\_NhHMPu\_S1; Human Fetal Brain; Early Stage Human Lung, subtracted;

- Stromal-Osteoclastoma; Smooth muscle, IL1b induced;
- Soares\_senescent\_fibroblasts\_NbHSF; Bone Marrow Stromal Cell, untreated; Human Whole Six Week Old Embryo; Smooth muscle, serum treated; Human Fetal Heart; Osteoblasts; Keratinocyte; Nine Week Old Early Stage Human; Soares fetal liver
- 5 spleen 1NFLS; Human Lung Cancer, re-excision; Stratagene hNT neuron (#937233); Amniotic Cells - Primary Culture; Stratagene HeLa cell s3 937216; Human endometrial stromal cells; Human Fetal Kidney; Human Osteoblasts II; Gessler Wilms tumor; Soares\_total\_fetus\_Nb2HF8\_9w; Stratagene NT2 neuronal precursor 937230; Human Adipose; Rejected Kidney, lib 4; Human fetal heart, Lambda ZAP
- 10 Express; Adipocytes; Endothelial cells-control; Soares\_pregnant\_uterus\_NbHPU; Smooth muscle, control; Human Testes; NCI\_CGAP\_Pr22; Human Umbilical Vein Endothelial Cells, fract. B; Human Adult Heart, subtracted; H. Adipose Tissue; Human Fibrosarcoma; Human Gall Bladder, fraction II; Human OB MG63 treated (10 nM E2) fraction I; Human Umbilical Vein Endothelial Cells, fract. A; H. Atrophic
- 15 Endometrium; Hodgkin's Lymphoma I; Human Fetal Spleen; Smooth Muscle Serum Treated, Norm; Aorta endothelial cells + TNF-a; Human T-cell lymphoma, re-excision; HSA 172 Cells; Smooth Muscle- HASTE normalized; Mesangial cell, frac 2; Soares adult brain N2b4HB55Y; Stomach cancer (human), re-excision; Human endometrial stromal cells-treated with estradiol; Stratagene placenta (#937225);
- 20 Human Umbilical Vein, Endo. remake; Human Fetal Epithelium (Skin); Soares\_fetal\_lung\_NbHL19W; Human Ovary; wilm's tumor; H. Lymph node breast Cancer; Human Chronic Synovitis; Human fetal lung; Human Umbilical Vein, Reexcision; 12 Week Old Early Stage Human, II; Human Jurkat Membrane Bound Polysomes; Human Pancreas Tumor; Jia bone marrow stroma; Normal Human
- 25 Trabecular Bone Cells; Soares\_NbHFB; Soares\_testis\_NHT; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Human Pancreas Tumor, Reexcision; Human

Thymus; Human Fetal Brain; Stratagene NT2 neuronal precursor 937230; Human Gall Bladder; NCI\_CGAP\_HN2; Stratagene HeLa cell s3 937216; 12 Week Old Early Stage Human; Human Fetal Kidney, Reexcision; Human Microvascular Endothelial Cells, fract. A; NCI\_CGAP\_Co9; NCI\_CGAP\_GC2; NCI\_CGAP\_Kid6; 5 Hodgkin's Lymphoma II; Human pancreatic islet; Human fetal heart, Lambda ZAP Express; NCI\_CGAP\_Br2; NCI\_CGAP\_GC3; NCI\_CGAP\_GCB1; and Stratagene neuroepithelium (#937231).

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 83 as residues: Ala-2 to Arg-16.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence 15 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2623 of SEQ ID NO:35, b is an integer of 15 to 2637, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a 20 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 26

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting 25 example, the sequence accessible through the following database accession no. gil3916212 (all information available through the recited accession number is

incorporated herein by reference) which is described therein as "cathepsin F [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

```

5   >gi|3916212 (AF071748) cathepsin F [Homo sapiens] >sp|G3916212|G3916212
    CATHEPSIN F. >gi|3916214 (AF071749) cathepsin F [Homo sapiens]
    {SUB
      37-338}
    Length = 338
10
    Plus Strand HSPs:

    Score = 1263 (444.6 bits), Expect = 4.8e-128, P = 4.8e-128
    Identities = 232/234 (99%), Positives = 233/234 (99%), Frame = +2
15
    Q:   56 TEVRKEPGNKMKQAKSVGDLAPPEWDWRSGAVTKVKDQGMCGSCWAFSVTGNVEGQWFL 235
        T +RKEPGNKMKQAKSVGDLAPPEWDWRSGAVTKVKDQGMCGSCWAFSVTGNVEGQWFL
    S:   105 TLLRKEPGNKMKQAKSVGDLAPPEWDWRSGAVTKVKDQGMCGSCWAFSVTGNVEGQWFL 164

20   Q:   236 NQGTLLSLSEQELLDCDKMDKACMGGGPSNAYSIAIKNLGGLETEDDYSYQGHMQSCNFSA 415
        NQGTLLSLSEQELLDCDKMDKACMGGGPSNAYSIAIKNLGGLETEDDYSYQGHMQSCNFSA
    S:   165 NQGTLLSLSEQELLDCDKMDKACMGGGPSNAYSIAIKNLGGLETEDDYSYQGHMQSCNFSA 224

25   Q:   416 EKAKVYINDSVELSQNEQKLAAWLAKRGPIISVAINAFGMQFYRHGISRPLRPLCSPWLID 595
        EKAKVYINDSVELSQNEQKLAAWLAKRGPIISVAINAFGMQFYRHGISRPLRPLCSPWLID
    S:   225 EKAKVYINDSVELSQNEQKLAAWLAKRGPIISVAINAFGMQFYRHGISRPLRPLCSPWLID 284

    Q:   596 HAVLLVGYNRSDVPPFWAIKNSWGTDWGEKGYYYLHRGSGACGVNTMASSAVVD 757
        HAVLLVGYNRSDVPPFWAIKNSWGTDWGEKGYYYLHRGSGACGVNTMASSAVVD
30   S:   285 HAVLLVGYNRSDVPPFWAIKNSWGTDWGEKGYYYLHRGSGACGVNTMASSAVVD 338

```

The segment of gi|3916212 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 131. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities.

Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 132 which



corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Adult Testes, Large Inserts, Reexcision and to a lesser extent in Human Cerebellum; Soares\_testis\_NHT; Soares\_fetal\_heart\_NbHH19W; H. Kidney Cortex, subtracted; Human Osteosarcoma; Human Chronic Synovitis; Human Primary Breast Cancer Reexcision; NCI\_CGAP\_Kid3; Human Gall Bladder; Soares breast 3NbHBst; Soares melanocyte 2NbHM; Human Amygdala; Soares ovary tumor NbHOT; Soares\_total\_fetus\_Nb2HF8\_9w; Soares\_parathyroid\_tumor\_NbHPA; H. Amygdala Depression, subtracted; Human Primary Breast Cancer, re-excision; H. Epididymus, cauda; Human Soleus; Human Pineal Gland; Soares adult brain N2b4HB55Y; Human Epididymus; Human Synovium; Human endometrial stromal cells-treated with estradiol; Amniotic Cells - Primary Culture; Human Pituitary, sub IX; H. Meningima, M1; Human Infant Brain; Temporal cortex-Alzheimer, subtracted; Human Brain, Striatum; Human Fetal Dura Mater; Human adult (K.Okubo); Human retina cDNA Tsp509I-cleaved sublibrary; NCI\_CGAP\_AA1; NCI\_CGAP\_Kid5; NCI\_CGAP\_Kid6; Human Hypothalamus, Schizophrenia; Hemangiopericytoma; Human Fetal Brain; Soares breast 2NbHBst; Hepatocellular Tumor, re-excision; Human Liver, normal; 12 Week Old Early Stage Human; Colon Normal II; Human Placenta; Normal colon; Human Synovial Sarcoma; Human Fetal Lung III and Osteoblasts.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 84 as residues: Glu-62 to Cys-76, Ser-94 to Lys-99, Tyr-148 to Asp-153, Thr-165 to Gly-180.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1246 of SEQ ID NO:36, b is an integer of 15 to 1260, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 27

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gi2529686 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "putative G-beta-repeat containing protein, 5' partial [*Arabidopsis thaliana*]." A partial alignment demonstrating the observed homology is shown immediately below.

```
>gi|2529686 (AC002535) putative G-beta-repeat containing protein, 5'
partial
[Arabidopsis thaliana] >sp|O22269|O22269 PUTATIVE G-BETA-
REPEAT
CONTAINING PROTEIN, 5' PARTIAL (FRAGMENT).
Length = 1269
```

Plus Strand HSPs:

```
Score = 204 (71.8 bits), Expect = 2.5e-21, Sum P(3) = 2.5e-21
Identities = 38/83 (45%), Positives = 55/83 (66%), Frame = +2
```

```
Q: 29 AFPGTM YQH I K M H R R I L G H L S A V Y C V A F D R T G H R I F T G S D D C L V K I W S T H N G R L L S T L R G 208
   A P T M Q ++ +++ GH +AVYC FDR+G + TGSDD LVKIWS L++ RG
S: 97 AKPSTMVQRMQNIKKLRGHRNAVYCAIFDRSGRYVITGSDDRLVKIWSMETALCLASCRG 156
```

Q: 209 HSAEISDMAVNYENTMIAAGSCD 277  
       H +I+D+AV+ N ++A+ S D  
 S: 157 HEGDITDLAVSSNNALVASASND 179

Score = 78 (27.5 bits), Expect = 2.5e-21, Sum P(3) = 2.5e-21  
 Identities = 13/26 (50%), Positives = 21/26 (80%), Frame = +3

Q: 282 IIRVWCLRTCAPVAVLQGHTGSITSL 359  
       +IRVW L P++VL+GHTG++T++  
 S: 181 VIRVWRLPDGMPISVLRGHTGAVTAI 206

Score = 39 (13.7 bits), Expect = 2.5e-21, Sum P(3) = 2.5e-21  
 Identities = 7/20 (35%), Positives = 14/20 (70%), Frame = +2

Q: 467 VLSKRSDNHSYKSYKSWKAD 526  
       ++ +R +N Y+S +S+K D  
 S: 1213 LIHERLENQYYRSIESFKHD 1232

The segments of gil2529686 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 133, SEQ ID NO. 135 and SEQ ID NO. 137. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 134, SEQ ID NO. 136 and/or SEQ ID NO. 138 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in human ovarian cancer.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 913 of SEQ ID NO:37, b is an integer of 15 to 927, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a + 14.

## 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 28

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil167778 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "protein-tyrosine kinase-2 (DPYK2) [Dictyostelium discoideum]." A partial alignment demonstrating the observed homology is shown immediately below.

```

20  .>gi|167778 protein-tyrosine kinase-2 (DPYK2) [Dictyostelium discoideum]
    >pir|B35670|B35670 protein-tyrosine kinase (EC 2.7.1.112) 2 -
    slime
        mold (Dictyostelium discoideum) (fragment)
    >sp|P18161|KYK2_DICDI
    TYROSINE-PROTEIN KINASE 2 (EC 2.7.1.112) (FRAGMENT).
25     Length = 410

    Minus Strand HSPs:

    Score = 214 (75.3 bits), Expect = 4.3e-16, Sum P(2) = 4.3e-16
30     Identities = 71/236 (30%), Positives = 121/236 (51%), Frame = -2

    Q: 1633 EKKKSVLCSTP-TINIPASPFMQKLGFGTGVNVYLMKRSPRGLSHSPWAVKKINPICNDH 1457
        E+ KS+L      I+I      F+QK+G G      V+      +      +G+ H      A+KK+      I      D
    S: 90 EELKSILGEREYIIDINDIQFIQKVGEGAPSEVW--EGWWKGI-HV--AIKKLK-IIGDE 143
35

```

Q: .1456 YRSVYXKRLMDEAKILKSLHHPNIVGYRAFTEASDGSCLAMEYGGKSLNDLIEERYKA 1277  
       + + +R + E + LK +H NIV F A C+ EY SL +++ +  
 S: 144 EQ--FKERFIREVQNLKKGNGHQNIV---MFIGACYKPACIITEYMAGGSLYNILHNPNS 198  
 5 Q: 1276 SQD--PFPAAILKVALNMARGLKYLHQEKLLHGDIKSSNVVIKGDFFETIKICDVGVSPL 1100  
       + + ++LK+A +MA GL +LH ++H D+ S N+++ + IKI D G+S  
 S: 199 TPKVKYSFPLVLKMATDMALGLLHLHSIT-IVHRDLTSQNILLD-ELGNIKISDFGLSAE 256  
 10 Q: 1099 LDE--NMTVTDPEACYIGTEPWKPKEAVEENGVITDKADIFAFGLTLWEMMTLSIPHINL 926  
       +MT+T+ C W+P E + G ++K D++ F L +WE++T IP +L  
 S: 257 KSREGSMTMTNGGIC---NPRWRPELTKNLGHYSEKVDVYCPSLVVWEILTGEIPFSDL 313

The segment of gil167778 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 139.

15 Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 140 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following  
 20 tissues/cDNA libraries: NCI\_CGAP\_GCB1 and to a lesser extent in Human Testes;  
 Human T-cell lymphoma, re-excision; Human Microvascular Endothelial Cells, fract.  
 A; Activated T-cells; Cem cells cyclohexamide treated; HEL cell line; Stromal-  
 Osteoclastoma; Myeloid Progenitor Cell Line; Soares\_fetal\_lung\_NbHL19W; Human  
 Bone Marrow, re-excision; human ovarian cancer; Human Uterine Cancer; Stromal  
 25 cell TF274; Bone Marrow Stromal Cell, untreated; PC3 Prostate cell line; 12 Week  
 Old Early Stage Human; Colon Carcinoma; Human Substantia Nigra; Hodgkin's  
 Lymphoma II; Keratinocyte and Nine Week Old Early Stage Human.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 86 as residues: Gly-1 to Leu-6.

30 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1860 of SEQ ID NO:38, b is an integer of 15 to 1874, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 29

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

gil3047334 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "HMG box transcription factor [Mus musculus]." A partial alignment demonstrating the observed homology is shown immediately below.

```
>gi|3047334 (AF057691) HMG box transcription factor [Mus musculus]
>sp|O70450|O70450 HMG BOX TRANSCRIPTION FACTOR (FRAGMENT).
Length = 412

Plus Strand HSPs:

Score = 193 (67.9 bits), Expect = 2.3e-12, P = 2.3e-12
Identities = 41/68 (60%), Positives = 42/68 (61%), Frame = +1

Q: 124 AFLXXXXXXXXXGQMGXXXXXXXXXXXXXXXXXMP TALLASPPSFPATLHAHQALPVLQAQPL 303
    AFL QMG MP ALL SPP+FPATLHAHQALPVLQAQPL
S: 345 AFLSAKAAASNSSQMGSPQLLSRPLPLGSM PAALLTSPPTFPATLHAHQALPVLQAQPL 404

Q: 304 SLVTKSAH 327
    SLVTKSAH
```

S: 405 SLVTKSAH 412

Score = 100 (35.2 bits), Expect = 0.12, P = 0.12  
Identities = 26/46 (56%), Positives = 29/46 (63%), Frame = +2

Q: 59 EAQPLSLTTKPETRAQLALHSAP-----SCRLRLQPPXLGR 166  
+AQPLSLTTKPE RAQLALHSA S ++ QPP L R  
S: 323 QAQPLSLTTKPEARAQLALHSAFLSAKAAASNSSQMGSPPLLSR 368

10 The segments of gil3047334 that are shown as "S" above are set out in the  
sequence listing as SEQ ID NO. 141 and SEQ ID NO. 143. Based on the structural  
similarity these homologous polypeptides are expected to share at least some  
biological activities. Such activities are known in the art, some of which are described  
elsewhere herein. Assays for determining such activities are also known in the art,  
15 some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the  
amino acid sequence set out in the sequence listing as SEQ ID NO. 142 and/or SEQ  
ID NO. 144 which correspond to the "Q" sequences in the alignment shown above  
(gaps introduced in a sequence by the computer are, of course, removed).

20 It has been discovered that this gene is expressed primarily in the following  
tissues/cDNA libraries: Soares breast 2NbHBst and to a lesser extent in  
Soares\_fetal\_heart\_NbHH19W; Human Placenta; Nine Week Old Early Stage  
Human; Soares breast 3NbHBst; Soares\_senescent\_fibroblasts\_NbHSF; Stratagene  
muscle 937209; Human Adult Pulmonary, re-excision; Soares fetal liver spleen  
25 1NFLS; Hypothalamus; Human Thymus; Bone Marrow Stromal Cell, untreated;  
Hemangiopericytoma; Colon Tumor II; Soares melanocyte 2NbHM; Human adult  
(K.Okubo) and NCI\_CGAP\_Br2.

Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
30 related to SEQ ID NO:39 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1331 of SEQ ID NO:39, b is an integer of 15 to 1345, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

#### 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 30

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares ovary tumor NbHOT; NCI\_CGAP\_GCB1; Soares\_pregnant\_uterus\_NbHPU; Human Neutrophil; Soares melanocyte 2NbHM; Soares\_fetal\_heart\_NbHH19W; Soares\_multiple\_sclerosis\_2NbHMSP and to a lesser extent in stomach cancer (human); Human Stomach; Activated T-cells; NCI\_CGAP\_AA1; NCI\_CGAP\_Co8; Human Brain, Striatum; Hemangiopericytoma; Human Fetal Lung III and Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1232 of SEQ ID NO:40, b is an integer of 15 to 1246, where both a and b correspond to the positions of



nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 31**

5           It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Neutrophil, Activated; Soares infant brain 1NIB and to a lesser extent in Activated T-Cells, 8 hrs., ligation 2; and neutrophils control.

          Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10   related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
15   general formula of a-b, where a is any integer between 1 to 2160 of SEQ ID NO:41, b is an integer of 15 to 2174, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

#### **20   FEATURES OF PROTEIN ENCODED BY GENE NO: 32**

          It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Osteoclastoma Stromal Cells - unamplified and to a lesser extent in Soares melanocyte 2NbHM; Soares placenta Nb2HP; Osteoblasts; Primary Dendritic Cells, lib 1; Human Rhabdomyosarcoma;  
25   Soares\_fetal\_heart\_NbHH19W; Soares infant brain 1NIB; Macrophage-oxLDL; Human Thymus; Macrophage (GM-CSF treated); PC3 Prostate cell line; Human

Testes, Reexcision; NCI\_CGAP\_Pr9; NCI\_CGAP\_GCB1; Colon Normal III; Human  
 Greater Omentum, fract II remake,; Human Adult Heart; Glioblastoma; Jurkat T-cell  
 G1 phase; Jurkat T-Cell, S phase; wilm's tumor; Human Manic Depression Tissue;  
 Human Prostate; Human placenta cDNA (TFujiwara); Monocyte activated, re-  
 5 excision; Human Heart; Human Adrenal Gland Tumor; Soares\_testis\_NHT; Human  
 Placenta; Bone marrow; Human Adult Pulmonary, re-excision; CD34 depleted Buffy  
 Coat (Cord Blood), re-excision; NCI\_CGAP\_Co2; Human Microvascular Endothelial  
 Cells, fract. A; Soares\_pregnant\_uterus\_NbHPU; Human B Cell Lymphoma;  
 Activated T-cell(12h)/Thiouridine-re-excision; Soares\_senescent\_fibroblasts\_NbHSF;  
 10 Hodgkin's Lymphoma II; NCI\_CGAP\_Pr25; Human Cerebellum; Soares fetal liver  
 spleen 1NFLS; Early Stage Human Liver, fract (II); H.Leukocytes, normalized cot  
 5B; Cem Cells, cyclohexamide treated, subtra; Human Kidney Tumor; Activated T-  
 Cells, 12 hrs, subtracted; Human Tongue, frac 1; Human Kidney Cortex, re-rescue;  
 LNCAP + 30nM R1881; Human epithelioid sarcoma; Human Gall Bladder, fraction  
 15 II; Human OB MG63 treated (10 nM E2) fraction I; Human Adult Pulmonary;  
 Smooth Muscle Serum Treated, Norm; Human Fetal Bone; Smooth muscle-ILb  
 induced; H. Epididymus, caput & corpus; Human Primary Breast Cancer; Human  
 Skin Tumor; Raji Cells, cyclohexamide treated; Messangial cell, frac 2; Human  
 Tonsils, Lib 2; Apoptotic T-cell, re-excision; Soares adult brain N2b4HB55Y; Human  
 20 Epididymus; Human Synovium; human corpus colosum; Alzheimers, spongy change;  
 Healing groin wound, 7.5 hours post incision; Synovial hypoxia-RSF subtracted;  
 Salivary Gland, Lib 2; Myeloid Progenitor Cell Line; Human Pituitary, subt IX;  
 Prostate BPH; Brain Frontal Cortex, re-excision; Human Adult Small Intestine; Mo7e  
 Cell Line GM-CSF treated (1ng/ml); Breast Cancer Cell line, angiogenic;  
 25 NCI\_CGAP\_Kid3; Apoptotic T-cell; Human Umbilical Vein Endothelial Cells,  
 uninduced; Human Fetal Dura Mater; Human Activated T-Cells; Human

Hypothalamus, Schizophrenia; Bone Marrow Stromal Cell, untreated; Rejected Kidney, lib 4; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Human Whole Six Week Old Embryo; Human adult testis, large inserts; NTERA2, control; Smooth muscle, serum induced, re-exc; Macrophage-oxLDL, re-excision; KG1-a Lambda Zap Express cDNA library; Colon Tumor; Resting T-Cell Library, II; 12 Week Old Early Stage Human; Smooth muscle, serum treated; breast lymph node CDNA library; Soares breast 3NbHBst; Adipocytes; Human Testes Tumor; Primary Dendritic cells, frac 2; NCI\_CGAP\_Br2; NCI\_CGAP\_Br3; NCI\_CGAP\_Co3; NCI\_CGAP\_Co9; NCI\_CGAP\_Lu1; NCI\_CGAP\_Pr5; NCI\_CGAP\_Co10; NCI\_CGAP\_Kid5; NCI\_CGAP\_Pr22; NCI\_CGAP\_Pr23; Smooth muscle, control; Monocyte activated; Human Bone Marrow, treated; Soares\_fetal\_lung\_NbHL19W; Bone Marrow Cell Line (RS4,11); NCI\_CGAP\_Lu5; and Keratinocyte.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 90 as residues: Pro-20 to Ala-25, Lys-41 to Ser-55.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 840 of SEQ ID NO:42, b is an integer of 15 to 854, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 33**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Resting T-Cell Library,II; Brain frontal cortex and to a lesser extent in H. Kidney Cortex, subtracted; Myeloid Progenitor Cell Line; Human Ovary; 5 wilm's tumor; Apoptotic T-cell; Human Fetal Dura Mater; Human Rhabdomyosarcoma; Human Fetal Brain and Human Fetal Heart.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 91 as residues: Gly-27 to Pro-35.

Many polynucleotide sequences, such as EST sequences, are publicly 10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention 15 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 762 of SEQ ID NO:43, b is an integer of 15 to 776, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

20

**FEATURES OF PROTEIN ENCODED BY GENE NO: 34**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Neutrophil, Activated and to a lesser extent in Soares\_fetal\_liver\_spleen\_1NFLS\_S1; normalized infant brain cDNA; Monocyte 25 activated; Soares ovary tumor NbHOT; Soares placenta Nb2HP; Soares fetal liver spleen 1NFLS; Primary Dendritic Cells, lib 1; Soares infant brain 1NIB;

- Soares\_testis\_NHT; NCI\_CGAP\_Lu1; NCI\_CGAP\_Lu5; Human Neutrophils, Activated, re-excision; Stratagene placenta (#937225); Amniotic Cells - Primary Culture; NTERA2, control; Stratagene liver (#937224); Stratagene muscle 937209; Normal colon; Soares melanocyte 2NbHM; Human Synovial Sarcoma; Human
- 5 Cerebellum; Soares\_total\_fetus\_Nb2HF8\_9w; H. Leukocytes, normalized cot 5A; Human Bone Marrow; LPS activated derived dendritic cells; NCI\_CGAP\_Pr2; NCI\_CGAP\_GCB1; NCI\_CGAP\_Kid5; NCI\_CGAP\_Brn23; Human Pre-Differentiated Adipocytes; H. Normalized Fetal Liver, II; H. Atrophic Endometrium; HSC172 cells; Stratagene pancreas (#937208); Stratagene hNT neuron (#937233);
- 10 Frontal lobe,dementia,re-excision; Aorta endothelial cells + TNF-a; Human Lung; Early Stage Human Lung, subtracted; Human Quadriceps; Resting T-Cell, re-excision; Human Pineal Gland; Human Prostate Cancer, Stage C fraction; Smooth muscle, IL1b induced; Synovial hypoxia-RSF subtracted; Healing groin wound, 6.5 hours post incision; Human Colon, re-excision; Soares\_parathyroid\_tumor\_NbHPA;
- 15 H. Lymph node breast Cancer; Human Neutrophil; Human Chronic Synovitis; L428; Human Osteoblasts II; Human Activated T-Cells; Human Heart; Human Activated T-Cells, re-excision; Soares adult brain N2b5HB55Y; Human Fetal Brain; Human Whole Six Week Old Embryo; Hepatocellular Tumor, re-excision; Colon Tumor; Neutrophils IL-1 and LPS induced; Colon Normal II; Adipocytes; Clontech human
- 20 aorta polyA+ mRNA (#6572); Human pancreatic islet; Human heart cDNA (YNakamura); Soares\_fetal\_lung\_NbHL19W; Soares\_senescent\_fibroblasts\_NbHSF; 12 Week Early Stage Human II, Reexcision; Human Fetal Lung III; Bone marrow; CD34 depleted Buffy Coat (Cord Blood), re-excision; Human B Cell Lymphoma; T cell helper II and Nine Week Old Early Stage Human.
- 25 Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 92 as residues: Ser-17 to Cys-22.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1719 of SEQ ID NO:44, b is an integer of 15 to 1733, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 35**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares placenta Nb2HP and to a lesser extent in Soares breast 2NbHBst; Human Cardiomyopathy, RNA remake; Soares fetal liver spleen INFLS; Human Cardiomyopathy, subtracted; Human Pituitary, subtracted; Aorta endothelial cells + TNF-a; Early Stage Human Lung, subtracted; Human Adult Heart, re-excision; Human adult small intestine, re-excision; Hepatocellular Tumor; Human Fetal Epithelium (Skin); Soares\_fetal\_heart\_NbHH19W; Stratagene neuroepithelium (#937231); Human Umbilical Vein Endothelial Cells, uninduced; Human Pancreas Tumor; Human Adipose; NCI\_CGAP\_Co3; NCI\_CGAP\_Lip2; Rejected Kidney, lib 4; Human Whole Six Week Old Embryo; Colon Tumor II; Human Placenta; human tonsils and Endothelial cells-control.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 93 as residues: Met-1 to Ala-6.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

5 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1904 of SEQ ID NO:45, b is an integer of 15 to 1918, where both a and b correspond to the positions of

10 nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 36**

It has been discovered that this gene is expressed primarily in the following

15 tissues/cDNA libraries: Prostate BPH.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

20 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1596 of SEQ ID NO:46, b is an integer of 15 to 1610, where both a and b correspond to the positions of

25 nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 37**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil3978240 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "rabkinesin6 [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```
>gi|3978240 (AF070672) rabkinesin6 [Homo sapiens] >sp|G3978240|G3978240
RABKINESIN6.
Length = 890
```

Plus Strand HSPs:

```
Score = 932 (328.1 bits), Expect = 6.3e-93, P = 6.3e-93
Identities = 184/196 (93%), Positives = 184/196 (93%), Frame = +3
```

```
Q: 9 KLQQCKAELNSTTEELHKYQKMLEPPPSAKPFTIDVDKKLEEGQKNIRLLRTELQKLGES 188
KLQQCKAELNSTTEELHKYQKMLEPPPSAKPFTIDVDKKLEEGQKNIRLLRTELQKLGES
S: 695 KLQQCKAELNSTTEELHKYQKMLEPPPSAKPFTIDVDKKLEEGQKNIRLLRTELQKLGES 754

Q: 189 LQSAERACCHSTGAGKLRQALTTCDDILIKDQTLAELQNNMVLVKLDLRKKAACIAEQY 368
LQSAERACCHSTGAGKLRQALTTCDDILIKDQTLAELQNNMVLVKLDLRKKAACIAEQY
S: 755 LQSAERACCHSTGAGKLRQALTTCDDILIKDQTLAELQNNMVLVKLDLRKKAACIAEQY 814

Q: 369 HTVLKLQGVSAKKRLGTXXXXXXXXXXXXGKKPFLRNLLPRTPTCQSSTDCSPYARILR 548
HTVLKLQGVSAKKRLGT GKKPFLRNLLPRTPTCQSSTDCSPYARILR
S: 815 HTVLKLQGVSAKKRLGTNQQPNQPPGKKPFLRNLLPRTPTCQSSTDCSPYARILR 874

Q: 549 SRRSPLLKSGPFGKKY 596
SRRSPLLKSGPFGKKY
S: 875 SRRSPLLKSGPFGKKY 890
```

The segment of gil3978240 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 145. Based on the structural similarity these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.



Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 146 which  
5 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Adult Testes, Large Inserts, Reexcision and to a lesser extent in NCI\_CGAP\_GCB1; Human adult testis, large inserts; Human Microvascular  
10 Endothelial Cells, fract. A; Soares fetal liver spleen 1NFLS; H. Lymph node breast Cancer; NCI\_CGAP\_Kid3; Human Thymus; Human Cerebellum; Human Epididymus; Amniotic Cells - Primary Culture; Soares\_NhHMPu\_S1; H. Meningima, M1; T-Cell PHA 16 hrs; NCI\_CGAP\_AA1; Soares\_senescent\_fibroblasts\_NbHSF; Soares\_fetal\_lung\_NbHL19W; Colon Tumor II;  
15 Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Nine Week Old Early Stage Human; Human Colon, differential expression; HBGB's differential consolidation; Human Colon Cancer, subtracted; Human epithelioid sarcoma; LNCAP untreated; Human OB HOS control fraction I; Human Neutrophils, Activated, re-excision; Smooth Muscle Serum Treated, Norm; H. Epididymus, caput & corpus; Soares retina N2b4HR; Human  
20 Adult Heart, re-excision; Human adult small intestine, re-excision; Hepatocellular Tumor; Stratagene NT2 neuronal precursor 937230; Human Adipose Tissue, re-excision; Human Osteosarcoma; Human endometrial stromal cells; Human Pituitary, subt IX; Fetal Liver, subtraction II; Breast Cancer Cell line, angiogenic; Human Fetal Kidney; Human Jurkat Membrane Bound Polysomes; Human Fetal Dura Mater;  
25 Human Primary Breast Cancer Reexcision; Human adult (K.Okubo); NCI\_CGAP\_Co3; NCI\_CGAP\_Co8; NCI\_CGAP\_Lu5; NCI\_CGAP\_Co12;

NCI\_CGAP\_Brn23; Human Adipose; Spinal cord; Human Rhabdomyosarcoma; Hemangiopericytoma; Soares breast 2NbHBst; Macrophage (GM-CSF treated); Human Liver, normal; Smooth muscle, serum induced, re-exc; Resting T-Cell Library, II; Adipocytes; H Macrophage (GM-CSF treated), re-excision; Human

5 Synovial Sarcoma; Human Fetal Lung III; Endothelial-induced; Activated T-Cell (12hs)/Thiouridine labelled Eco; Endothelial cells-control; Colon Normal III; Smooth muscle, control; T cell helper II; Keratinocyte; Human 8 Week Whole Embryo and Primary Dendritic Cells, lib 1.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.

10 95 as residues: Glu-3 to Phe-9, Gln-17 to Leu-50.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:47 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

15 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 865 of SEQ ID NO:47, b is an integer of 15 to 879, where both a and b correspond to the positions of

20 nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 38**

It has been discovered that this gene is expressed primarily in the following

25 tissues/cDNA libraries: NCI\_CGAP\_Pr22 and to a lesser extent in Amniotic Cells - TNF induced; Stratagene pancreas (#937208); Stratagene placenta (#937225);

Amniotic Cells - Primary Culture; Breast Cancer Cell line, angiogenic;  
NCI\_CGAP\_Co3; NCI\_CGAP\_GC4; NCI\_CGAP\_GCB1; Soares infant brain INIB;  
Normal Ovary, Premenopausal; LNCAP untreated; Human Primary Breast Cancer;  
Apoptotic T-cell, re-excision; H Female Bladder, Adult; Human endometrial stromal  
5 cells-treated with progesterone; Soares\_testis\_NHT; Spleen metastatic melanoma;  
NCI\_CGAP\_Br2; NCI\_CGAP\_Co9; NCI\_CGAP\_Lu1; NCI\_CGAP\_Kid3; Human  
Ovarian Cancer Reexcision; Pancreas Islet Cell Tumor; Normal colon; Bone marrow;  
Human Testes; Bone Marrow Cell Line (RS4,11); Osteoblasts; T cell helper II;  
Human Cerebellum and Primary Dendritic Cells, lib 1.

10 Preferred epitopes include those comprising a sequence shown in SEQ ID NO.  
96 as residues: Arg-31 to Gln-44.

Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:48 and may have been publicly available prior to conception of  
15 the present invention. Preferably, such related polynucleotides are specifically  
excluded from the scope of the present invention. To list every related sequence  
would be cumbersome. Accordingly, preferably excluded from the present invention  
are one or more polynucleotides comprising a nucleotide sequence described by the  
general formula of a-b, where a is any integer between 1 to 1316 of SEQ ID NO:48, b  
20 is an integer of 15 to 1330, where both a and b correspond to the positions of  
nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a  
+ 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 39**

25 It has been discovered that this gene is expressed primarily in the following  
tissues/cDNA libraries: Soares\_fetal\_heart\_NbHH19W and to a lesser extent in

Human Cerebellum; Soares\_NhHMPu\_S1; Human Adult Testes, Large Inserts, Reexcision; NCI\_CGAP\_Pr11; Osteoblasts; Soares\_pregnant\_uterus\_NbHPU; Soares fetal liver spleen INFLS; Pancreas Tumor PCA4 Tu; Human Hypothalamus, schizophrenia, re-excision; Human Adipose Tissue, re-excision;

5 Human Chronic Synovitis; human ovarian cancer; NCI\_CGAP\_AA1; Human umbilical vein endothelial cells, IL-4 induced; Spinal cord; Human Fetal Brain; Human Gall Bladder; Human Testes, Reexcision; Neutrophils IL-1 and LPS induced; Human Testes; HM1; NCI\_CGAP\_AA1; NCI\_CGAP\_Co9 and NCI\_CGAP\_Kid6.

Many polynucleotide sequences, such as EST sequences, are publicly

10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

15 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1086 of SEQ ID NO:49, b is an integer of 15 to 1100, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 40**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Apoptotic T-cell.

Many polynucleotide sequences, such as EST sequences, are publicly

25 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 876 of SEQ ID NO:50, b is an integer of 15 to 890, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

#### 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 41

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Testes and to a lesser extent in Soares\_testis\_NHT; Soares placenta Nb2HP; Morton Fetal Cochlea; Soares\_fetal\_heart\_NbHH19W; NCI\_CGAP\_GCB1; Human Fetal Lung III; Soares fetal liver spleen 1NFLS; Saos2 Cells, Vitamin D3 Treated; H Umbilical Vein Endothelial Cells, frac A, re-excision; Soares\_multiple\_sclerosis\_2NbHMSP; Human Cerebellum, subtracted; H. Atrophic Endometrium; Human Skin Tumor; Human Pineal Gland; Human Umbilical Vein, Endo. remake; Human Frontal Cortex, Schizophrenia; Human Ovary; Clontech human aorta polyA+ mRNA (#6572); NCI\_CGAP\_Lu5; NCI\_CGAP\_Co10; Monocyte activated, re-excision; Stromal cell TF274; Human umbilical vein endothelial cells, IL-4 induced; Synovial Fibroblasts (control); Colon Tumor II; Normal colon; Human Neutrophil, Activated; Human Bone Marrow, treated; Bone Marrow Cell Line (RS4,11); Keratinocyte; and Nine Week Old Early Stage Human.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO. 99 as residues: Ser-29 to Phe-34.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1509 of SEQ ID NO:51, b is an integer of 15 to 1523, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 42

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnllPIDd1019861 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "unnamed protein product [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

```
>gnl|PID|d1019861 (AB000459) unnamed protein product [Homo sapiens]
      >sp|P78311|P78311 HYPOTHETICAL 135.9 KD PROTEIN.
>gnl|PID|d1032819
      (AB001563) RES4-22D [Homo sapiens] {SUB 147-808}
      Length = 1224
```

Plus Strand HSPs:

```
Score = 263 (92.6 bits), Expect = 9.6e-28, Sum P(4) = 9.6e-28
Identities = 63/162 (38%), Positives = 96/162 (59%), Frame = +3
```

5 Q: 1191 PGRWPQAARQGPRASQSRQLC\*GLEEGKPGEAGQDQVGLAVPKLRRRRRAAPGETGQARPR 1370  
     P R P    + P+A++ +       E K       D + +   K   R+       + +  
 S: 1059 PARRPT---EPPKATEGQSKPRAQTESKAKVV--DLMSITEQKREERKVNSNNNNKKQLN 1113  
  
 Q: 1371 HGPQEQESVQPPGPARP-----QSL-----PQGKGRSRRSRNKQ-EKPASSLDDVFLPK 1514  
     H   E+ +   P   P   P    Q+       PQ KG+++++ K+ ++   +S+DDVFLPK  
 S: 1114 HIKDEKSNPTPMEPTSPGEGHQQNSKLVLAESPQPKGKNKKKKKKGDRVNSIDDVFLPK 1173  
  
 10 Q: 1515 D--MDGVEMDETREVEYFKRFCLDSAKQTRQKVAVNWTNFSLKKT 1649  
     D   +D V+MDET+REVEYFKRFCLDSA+QTRQ+++NW+NFSLKK T  
 S: 1174 DIDLDSVMDETEREVEYFKRFCLDSARQTRQLSINWSNFSLKKAT 1220

The segment of gnlPIDId1019861 that is shown as "S" above is set out in the  
 15 sequence listing as SEQ ID NO. 147.

Preferred polypeptides of the invention comprise a polypeptide having the  
 amino acid sequence set out in the sequence listing as SEQ ID NO. 148 which  
 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a  
 sequence by the computer are, of course, removed).

20 It has been discovered that this gene is expressed primarily in the following  
 tissues/cDNA libraries: Soares\_total\_fetus\_Nb2HF8\_9w and to a lesser extent in  
 Human Testes Tumor; Soares placenta Nb2HP; Soares fetal liver spleen 1NFLS;  
 normalized infant brain cDNA; Stratagene NT2 neuronal precursor 937230; breast  
 lymph node CDNA library; Human Testes; HE6W; Kidney cancer; Human  
 25 Epididymus; pBMC stimulated w/ poly I/C; Soares\_NhHMPu\_S1; H Female Bladder,  
 Adult; LNCAP prostate cell line; Human Osteosarcoma; Myeloid Progenitor Cell  
 Line; H. Meningioma, M1; Human Manic Depression Tissue; L428; Apoptotic T-cell;  
 Human Activated T-Cells; Human Primary Breast Cancer Reexcision; Human  
 Pancreas Tumor; Human Ovarian Cancer Reexcision; Soares\_testis\_NHT;  
 30 Soares\_NFL\_T\_GBC\_S1; Soares\_pregnant\_uterus\_NbHPU;  
 Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Human Activated T-Cells, re-excision;  
 Human Testes Tumor, re-excision; Rejected Kidney, lib 4; NTERA2, control; Normal

colon; Human Placenta; Activated T-Cell (12hs)/Thiouridine labelledEco; Endothelial cells-control; Soares\_fetal\_lung\_NbHL19W; Human Microvascular Endothelial Cells, fract. A; Human Bone Marrow, treated; Keratinocyte; Human 8 Week Whole Embryo; Primary Dendritic Cells, lib 1 and Soares infant brain 1NIB.

5           Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
10 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2064 of SEQ ID NO:52, b is an integer of 15 to 2078, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a  
15 + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 43**

It has been discovered that this gene is expressed primarily in Neutrophils IL-1 and LPS induced.

20           Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
25 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the



general formula of a-b, where a is any integer between 1 to 889 of SEQ ID NO:53, b is an integer of 15 to 903, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 44

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

10 gil1710216 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "unknown [Homo sapiens]." A partial alignment demonstrating the observed homology is shown immediately below.

15 >gi|1710216 unknown [Homo sapiens] >sp|Q99770|Q99770 HYPOTHETICAL 15.4 KD  
PROTEIN.  
Length = 139

Minus Strand HSPs:

20

Score = 214 (75.3 bits), Expect = 8.7e-22, Sum P(2) = 8.7e-22  
Identities = 44/68 (64%), Positives = 48/68 (70%), Frame = -3

25

Q: 1081 EMESRCINRLECSGAISTHCNHLHLGLSNSPASASRVAGTTGARHHAQPTLVSLAETGFH 902  
E +S + RLECSG IS HCNL L G SNSPASASRVAGT G AQ V LAE GFH  
S: 54 ETQSHSVTRLECSGTISAHCNLCPLPGSSNSPASASRVAGTAGTCRRAQLIFVFLAEMGFH 113

Q: 901 HVGQAGLE 878  
HVG+ GL+

30

S: 114 HVGRDGLD 121

Score = 61 (21.5 bits), Expect = 8.7e-22, Sum P(2) = 8.7e-22  
Identities = 12/15 (80%), Positives = 12/15 (80%), Frame = -1

35

Q: 864 VIHQRPPKVLGLQA 820  
VIH PR PK LGLQA  
S: 125 VIHPPRSPKALGLQA 139

The segments of gil1710216 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 149 and SEQ ID NO. 151.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 150 and/or SEQ  
5 ID NO. 152 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in Apoptotic T-cell.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.  
10 102 as residues: Phe-25 to Gly-32.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
15 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1090 of SEQ ID NO:54, b is an integer of 15 to 1104, where both a and b correspond to the positions of  
20 nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 45**

It has been discovered that this gene is expressed primarily in the following  
25 tissues/cDNA libraries: Soares infant brain 1NIB; Human Pituitary, subt IX and to a

lesser extent in Weizmann Olfactory Epithelium; Human Epididymus;  
NCI\_CGAP\_GC4; NCI\_CGAP\_Kid3 and Soares fetal liver spleen INFLS.

Preferred epitopes include those comprising a sequence shown in SEQ ID NO.  
103 as residues: Met-1 to Pro-7.

5 Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:55 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
excluded from the scope of the present invention. To list every related sequence  
10 would be cumbersome. Accordingly, preferably excluded from the present invention  
are one or more polynucleotides comprising a nucleotide sequence described by the  
general formula of a-b, where a is any integer between 1 to 678 of SEQ ID NO:55, b  
is an integer of 15 to 692, where both a and b correspond to the positions of  
nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a  
15 + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 46**

It has been discovered that this gene is expressed primarily in Spleen, Chronic  
lymphocytic leukemia.

20 Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:56 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
excluded from the scope of the present invention. To list every related sequence  
25 would be cumbersome. Accordingly, preferably excluded from the present invention  
are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 775 of SEQ ID NO:56, b is an integer of 15 to 789, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

5

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 47

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

10 gnl|PID|e1347305 (all information available through the recited accession number is incorporated herein by reference) which is described therein as a *C. elegans* protein. A partial alignment demonstrating the observed homology is shown immediately below.

15 >gnl|PID|e1347305 cDNA EST yk472b5.3 comes from this gene; cDNA EST yk474a7.3 comes from this gene; cDNA EST yk472b5.5 comes from this gene; cDNA EST yk468c10.3 comes from this gene; cDNA EST yk468c10.5 comes from this gene; cDNA EST EMBL:C08329 comes from this>  
20 >sp|O62265|O62265 F57C2.5 PROTEIN.  
Length = 387

25

Plus Strand HSPs:

Score = 180 (63.4 bits), Expect = 2.1e-10, P = 2.1e-10  
Identities = 41/116 (35%), Positives = 63/116 (54%), Frame = +1

30

Q: 1 PRVRDNIRPSSGGYVWGMSTIRPNPGFSMLDFLSERPWIKRMIFKL----FSQETVMKF 168  
P + DNIR S G YWVG++ R S+LD L P I++ + + + + F  
S: 272 PGLPDNIRSSGRGTYWVGLTATRSATHPSLLDRLGSLPGIRQFLVDIVPGPYWKPLLGLF 331

35 Q: 169 VPRYSLVLELSDSGAFRRSLHDPDGLVATYISEVHEHDGHLVYLGSRSPFLCRLSL 336  
+S+++EL G RSLHD G S+V EH+GHLY+GSF ++ ++ L  
S: 332 KNPHSIIIELDSVGKIVRSLHDVDTGKHVGDASQVTEHNGHLYIGSFADHYIAKVKL 387

The segment of gnlIPIDle1347305 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 153.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 154 which  
 5 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Microvascular Endothelial Cells, fract. A and to a lesser extent in Soares infant brain 1NIB; Soares fetal liver spleen 1NFLS; Soares  
 10 breast 3NbHBst; Soares placenta Nb2HP; Adipocytes; Primary Dendritic cells, frac 2; Osteoblasts; Stratagene HeLa cell s3 937216; Stratagene colon (#937204); Human Gall Bladder; Smooth muscle, serum treated; Human Neutrophil, Activated; Soares retina N2b4HR; Soares adult brain N2b4HB55Y; NCI\_CGAP\_AA1; Human Uterine Cancer; Human Pancreas Tumor; Colon Tumor II; Human Placenta; Human Adult  
 15 Pulmonary, re-excision; Endothelial-induced; Activated T-Cell (12hs)/Thiouridine labelledEco; Human Amygdala; Soares\_NhHMPu\_S1; Activated T-cell(12h)/Thiouridine-re-excision; Nine Week Old Early Stage Human; Primary Dendritic Cells, lib 1; Human Umbilical Vein Endothelial cells, frac B, re-excision; H Umbilical Vein Endothelial Cells, frac A, re-excision; Stratagene colon HT29  
 20 (#937221); Human Prostate Cancer, Stage C fraction; LNCAP prostate cell line; Stratagene ovarian cancer (#937219); Prostate BPH; Soares\_testis\_NHT; Soares\_fetal\_heart\_NbHH19W; Human Bone Marrow, re-excision; NCI\_CGAP\_Co3; NCI\_CGAP\_Lu5; NCI\_CGAP\_Pr12; NCI\_CGAP\_Thy1; Stratagene fetal spleen (#937205); Stromal cell TF274; Human umbilical vein  
 25 endothelial cells, IL-4 induced; Spinal cord; Human Activated T-Cells, re-excision; NCI\_CGAP\_Lu5; Human Thymus; Macrophage (GM-CSF treated); Stratagene lung

(#937210); Fetal Heart; Human T-Cell Lymphoma; Human Eosinophils; Human Substantia Nigra; Soares\_pregnant\_uterus\_NbHPU; Soares melanocyte 2NbHM; Endothelial cells-control; Smooth muscle,control; Monocyte activated; Stratagene hNT neuron (#937233); Keratinocyte; Human 8 Week Whole Embryo; Human

5 Cerebellum; H. Striatum Depression, subt II; Brain pons; Soares ovary tumor NbHOT; Crohn's Disease; Human Hypothalamus, Alzheimer's; H. Adipose Tissue; Resting T-Cell; Frontal Lobe, Dementia; Human Fetal Brain; Human OB MG63 treated (10 nM E2) fraction I; Human (HCC) cell line liver (mouse) metastasis, remake; Human Placenta; Smooth muscle, control, re-excision; Smooth muscle-ILb

10 induced; Aorta endothelial cells + TNF-a; Human T-cell lymphoma,re-excision; HSA 172 Cells; Smooth Muscle- HASTE normalized; Human Pineal Gland; Messangial cell, frac 2; human corpus colosum; Human Whole Brain #2 - Oligo dT > 1.5Kb; Synovial hypoxia; Jurkat T-cell G1 phase; Synovial Fibroblasts (II1/TNF), subt; H. Lymph node breast Cancer; Human Infant Brain; Human Prostate; CD34 depleted

15 Buffy Coat (Cord Blood); NCI\_CGAP\_Br2; NCI\_CGAP\_Co9; NCI\_CGAP\_GC3; NCI\_CGAP\_GC4; NCI\_CGAP\_CNS1; NCI\_CGAP\_Co10; NCI\_CGAP\_Co12; NCI\_CGAP\_GCB1; NCI\_CGAP\_Kid3; NCI\_CGAP\_Pr22; NCI\_CGAP\_Sch1; Monocyte activated, re-excision; Human Fetal Kidney; Merkel Cells; Human Hypothalamus,Schizophrenia; Ulcerative Colitis; NCI\_CGAP\_Kid5;

20 Soares\_placenta\_8to9weeks\_2NbHP8to9W; Bone Marrow Stromal Cell, untreated; Human Adrenal Gland Tumor; Hepatocellular Tumor, re-excision; Stratagene liver (#937224); Macrophage-oxLDL, re-excision; H. Frontal cortex,epileptic,re-excision; Human Placenta; Human Testes Tumor; Human fetal heart, Lambda ZAP Express; Normal colon; Human Synovial Sarcoma; Human Bone Marrow, treated; Spleen,

25 Chronic lymphocytic leukemia; Human Testes; Human Endometrial Tumor; and Hodgkin's Lymphoma II.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:57 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1222 of SEQ ID NO:57, b is an integer of 15 to 1236, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 48**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Smooth Muscle- HASTE normalized; Synovial hypoxia-RSF subtracted and to a lesser extent in Human OB MG63 treated (10 nM E2) fraction I; Smooth muscle, IL1b induced; H. Meningioma, M1; Hemangiopericytoma; NCI\_CGAP\_Lu5; NCI\_CGAP\_Brn23; Pancreas Islet Cell Tumor; Brain frontal cortex; Human Fetal Heart and Nine Week Old Early Stage Human.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

general formula of a-b, where a is any integer between 1 to 1051 of SEQ ID NO:58, b is an integer of 15 to 1065, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:58, and where b is greater than or equal to a + 14.



Table 1

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HOUHQ36	203959 4/26/99	Uni-ZAP XR	11	979	1	979	376	376	59	1	41	42	53
2	HOUIG68	203959 4/26/99	Uni-ZAP XR	12	2952	1423	2569	1509	1509	60	1	16	17	18
3	HOUIG92	203959 4/26/99	Uni-ZAP XR	13	1117	1	1117	343	343	61	1	21	22	61
4	HSAZP90	203959 4/26/99	Uni-ZAP XR	14	1073	1	1073	136	136	62	1	30	31	48
5	HWLJN08	203959 4/26/99	pSport1	15	1030	1	1030	594	594	63	1	24	25	31

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
6	HSPAY90	203959 4/26/99	pSport1	16	1164	1	1164	190	190	64	1	29	30	49
7	HWHPU44	203959 4/26/99	pCMVSPORT 3.0	17	871	1	871	166	166	65	1	28	29	40
8	HWBFX16	203959 4/26/99	pCMVSPORT 3.0	18	1497	1	1497		267	66	1			3
9	HWACH06	203959 4/26/99	pCMVSPORT 3.0	19	1161	1	1161	318	318	67	1			15
10	HWACZ33	203959 4/26/99	pCMVSPORT 3.0	20	1462	1	1462		110	68	1	22	23	62
11	HOHEB48	203959 4/26/99	pCMVSPORT 2.0	21	1579	1	1579	126	126	69	1	22	23	23

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
12	HRADA42	203959 4/26/99	pCMVSPORT 3.0	22	1135	1	1135		122	70	1	24	25	44
13	HRADN25	203959 4/26/99	pCMVSPORT 3.0	23	1225	17	1206	198	198	71	1	23	24	65
14	HRADT25	203959 4/26/99	pCMVSPORT 3.0	24	1324	1	1324	233	233	72	1	28	29	63
15	HOHEC84	203959 4/26/99	pCMVSPORT 2.0	25	1782	1	1782	63	63	73	1	24	25	170
16	HRADU15	203959 4/26/99	pCMVSPORT 3.0	26	849	1	849	304	304	74	1	34	35	46
17	HWDAAG96	203959 4/26/99	pCMVSPORT 3.0	27	1147	300	1147	866	866	75	1	21	22	32

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
18	HWDAJ01	203959 4/26/99	pCMVSPORT 3.0	28	781	1	781	288	288	76	1			24
19	HDPPW82	203959 4/26/99	pCMVSPORT 3.0	29	552	1	552	395	395	77	1			29
20	HRLAT43	203959 4/26/99	ZAP Express	30	451	1	451	158	158	78	1			21
21	HMBSF85	203959 4/26/99	Uni-ZAP XR	31	1558	16	1542	105	105	79	1			28
22	HSHAG54	203959 4/26/99	Uni-ZAP XR	32	1501	20	1358		155	80	1	18	19	38
23	HCEMA08	203959 4/26/99	Uni-ZAP XR	33	1880	1	1880	37	37	81	1	22	23	60

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
24	HPRCF40	203959 4/26/99	Uni-ZAP XR	34	2904	2001	2882	2217	2217	82	1	28	29	34
25	HSREG42	203959 4/26/99	Uni-ZAP XR	35	2637	578	2282	730	730	83	1			27
26	HTLBF46	203959 4/26/99	Uni-ZAP XR	36	1260	1	1235	176	176	84	1	19	20	194
27	HODCZ32	203959 4/26/99	Uni-ZAP XR	37	927	1	927		248	85	1			10
28	HODDQ06	203959 4/26/99	Uni-ZAP XR	38	1874	583	1598		834	86	1	22	23	28
29	HTSET62	203959 4/26/99	pBluescript	39	1345	968	1345	1147	1147	87	1	15	16	17

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
30	HBIAU43	203959 4/26/99	Uni-ZAP XR	40	1246	1	1246	202	202	88	1	18	19	18
31	HT3BF49	203959 4/26/99	Uni-ZAP XR	41	2174	1	2174		306	89	1			4
32	HSRHB59	203959 4/26/99	Uni-ZAP XR	42	854	1	844	308	308	90	1	20	21	56
33	HRDDQ39	203959 4/26/99	Uni-ZAP XR	43	776	1	773		215	91	1	32	33	46
34	HSSEL28	203959 4/26/99	Uni-ZAP XR	44	1733	1	1733		166	92	1	18	19	27
35	HTOHG63	203959 4/26/99	Uni-ZAP XR	45	1918	773	1918	922	922	93	1	31	32	37

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
36	HPWBA36	203959 4/26/99	Uni-ZAP XR	46	1610	1	1609	83	94	1	23	24	24
37	HJPCH08	203959 4/26/99	Uni-ZAP XR	47	879	1	879	374	95	1	10	11	117
38	HOEBJ70	203959 4/26/99	Uni-ZAP XR	48	1330	1	1330	197	96	1	28	29	44
39	HOECB33	203959 4/26/99	Uni-ZAP XR	49	1100	1	1100	302	97	1			23
40	HTGAD74	203959 4/26/99	Uni-ZAP XR	50	890	7	890	311	98	1	17	18	23
41	HTEHU59	203959 4/26/99	Uni-ZAP XR	51	1523	1	1504	170	99	1	28	29	34

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
42	HTPDU17	203959 4/26/99	Uni-ZAP XR	52	2078	1	2078		52	100	1	18	19	33
43	HNHFE71	203959 4/26/99	Uni-ZAP XR	53	903	1	903	598	598	101	1	21	22	21
44	HTGAR21	203959 4/26/99	Uni-ZAP XR	54	1104	1	1104	97	97	102	1	23	24	34
45	HPTRL95	203959 4/26/99	pBluescript	55	692	1	692	149	149	103	1	32	33	37
46	HL YBL67	203959 4/26/99	pSport1	56	789	1	789	497	497	104	1			29
47	HUSIR70	203959 4/26/99	pSport1	57	1236	1	1236	281	281	105	1	23	24	26



Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
48	HSKXB14	203959 4/26/99	pBluescript	58	1065	244	1058	315	106	1	21	22	38

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is

identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted

translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods.

5 The predicted amino acid sequence can then be verified from such deposits.

Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

10 The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate  
15 sources of genomic material.

Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a  
20 deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

25 The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly

produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

#### Signal Sequences

The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretary leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.

In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty.

Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

**Polynucleotide and Polypeptide Variants**

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of these nucleic acid molecules (e.g., those fragments described herein).

Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence



shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95%  
5 "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95%  
10 identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified  
15 as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best  
20 overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by  
25 converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to

calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

5           If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent  
10 identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using  
15 the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

20           For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number  
25 of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly

matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject

sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10

5 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100  
10 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not  
15 matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter  
20 the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host  
25 (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See, Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500

nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

- 5 (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the  
10 protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic  
15 residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues,  
20 where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino  
25 acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory



sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

## **Polynucleotide and Polypeptide Fragments**

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in  
5 a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt,  
10 and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger  
15 or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the  
20 invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500,  
25 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the

complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini.

Preferably, these fragments encode a polypeptide which has biological activity. More

5 preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid  
10 sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments  
15 comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or  
20 smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the  
25 carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the

mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form.

Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete) polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a

polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

5           The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel

chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

5           In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope  
10 of the invention.

### **Epitopes and Antibodies**

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID  
15 NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses  
20 polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower  
25 stringency hybridization conditions defined supra.

The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross-reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies,

that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-2354.(1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a



carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or

5 intradermal injection of emulsions containing about 100  $\mu$ g of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid  
10 surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the  
15 polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof) resulting in chimeric polypeptides. Such fusion proteins  
20 may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4- polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the  
25 immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO

96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion desulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., J. Biochem., 5 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, 10 Proc. Natl. Acad. Sci. USA 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni<sup>2+</sup> 15 nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to 20 modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. 25 Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in

its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

#### Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM,

IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')<sub>2</sub>, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, sheep rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in  
5 contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in  
10 terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described  
15 herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%,  
20 less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific  
25 antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides

which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, or  $10^{-15}$  M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described

supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

5           The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as  
10   well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the  
15   receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res.  
20   58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al.,  
25   Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998);

Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entireties).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques,



including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone,

including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the

5 Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells, 10 for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

15 Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the 20 hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such 25 as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments).

F(ab')<sub>2</sub> fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies,

including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864-869 (1992); and Sawai et al., *AJRI* 34:26-34 (1995); and Better et al., *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entirety).

Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology* 203:46-88 (1991); Shu et al., *PNAS* 90:7995-7999 (1993); and Skerra et al., *Science* 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Gillies et al., (1989) *J. Immunol. Methods* 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve,

antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g.,  
5 Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP  
10 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods  
15 known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

20 Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the  
25 human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes.

The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified

5 embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the

10 immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human

15 antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.* 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825;

20 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

25 Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a

selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

#### Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the

nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., *BioTechniques* 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence  
5 encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is  
10 known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable  
15 to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

20 Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor,  
25 NY and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John



Wiley & Sons, NY, which are both incorporated by reference herein in their entireties ), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes

from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived  
5 from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423- 42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature  
10 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038- 1041 (1988)).

#### 15 Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

20 Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an  
25 antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the

antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be

5 used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or

10 light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or

15 light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain

20 thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the

25 antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently

purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the

generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region

E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the

5 ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate

10 transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g.,

15 cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which

20 possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell

25 line such as, for example, CRL7030 and Hs578Bst.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgp<sup>rt</sup>- or ap<sup>rt</sup>- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science

260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, 1993, *TIB TECH* 11(5):155-215); and hygromycin, which confers resistance to hygromycin (Santerre et al., *Gene* 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), *Current Protocols in Human Genetics*, John Wiley & Sons, NY (1994); Colberre-Garapin et al., *J. Mol. Biol.* 150:1 (1981), which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning*, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., *Mol. Cell. Biol.* 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, *Nature* 322:52 (1986); Kohler, *Proc. Natl. Acad. Sci.*



USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any  
5 method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or  
10 fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80,  
15 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be  
20 used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g.,  
25 Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS

89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entirety.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337- 11341(1992) (said references incorporated by reference in their entirety).

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins

consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., Nature 331:84-86 (1988). The polypeptides of the present invention fused or conjugated to an antibody having

5 disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A

10 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to

15 identify antagonists of hIL-5. (See, Bennett et al., J. Molecular Recognition 8:52-58 (1995); Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the

20 tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which

25 corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given

5 treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable

10 substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish

15 peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material

20 includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$  or  $^{99}\text{Tc}$ .

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or

25 a radioactive metal ion, e.g., alpha-emitters such as, for example,  $^{213}\text{Bi}$ . A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include

paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- $\alpha$ , TNF- $\beta$ , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"),

granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

### Immunophenotyping

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular  
5 marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and  
10 include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual  
15 disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

### 20 Assays For Antibody Binding

The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent  
25 assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays,

complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by  
5 reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1%  
10 Trasyolol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in  
15 SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding  
20 immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein  
25 sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-



fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g.,  $^{32}\text{P}$  or  $^{125}\text{I}$ ) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al,

eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g.,  $^3\text{H}$  or  $^{125}\text{I}$ ) in the presence of increasing amounts of an unlabeled second antibody.

### Therapeutic Uses

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment

and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC).

Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, and  $10^{-15}$  M.

#### Gene Therapy

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217

(1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY  
5 (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters  
10 operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue- specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the  
15 antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

20 Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

25 In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be

accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct  
5 injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see,  
10 e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for  
15 cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al.,  
20 Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral  
25 genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which

facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Kiem et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy.

Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Patent No.

5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection  
5 to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection,  
10 electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth.  
15 Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and  
20 expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be  
25 determined by one skilled in the art.



Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or Prophylactic Activity

The compounds or pharmaceutical compositions of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the

therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

#### Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)),

construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion  
5 or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route,  
10 including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical  
15 compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material,  
20 including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et  
25 al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein

and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, 5 *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and 10 Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose 15 (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic 20 acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating 25 with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g.,

Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such  
5 compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term  
10 "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline  
15 solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired,  
20 can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as  
25 pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable

pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation  
5 should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the  
10 composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the  
15 composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms.  
20 Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

25 The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant

expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. Diagnosis and Imaging

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect,

diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody



assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99}\text{Tc}$ ); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

5           One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which  
10           specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that  
15           detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

20           It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially  
25           accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of

Radiolabeled Antibodies and Their Fragments.” (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In

yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI). Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified  
5 antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present  
10 invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

15 In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically  
20 immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide  
25 antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by  
5 binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of  
10 the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

15 In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of  
20 bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

25 The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip

sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group.

- 5 Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting  
10 surface-bound anti-antigen antibody.

### **Fusion Proteins**

Any polypeptide of the present invention can be used to generate fusion  
15 proteins. For example, the polypeptide of the present invention, when fused to a second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present  
20 invention can be used as targeting molecules once fused to other proteins.

Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

25 Moreover, fusion proteins may also be engineered to improve characteristics of the polypeptide of the present invention. For instance, a region of additional amino

acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final  
5 preparation of the polypeptide. The addition of peptide moieties to facilitate handling of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any  
10 combination thereof, including both entire domains and portions thereof), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian  
15 immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).)

Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem.  
270:3958-3964 (1995).)

20 Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively,  
25 deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if

the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)

Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

#### **Vectors, Host Cells, and Protein Production**

The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells (e.g., *Saccharomyces cerevisiae* or *Pichia pastoris* (ATCC Accession No. 201178)); insect cells such as *Drosophila* S2 and *Spodoptera Sf9* cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A,



pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech, Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical

synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A main step in the methanol metabolism pathway is the oxidation of methanol to formaldehyde using O<sub>2</sub>. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O<sub>2</sub>. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., *et al.*, *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., *et al.*, *Yeast* 5:167-77 (1989); Tschopp, J.F., *et al.*, *Nucl. Acids Res.* 15:3859-76 (1987).

Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1* regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

5 In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOX1*  
10 promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily  
15 appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like, including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be  
20 achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and  
25 immortalized host cells of vertebrate origin, particularly mammalian origin, that have

been engineered to delete or replace endogenous genetic material (e.g., coding sequence), and/or to include genetic material (e.g., heterologous polynucleotide sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid,  $\gamma$ -Abu,  $\epsilon$ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-

amino acids, designer amino acids such as D-methyl amino acids, L-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH<sub>4</sub>; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random

positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between  
5 about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or  
10 lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those  
15 skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated  
20 polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for  
25 therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.

One may specifically desire proteins chemically modified at the N-terminus.

Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein

5 (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules.

10 Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl  
15 group containing polymer is achieved.

The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, *Therapeutics*) containing them. In specific  
20 embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers.

As used herein, the term homomer, refers to a multimer containing only polypeptides  
25 corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and

fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another  
5 specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (*e.g.*, containing polypeptides having identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptides having identical and/or different amino acid sequences). In additional  
10 embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the  
15 invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example,  
20 liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the  
25 invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the



invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence ( e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one

5 instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the  
10 heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as  
15 described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another  
20 embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

25 Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper

polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different

5 proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide

10 sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are

15 those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

20 In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-

25 Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent  
5 Number 5,478,925, which is herein incorporated by reference in its entirety).

Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by  
10 reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally,  
15 techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic  
20 engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are  
25 generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic

polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described  
5 herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

10

#### Uses of the Polynucleotides

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

15

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

20

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids  
25 containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and

one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.

- 5 First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide  
10 and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

- Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using  
15 polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

- Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the  
20 present invention in cells or body fluid from an individual and comparing the measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

- In still another embodiment, the invention includes a kit for analyzing samples  
25 for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe

containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand  
5 containing a 31' mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present  
10 invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the  
15 polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard  
20 being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

25 By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the

polypeptide of the present invention or mRNA. As indicated, biological samples include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine, thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose



derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, *Science* 254, 1497 (1991); and M. Egholm, O. Buchardt, L.Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, *Nature* 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ( $T_{sub.m}$ ) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)).

5 Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., supra) It is likely that mutated or altered expression of specific genes is  
10 involved in the pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia  
15 cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb  
20 proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of  
25 hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. *Neurochem.* 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., *Nucleic Acids Research* 6: 3073 (1979); Cooney et al., *Science* 241: 456 (1988); and Dervan et al., *Science* 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., *Nucl. Acids Res.* 6:3073 (1979); Cooney et al., *Science* 241:456 (1988); and Dervan et al., *Science* 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J. *Neurochem.* 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more  
5 restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

10 The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a  
15 unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological  
20 samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR  
25 Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an

identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

#### **Uses of the Polypeptides**

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene

expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein.

In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging:

The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds.,  
Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells  
5 or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a  
10 predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

15 Moreover, polypeptides of the present invention can be used to treat, prevent, and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair  
20 proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune  
25 response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can  
5 activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also  
10 be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

### 15 Gene Therapy Methods

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present invention. This  
20 method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

25 Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a



polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Belldegrün et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J.

5 Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are  
10 arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver,  
15 and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry  
20 into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and  
25 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; 5 pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of polynucleotide sequence of the invention. Suitable promoters 10 include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoA1 promoter; human globin promoters; viral thymidine kinase promoters, 15 such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the 20 polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, 25 spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye,

gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic acid* sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

5       The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant  
10   invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA ,  
15   84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

20       Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially  
25   available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to

produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred.

- 5 The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology*, 101:512-527 (1983), which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated.
- 10 SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and
- 15 then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include  $\text{Ca}^{2+}$ -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta*, 394:483 (1975); Wilson et al., *Cell*, 17:77 (1979)); ether injection (Deamer et al., *Biochim. Biophys. Acta*, 443:629 (1976); Ostro et al., *Biochem. Biophys. Res. Commun.*, 76:836 (1977); Fraley et al., *Proc. Natl. Acad. Sci. USA*, 76:3348 (1979)); detergent dialysis (Enoch et al., *Proc. Natl. Acad. Sci. USA*, 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., *J. Biol. Chem.*, 255:10431 (1980);
- 25 Szoka et al., *Proc. Natl. Acad. Sci. USA*, 75:145 (1978); Schaefer-Ridder et al., *Science*, 215:166 (1982)), which are herein incorporated by reference.

Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ration will be from about 5:1 to about 1:5. More preferably, the ration will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports  
5 on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622,  
10 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding  
15 polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

20 The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy , 1:5-14 (1990), which is incorporated herein by  
25 reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation,

the use of liposomes, and  $\text{CaPO}_4$  precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which  
5 include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotides of the invention contained in an adenovirus vector. Adenovirus can  
10 be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for  
15 many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science, 252:431-434 (1991); Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt  
20 to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA, 76:6606 (1979)).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993); Rosenfeld et al., Cell, 68:143-155 (1992); Engelhardt et al., Human Genet. Ther.,  
25 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein



incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express E1a and E1b, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other  
5 varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of  
10 infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*,  
15 using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is  
20 limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell  
25 integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found

in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper  
5 viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention. These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its  
10 genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO  
15 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

20 Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting  
25 sequence will be sufficiently near the 5' end of the desired endogenous

polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR.

Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

10 The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, 15 topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The 20 promoter then drives the expression of the endogenous sequence.

The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor 25 alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth

factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein.

5 Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

10 Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available  
15 depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the  
20 rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries.

Administration of a composition locally within the area of arteries refers to injecting  
25 the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue  
5 inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a  
10 particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad.  
15 Sci. USA , 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a  
20 polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise  
25 condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of

polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and  
5 birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

### **Biological Activities**

The polynucleotides or polypeptides, or agonists or antagonists of the present  
10 invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

15

### **Immune Activity**

The polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of the immune system, by activating or inhibiting the proliferation,  
20 differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer or some autoimmune diseases,  
25 disorders, and/or conditions, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present

invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. A polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, DiGeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies), blood platelet diseases, disorders, and/or conditions (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used

to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be useful in treating, preventing, and/or diagnosing autoimmune diseases, disorders, and/or conditions. Many autoimmune diseases, disorders, and/or conditions result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune diseases, disorders, and/or conditions.

Examples of autoimmune diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed or detected by the present invention include, but are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the



present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to treat, prevent, and/or diagnose organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide or agonists or antagonist may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat, prevent, and/or diagnose inflammatory conditions, both chronic and acute conditions, including chronic prostatitis, granulomatous prostatitis and malacoplakia, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

## **Hyperproliferative Disorders**

A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or  
5 indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating,  
10 differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases,  
15 disorders, and/or conditions, such as a chemotherapeutic agent.

Examples of hyperproliferative diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver,  
20 pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or  
25 agonists or antagonists of the present invention. Examples of such hyperproliferative diseases, disorders, and/or conditions include, but are not limited to:

hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

5           One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

          Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally  
10   proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

          Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals comprising administration of one or more active gene copies of the present invention  
15   to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to  
20   be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating  
25   cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule,

chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said  
5 external stimulus.

Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the  
10 destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in  
15 the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature  
20 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating  
25 and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in

the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to

5 abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at

10 the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

15 Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as

20 decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

25 The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a

mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may  
5 be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the  
10 antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

15 In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing cell proliferative and/or differentiation diseases, disorders, and/or conditions as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

20 The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or  
25 neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and

therapy of diseases, disorders, and/or conditions related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those  
5 with a dissociation constant or  $K_d$  less than  $5 \times 10^{-6}M$ ,  $10^{-6}M$ ,  $5 \times 10^{-7}M$ ,  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ , and  $10^{-15}M$ .

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in  
10 combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference).

15 Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments  
20 thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related  
25 apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference).

Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.



Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and  
5 immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

### **Cardiovascular Disorders**

Polynucleotides or polypeptides, or agonists or antagonists of the invention  
10 may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders, and/or conditions, including peripheral artery disease, such as limb ischemia.

Cardiovascular diseases, disorders, and/or conditions include cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and  
15 Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such  
20 as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

Cardiovascular diseases, disorders, and/or conditions also include heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac  
25 arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular

hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease,  
5 rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial  
10 block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic  
15 junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

Heart valve disease include aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve  
20 insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

Myocardial diseases include alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy,  
25 endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

Myocardial ischemias include coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, 5 angiodyplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, 10 erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, 15 vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, 20 carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral 25 arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis,

Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

5            Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

10           Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura,  
15           allergic cutaneous vasculitis, and Wegener's granulomatosis.

            Polynucleotides or polypeptides, or agonists or antagonists of the invention, are especially effective for the treatment of critical limb ischemia and coronary disease.

            Polypeptides may be administered using any method known in the art,  
20           including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the  
25           art. Polypeptides of the invention may be administered as part of a *Therapeutic*,

described in more detail below. Methods of delivering polynucleotides of the invention are described in more detail herein.

### Anti-Angiogenesis Activity

5           The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive  
10           processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization  
15           including solid tumor growth and metastases, arthritis, some types of eye diseases, disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-  
20           203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

25           The present invention provides for treatment of diseases, disorders, and/or conditions associated with neovascularization by administration of the

polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers

5 described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, Medicine, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating, preventing, and/or diagnosing an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide,

10 polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat or prevent a cancer or tumor. Cancers which may be treated, prevented, and/or diagnosed with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors,

15 including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example,

20 polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example,

25 intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a

catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

Polynucleotides, polypeptides, antagonists and/or agonists may be useful in  
5 treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions, besides cancers, which involve angiogenesis. These diseases, disorders, and/or conditions include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy,  
10 retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial  
15 angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided  
20 for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar  
25 or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result

in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating, preventing, and/or

5 diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the  
10 polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris  
15 neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalm.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalm.* 22:291-312 (1978).

Thus, within one aspect of the present invention methods are provided for treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step  
20 of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it  
25 also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of



diseases, disorders, and/or conditions can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause),  
5 toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in  
10 eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-  
15 angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent  
20 complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing  
25 front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the

cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such

5 methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for

10 treating or preventing neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other

15 embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating or preventing proliferative diabetic retinopathy, comprising the step of

20 administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the

25 vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should

be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating or preventing retrolental fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist  
5 and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or  
10 agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

Moreover, diseases, disorders, and/or conditions and/or states, which can be  
15 treated, prevented, and/or diagnosed with the the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas; and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example,  
20 diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals,  
25 arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophilic joints, angiofibroma

fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (Rochele minalia quintosa), ulcers (Helicobacter pylori),

5 Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or  
10 agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch  
15 granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal  
20 surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti- angiogenic  
25 compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the

invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

5           Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic  
10   compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied  
15   after hepatic resections for malignancy, and after neurosurgical operations.

          Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may  
20   be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

          The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors.

Representative examples of other anti-angiogenic factors include: Anti-Invasive  
25   Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator

Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan  
5 Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin;  
10 Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum;  
15 alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolimidazole; and metalloproteinase inhibitors such as BB94.

20

#### **Diseases at the Cellular Level**

Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as  
25 follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer,

melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic



cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

- 10 Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or
- 15 prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as
- 20 that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

### **Wound Healing and Epithelial Cell Proliferation**

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, for therapeutic purposes, for example, to stimulate  
5 epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds.

Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye  
10 tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and  
15 antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and  
20 to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepdermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft,  
25 epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-

Thiersch graft, omentoplastic graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the appearance of aged skin.

5           It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as  
10   sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

15           The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or  
20   polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

          The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial  
25   thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The

polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or

5 agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly.

Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large

10 intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production

15 of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat diseases associate with the under expression of the polynucleotides of the invention.

20 Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to

25 prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from

smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention.

Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins known in the art).

In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

## **Neurological Diseases**

Nervous system diseases, disorders, and/or conditions, which can be treated, prevented, and/or diagnosed with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases, disorders, and/or conditions which

5 result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or diagnosed in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1)

10 ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of

15 the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex

20 virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6)

25 lesions associated with nutritional diseases, disorders, and/or conditions, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic

acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus

5 erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive  
10 multifocal leukoencephalopathy, and central pontine myelinolysis.

In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with

15 cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell  
20 injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke.

In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell

25 injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, *e.g.*, choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci. 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, *e.g.*, weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous



system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motor-sensory Neuropathy (Charcot-Marie-Tooth Disease).

### **Infectious Disease**

A polypeptide or polynucleotide and/or agonist or antagonist of the present invention can be used to treat, prevent, and/or diagnose infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated, prevented, and/or diagnosed. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polypeptide or polynucleotide and/or agonist or antagonist of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae),

Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a

5 variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox,

10 hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or

15 antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or

20 agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to,

25 include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., Corynebacterium,

Mycobacterium, Norcardia), Cryptococcus neoformans, Aspergillosis, Bacillaceae  
 (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia  
 (e.g., Borrelia burgdorferi), Brucellosis, Candidiasis, Campylobacter,  
 Coccidioidomycosis, Cryptococcosis, Dermatocycoses, E. coli (e.g., Enterotoxigenic  
 5 E. coli and Enterohemorrhagic E. coli), Enterobacteriaceae (Klebsiella, Salmonella  
 (e.g., Salmonella typhi, and Salmonella paratyphi), Serratia, Yersinia), Erysipelothrix,  
 Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales,  
 Mycobacterium leprae, Vibrio cholerae, Neisseriaceae (e.g., Acinetobacter,  
 Gonorrhea, Meningococcal), Meisseria meningitidis, Pasteurellacea Infections (e.g.,  
 10 Actinobacillus, Heamophilus (e.g., Heamophilus influenza type B), Pasteurella),  
 Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, Shigella spp.,  
 Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g.,  
 Streptococcus pneumoniae and Group B Streptococcus). These bacterial or fungal  
 families can cause the following diseases or symptoms, including, but not limited to:  
 15 bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis),  
 gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia,  
 prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as  
 Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease,  
 Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea,  
 20 meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy,  
 Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo,  
 Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g.,  
 cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections.  
 Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used  
 25 to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific  
 embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention

are used to treat, prevent, and/or diagnose: tetanus, Diphtheria, botulism, and/or meningitis type B.

Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

Preferably, treatment or prevention using a polypeptide or polynucleotide and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

25

### **Regeneration**

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated, prevented, and/or diagnosed include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide and/or agonist or antagonist of the present invention to proliferate and differentiate nerve cells. Diseases that could be treated, prevented, and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or

conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, 5 Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated, prevented, and/or diagnosed using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

### **Chemotaxis**

10 A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then 15 fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection, hyperproliferative diseases, disorders, and/or conditions, or any immune system 20 disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat, prevent, and/or diagnose wounds.

25 It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules

could also be used to treat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the present invention could be used as an inhibitor of chemotaxis.

5

### **Binding Activity**

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit  
10 (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural  
15 or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

20 Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially  
25 containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

5        Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a  
10        standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

15        Additionally, the receptor to which a polypeptide of the invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for  
20        example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides  
25        can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.



Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

5           As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein  
10   microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be  
15   employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, S. Trends Biotechnol. 16(2):76-82 (1998); Hansson, L. O., et al., J. Mol.  
20   Biol. 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. Biotechniques 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide  
25   sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the

invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and  $^3\text{H}$  thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the

compound to determine if the compound stimulates proliferation by determining the uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of 3[H] thymidine. Both agonist and antagonist compounds may be identified by this  
5 procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured.

10 Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase,  
15 ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays  
20 can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the  
25 invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a

biological activity , and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, any combination or all of contained in the polypeptide sequences of the invention. Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

### **Targeted Delivery**

In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention

(including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

### **Drug Screening**

Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which  
5 modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by  
10 using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids  
15 expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

Thus, the present invention provides methods of screening for drugs or any  
20 other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically  
25 labeled. Following incubation, free agent is separated from that present in bound

form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

#### Antisense And Ribozyme (Antagonists)

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered

(see, for example, O'Connor, *Neurochem.*, 56:560 (1991). *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988).

Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, *Neurochem.*, 56:560 (1991); *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., *Nucleic Acids Research*, 6:3073 (1979); Cooney et al., *Science*, 241:456 (1988); and Dervan et al., *Science*, 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed in vitro by incubating cells with the oligoribonucleotide.

A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl<sub>2</sub>, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense



RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or  
5 a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA.

Such vectors can be constructed by recombinant DNA technology methods standard  
10 in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early  
15 promoter region (Bernoist and Chambon, *Nature*, 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster et al., *Nature*, 296:39-42 (1982)), etc.

20 The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA,  
25 forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation

may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be).

- 5 One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

- Oligonucleotides that are complementary to the 5' end of the message, *e.g.*, the 5' untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non- translated, non-coding regions of a polynucleotide sequence of the invention could be used in an antisense approach to inhibit translation of endogenous mRNA.
- 10 Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six
- 20 nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

- The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-
- 25 stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization,

etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556 (1989); Lemaitre et al., Proc. Natl. Acad. Sci., 84:648-652 (1987); PCT Publication

- 5 NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., BioTechniques, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, Pharm. Res., 5:539-549 (1988)). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide,
- 10 hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine,

15 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil,

20 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v),

25 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least  
5 one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric  
10 oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)). The oligonucleotide is a 2-O-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett.  
15 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al.  
20 (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated  
25 region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5' -UG-3' . The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo.

DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since

ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic  
5 cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular  
10 cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirable in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

15 The antagonist/agonist may also be employed to treat, prevent, and/or diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with  
20 overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

invention, and/or (b) a ribozyme directed to the polynucleotide of the present  
25 invention.

### Other Activities

The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as

5 thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells  
10 of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's  
15 disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

The polypeptide of the present invention may be also be employed to prevent  
20 skin aging due to sunburn by stimulating keratinocyte growth.

The polypeptide of the invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone  
25 marrow cells when used in combination with other cytokines.

The polypeptide of the invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues.

The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

5

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

10 The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing,  
15 utilization, and storage of energy.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive diseases, disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive  
20 capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins,  
25 minerals, cofactors or other nutritional components.



**Other Preferred Embodiments**

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide  
5 sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3'  
10 Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3'  
15 Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the  
20 nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a  
5 nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

10 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic  
15 acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1,  
20 which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous  
25 nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA

Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said  
5 step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

A further preferred embodiment is a method for identifying the species, tissue  
10 or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by  
15 a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a  
20 nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted  
25 protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any,

comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA

5 Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least  
10 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said  
15 panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA  
20 clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

25 Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of

positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence  
5 at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

10 Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino  
15 acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted  
20 protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the  
25 amino acid sequence of the secreted portion of the protein encoded by a human cDNA

clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained

in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining whether the sequence of said polypeptide molecule in said sample is  
5 at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide  
10 comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit  
15 with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a  
20 biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted  
25 protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in



Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y

wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

- 5           Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

- Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino  
10   acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

- Further preferred is a method of making a recombinant vector comprising  
15   inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

- Also preferred is a method of making an isolated polypeptide comprising  
20   culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of  
25   SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and

said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 2, preferably excluded are one or more polynucleotides comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 2 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 2. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences referred to in the fifth column of Table 2. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a

representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 2

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
1	HOUHQ36	11	793750	AA149938, AA150524
2	HOUIG68	12	793749	H84655, H85188, N54034, N66224, N98296, AA001551, AA000974, AA035249, AA035250, AA035143, AA037630, AA040701, AA043165, AA086078, AA429077
3	HOUIG92	13	793764	R21508, R21610, R28152, R28153, R40440, R49431, R49431, R40440, R63091, R66491, R67328, R71330, R71331, H09259, H18093, H18133, H21766, H21961, H43941, H45286, H45361, H46412, H46652, R86886, R86967, R89156, N22061, N22589, N23349, N32779, N45208, N68346, N71622, N71660, N72910, W02847, W02901, W04681, W35294, W42922, W42921, W57933, W86193, W86320, W93526, AA002134, AA002089, AA010120, AA010119, AA013486, AA026546, AA026547, AA029870, AA029318, AA034261, AA063540, AA114912, AA114911, AA151787, AA460988
5	HWLJN08	15	800626	T78326, T78708, R28029, R28145, R96685, N80272, N94975, W67311, AA035216, AA148610
9	HWACH06	19	799620	T82022
11	HOHEB48	21	800629	H61078
13	HRADN25	23	800628	T91307, R09748, R09749, T84887, H06700, H06750, H15344, H15722, H18813, H20195, H20386, H30571, H41770, H50235, H64022, H64785, AA025560, AA025704, AA081540, AA084391
17	HWDAG96	27	796743	T59706, R48614, R75634, R75737, H26572, H26579, H87499, H90425, H90481, H91724, H99937, N35146, N35702, N42132, N43897, N47153, N47236, N47235, N78941, W17023, W32796, W52525, W52932, W57987, W58071, W84756, W84761, N89629, AA063253, AA070136, AA070135, AA088478, AA088477, AA126430, AA126574, AA132550, AA132673, AA143423, AA143424, AA147068, AA147126, AA157980, AA158426, AA179882, AA180279, AA181820, AA186626, AA186916, AA430427, AA428243
21	HMBSF85	31	843047	T91111, R20575, R60127, H17174, N26046, AA128049, AA133901, AA423892, AA423950, AA428623, AA279805, AA282854, AA283632, AA483283, AA502773, AA502933, AA743427,

				AA811159, AA814840, AA832201, AA866184, AA939190, AA961803, AI016017, AA293639, AA292922, AA402228, AA599493, AA448182, AA703754, AA774411, Z38216, Z46110
22	HSAG54	32	834781	H29679, H69544, H69556, H71113, H71900, H91324, H91428, N26318, N76002, W04421, AA115136, AA126302, AA188567, AA233448, AA229153, AA483565, AA557418, AA588530, AA587665, AA640326, AA765418, AA888693, AA902652, AA977652, AA977657, AA206361, AA204872, AA649753
24	HPRCF40	34	834808	R21203, R22817, R38326, R39650, R48554, R54000, R59102, R59103, R77464, R77563, R84852, R86225, R86224, R92960, R98711, R98935, H64896, H64897, H66175, H66174, H72726, H82743, H83618, H85264, H84927, H86386, H86552, H86547, H86635, H86640, N46930, N69536, N71952, N77699, N99687, W00822, AA017282, AA020768, AA031914, AA032025, AA047451, AA047508, AA056300, AA083799, AA113340, AA112637, AA764956, AA768433, AA805651, AA825450, AA830217, AA917319, AA911023, D79918, N84068, C01333, AA020767
25	HSREG42	35	839481	T54461, T69976, T92956, T93022, T94048, T94798, T98172, T98173, R36584, R75810, R75809, H01012, H01758, R84542, H49173, W04807, W19187, W42499, W42650, W86533, AA025420, AA029866, AA029313, AA083184, AA083299, AA085855, AA085633, AA101407, AA101439, AA113267, AA113413, AA152247, AA152257, AA155912, AA155941, AA164857, AA166680, AA179761, AA180337, AA187246, AA187378, AA190681, AA190829, AA191263, AA196125, AA196274, AA227254, AA242739, AA242813, AA242840, AA252153, AA461165, AA461339, AA455307, AA555181, AA565674, AA588198, AA588209, AA614456, AA639852, AA834225, AA923800, AA961813, AI081054, N55866, D83862, AA642345, AA206017, AA216443, AA242879, AA242948, AA248351, AA248840, AA450105, AA450170, AA488403, AA486286, AA489307, AA489491, AA495727, AA653390, AA669825, AA678601, AA716174, AA723217, AA775586, AA775800, AA852329, AA993392, AI040375, AI083602, AI085783, AI090590, AI092729, AI092999, AI093294, D31085
26	HTLBF46	36	839774	R53414, H15748, H28161, H39591, N24530, N33969, W72567, W76561, AA564691, AA887297, AA937142, AA961641, AI050849, W23209, C20566, AA421327, AA478441, AA770094, AI028147, AI028709
28	HODDQ06	38	834824	W25389, AA737663, AA740847, AA768652, AA830977, AA651780
29	HTSET62	39	833692	T88820, T91787, R48660, R52245, R52246, R54924, R54997, R69509, R74341, R74437,

				H43023, H43024, H97902, W48752, W48753, W72347, W73996, AA046103, AA045998, AA180237, AA180855, AA573239, C00267
35	HTOHG63	45	834832	T86650, R48242, R48339, R48387, R64270, R68234, R68527, R81433, R81636, H71729, AA025362, AA069927, AA502578, AA514289, AA025351
48	HSKXB14	58	834517	AA931794, A1096761

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.

- 10 Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being
- 15 isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSport 2.0	pCMVSport 2.0
25	pCMVSport 3.0	pCMVSport 3.0
	pCR®2.1	pCR®2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention



does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional  
5 plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample  
10 may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ  
15 ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ - $\gamma$ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular  
20 Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection  
25 agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for

bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the  
5 SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and  
the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the  
desired cDNA using the deposited cDNA plasmid as a template. The polymerase  
chain reaction is carried out under routine conditions, for instance, in 25 ul of reaction  
mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is  
10 1.5-5 mM MgCl<sub>2</sub>, 0.01% (w/v) gelatin, 20 uM each of dATP, dCTP, dGTP, dTTP, 25  
pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR  
(denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation  
at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated  
thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and  
15 the DNA band with expected molecular weight is excised and purified. The PCR  
product is verified to be the selected sequence by subcloning and sequencing the  
DNA product.

Several methods are available for the identification of the 5' or 3' non-coding  
portions of a gene which may not be present in the deposited clone. These methods  
20 include but are not limited to, filter probing, clone enrichment using specific probes,  
and protocols similar or identical to 5' and 3' "RACE" protocols which are well  
known in the art. For instance, a method similar to 5' RACE is available for  
generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et  
al., *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

25 Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a  
population of RNA presumably containing full-length gene RNA transcripts. A

primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

- 5           This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order
- 10   to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

- This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is
- 15   used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

20   **Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

          A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

25   **Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P<sup>32</sup> using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

#### **Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose

gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

**Example 5: Bacterial Expression of a Polypeptide**

5           A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product  
10 into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>r</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning  
15 sites.

          The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which  
20 expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

          Clones containing the desired constructs are grown overnight (O/N) in liquid  
25 culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The

cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

5           Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from  
10   QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

          Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then  
15   washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

          The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-  
20   NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50  
25   mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains:

- 5 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

- 10 DNA can be inserted into the pHEa by restricting the vector with *NdeI* and *XbaI*, *BamHI*, *XhoI*, or *Asp718*, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for *NdeI* (5' primer) and *XbaI*, *BamHI*, *XhoI*, or  
15 *Asp718* (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

20 **Example 6: Purification of a Polypeptide from an Inclusion Body**

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

- 25 Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield

of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

5           The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

10           The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

          Following high speed centrifugation (30,000 xg) to remove insoluble particles,  
15           the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

          To clarify the refolded polypeptide solution, a previously prepared tangential  
20           filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a  
25           stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.



Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are  
5 equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the  
10 polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS  
15 contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

### **Example 7: Cloning and Expression of a Polypeptide in a Baculovirus**

#### **Expression System**

20 In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40")  
25 is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak

Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

5 Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-  
10 39 (1989).

Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does  
15 not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

20 The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

The plasmid is digested with the corresponding restriction enzymes and  
25 optionally, can be dephosphorylated using calf intestinal phosphatase, using routine

procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue

5 (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

10 Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a  
15 microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is  
20 then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life  
25 Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of

a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then  
5 resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's  
10 medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5  
15 uCi of  $^{35}\text{S}$ -methionine and 5 uCi  $^{35}\text{S}$ -cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of  
20 purified protein may be used to determine the amino terminal sequence of the produced protein.

#### **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which  
25 mediates the initiation of transcription of mRNA, a protein coding sequence, and

signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long  
5 terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden),  
10 pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human HeLa, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

15 Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the  
20 encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker  
25 is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers,

the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

- 5 Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g.,  
10 with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

- Specifically, the plasmid pC6, for example, is digested with appropriate  
15 restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

- A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide.  
20 Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

- The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1%  
25 agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five  $\mu$ g of the expression plasmid pC6 a pC4 is cotransfected with 0.5  $\mu$ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1  $\mu$ M, 2  $\mu$ M, 5  $\mu$ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200  $\mu$ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

#### **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG

domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)



Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAACTCACACATGCCCACCGTGC  
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA  
5 CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT  
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG  
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA  
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT  
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA  
10 ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC  
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG  
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT  
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT  
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG  
15 GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA  
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG  
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

**Example 10: Production of an Antibody from a Polypeptide**

20 The antibodies of the present invention can be prepared by a variety of  
methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells  
expressing a polypeptide of the present invention is administered to an animal to  
induce the production of sera containing polyclonal antibodies. In a preferred  
method, a preparation of the secreted protein is prepared and purified to render it  
25 substantially free of natural contaminants. Such a preparation is then introduced into  
an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., *Nature* 256:495 (1975); Köhler et al., *Eur. J. Immunol.* 6:511 (1976); Köhler et al., *Eur. J.*

5 *Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's  
10 modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the  
15 present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which  
20 secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with  
25 this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells,

and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of  
5 further protein-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub>  
10 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced  
15 using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson  
20 et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

**Example 11: Production Of Secreted Protein For High-Throughput Screening Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution  
5 (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered  
10 Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x  
15 Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods  
20 described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be  
25 transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates  
 5 off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in  
 10 DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of  $\text{CaCl}_2$  (anhyd); 0.00130 mg/L  $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ ; 0.050 mg/L of  $\text{Fe}(\text{NO}_3)_3 \cdot 9\text{H}_2\text{O}$ ; 0.417 mg/L of  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ ; 311.80 mg/L of KCl; 28.64 mg/L of  $\text{MgCl}_2$ ; 48.84 mg/L of  $\text{MgSO}_4$ ; 6995.50 mg/L of NaCl; 2400.0 mg/L of  $\text{NaHCO}_3$ ; 62.50 mg/L of  $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ ; 71.02 mg/L of  $\text{Na}_2\text{HPO}_4$ ; .4320 mg/L of  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ ; .002 mg/L of Arachidonic Acid ; 1.022 mg/L  
 15 of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml  
 20 of L-Asparagine- $\text{H}_2\text{O}$ ; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL- $\text{H}_2\text{O}$ ; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL- $\text{H}_2\text{O}$ ; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0  
 25 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2 $\text{H}_2\text{O}$ ; 99.65 mg/ml of L-

Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and  
5 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed  
10 with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end  
15 of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants  
20 from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the  
25 invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

**Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class I, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b)

Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn  
5 activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines  
10 are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.



305

	<u>Ligand</u>		<u>JAKs</u>		<u>STATS</u>	<u>GAS(elements) or ISRE</u>	
		<u>tyk2</u>	<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
	<u>IFN family</u>						
5	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	Il-10	+	?	?	-	1,3	
	<u>gp130 family</u>						
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	Il-11(Pleiotrophic)	?	+	?	?	1,3	
	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)	?	+	+	?	1,3	
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
	<u>g-C family</u>						
	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
20	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
	IL-15	?	+	?	+	5	GAS
25	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
	GM-CSF (myeloid)	-	-	+	-	5	GAS
30	<u>Growth hormone family</u>						
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
	EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
35	<u>Receptor Tyrosine Kinases</u>						
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	

306

CSF-1	?	+	+	-	1,3	GAS (not IRF1)
-------	---	---	---	---	-----	----------------

To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

10 5':GCGCCTCGAGATTTCCTCGAAATCTAGATTTCCTCGAAATGATTTCCTCGAAATGATTTCCTCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

15 PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

20 5':CTCGAGATTTCCTCGAAATCTAGATTTCCTCGAAATGATTTCCTCGAAATGATTTCCTCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCT  
25 AGGCTTTTGGCAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and 16. However, many other promoters can be substituted using the protocols described in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-

2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

5 **Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP  
10 activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate  
15 stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMRIE-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing  
20 concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in  
25 RPMI + 10% serum with 1%Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life

Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final  
5 concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with  
10 supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being  
15 screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100,000 cells per well).

20 After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

25 The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul

samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve  
5 as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as,  
10 stable transfected cells, which would be apparent to those of skill in the art.

#### **Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells.

15 Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct  
20 produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

25 Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM

KCl, 375  $\mu$ M  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 1 mM  $\text{MgCl}_2$ , and 675  $\mu$ M  $\text{CaCl}_2$ . Incubate at 37 degrees C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

- 5        The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400  $\mu$ g/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400  $\mu$ g/ml G418 for couple of passages.

These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described  
10    growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200  $\mu$ l cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).

Add 50  $\mu$ l of the supernatant prepared by the protocol described in Example 11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate U937 cells. Over 30 fold  
15    induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

**Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

When cells undergo differentiation and proliferation, a group of genes are  
20    activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

Particularly, the following protocol is used to assess neuronal activity in PC12  
25    cell lines. PC12 cells (rat pheochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl



phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).

The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

5           The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

10           5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1  
15 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

20           PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and  
25 resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

#### **Example 16: High-Throughput Screening Assay for T-cell Activity**

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of

apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded,  
5 causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants  
10 produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based  
15 strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC  
20 TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in  
25 the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)

Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5' : CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCCATCTGCCATCTCAATTA  
GTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTC  
TCCGCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCTCGGCCCTCTGAGCTATT  
CCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCCTTTTGCAAAAAGCTT:3' (SEQ ID  
NO:10)

10           Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes SalI and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with SalI and NotI.

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

## 25 Example 17: Assay for SEAP Activity

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the

following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

**Reaction Buffer Formulation:**

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5
21	115	5.75
22	120	6
23	125	6.25
24	130	6.5

25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

---

**Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to  $2-5 \times 10^6$  cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to  $1 \times 10^6$  cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4

second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an extracellular signaling event which has resulted in an increase in the intracellular  $\text{Ca}^{++}$  concentration.

5

**Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

15       Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, 20       members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the 25       following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.



Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr  
5 with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of  
10 cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

15 To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM  
20 HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane  
25 bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on

ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4 degrees C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many  
5 methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include  
10 PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2+</sub> (5mM  
15 ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

20 The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20 min. This allows the streptavidin coated 96 well plate to associate with the  
25 biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times.

Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of tyrosine kinase activity.

10 **Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

As a potential alternative and/or compliment to the assay of protein tyrosine kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase, Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any

of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

**Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for 30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and

translocations. These alterations are used as a diagnostic marker for an associated disease.

**Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a**

**5 Biological Sample**

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbounded polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbounded conjugate.

25 Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room

temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale). Interpolate the concentration of the polypeptide in the sample using the standard  
5 curve.

### **Example 23: Formulation**

The invention also provides methods of treatment and/or prevention diseases, disorders, and/or conditions (such as, for example, any one or more of the diseases or  
10 disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

15 The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus  
20 determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about 1ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01  
25 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a

dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray.

"Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials



(for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al.,  
5 Biopolymers 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., J. Biomed. Mater. Res. 15:167-277 (1981), and Langer, Chem. Tech. 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., Id.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

Sustained-release Therapeutics also include liposomally entrapped  
10 Therapeutics of the invention (*see* generally, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)). Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang  
15 et al., Proc. Natl. Acad. Sci.(USA) 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the  
20 optimal Therapeutic.

In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see* Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)).

25 Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both.

Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

5           Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

10           Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by  
15           reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

          The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or  
20           biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

          The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the  
25           Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG,

and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to,

- 5 Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B,
- 10 whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic
- 15 mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

- The Therapeutics of the invention may be administered alone or in
- 20 combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either
- 25 concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are

administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors.

Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™

5 (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to,  
10 CRIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

15 In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™,  
20 RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICLOVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™  
25 (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention

are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

5 In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin,  
10 erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are  
15 not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may  
20 be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™ (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucocorticosteroids, and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone  
25 marrow transplantation.



In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™,

5 IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™.

In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are  
10 administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives,  
15 pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

20 In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-  
25 FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU,

lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephallen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

10 In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered  
15 with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4,  
20 IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

25 In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may

be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as  
5 disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as  
10 disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in  
15 International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are incorporated herein by reference herein.

20 In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

25 In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth

Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

**Example 24: Method of Treating Decreased Levels of the Polypeptide**

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 23.

**Example 25: Method of Treating Increased Levels of the Polypeptide**

The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and  
5 antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally  
10 increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided in Example 23.

15 **Example 26: Method of Treatment Using Gene Therapy-Ex Vivo**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of  
20 a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C  
25 for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long  
5 terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set  
10 forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is  
15 maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+am12 packaging cells are grown in tissue  
20 culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

25 Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media,

containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media.

5 If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

10 The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

**Example 27: Gene Therapy Using Endogenous Genes Corresponding To  
Polynucleotides of the Invention**

15 Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650,  
20 published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting  
25 sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be

sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends.

- 5 Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

- 10 The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol  
15 precipitation.

- In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are  
20 known in the art.

- Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the polynucleotide in the cell. Expression may be detected by immunological staining, or  
25 any other method known in the art.



Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining  
5 cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub> HPO<sub>4</sub>, 6 mM dextrose). The cells are recentrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains  
10 approximately  $3 \times 10^6$  cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with  
15 HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3'end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and the  
20 fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap  
25 (Bio-Rad). The final DNA concentration is generally at least 120  $\mu\text{g/ml}$ . 0.5 ml of the cell suspension (containing approximately  $1.5 \times 10^6$  cells) is then added to the cuvette,

and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960  $\mu$ F and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

#### **Example 28: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622,

5705151, 5580859; Tabata et al., *Cardiovasc. Res.* 35(3):470-479 (1997); Chao et al., *Pharmacol. Res.* 35(6):517-522 (1997); Wolff, *Neuromuscul. Disord.* 7(5):314-318 (1997); Schwartz et al., *Gene Ther.* 3(5):405-411 (1996); Tsurumi et al., *Circulation* 94(12):3281-3290 (1996) (incorporated herein by reference).

5           The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

10           The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in  
15   Felgner P.L. et al. (1995) *Ann. NY Acad. Sci.* 772:126-139 and Abdallah B. et al. (1995) *Biol. Cell* 85(1):1-7) which can be prepared by methods well known to those skilled in the art.

          The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain  
20   sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to  
25   provide production of the desired polypeptide for periods of up to six months.

          The polynucleotide construct can be delivered to the interstitial space of

tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an

aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

**Example 29: Transgenic Animals.**

The polypeptides of the invention can also be expressed in transgenic animals.

Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters,

5 guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

10 Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology  
15 (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the  
20 polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229  
25 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-  
5 813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or  
10 head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When  
15 it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the  
20 nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent  
25 to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA  
5 expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies  
10 specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate  
15 lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to  
20 produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of  
25 polypeptides of the present invention, studying diseases, disorders, and/or conditions



associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

**Example 30: Knock-Out Animals.**

5           Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson et al., *Cell* 5:313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional  
10   polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express  
15   polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas &  
20   Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

          In further embodiments of the invention, cells that are genetically engineered  
25   to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are

administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing

for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and “knock-out” animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

#### **Example 31: Production of an Antibody**

##### **a) Hybridoma Technology**

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing polypeptide(s) of the invention are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of polypeptide(s) of the invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for polypeptide(s) of the invention are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with polypeptide(s) of the invention or, more preferably, with a secreted polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10

g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100  $\mu$ g/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide(s) of the invention.

Alternatively, additional antibodies capable of binding to polypeptide(s) of the invention can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by polypeptide(s) of the invention. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and are used to immunize an animal to induce formation of further protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214

(1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

5

b) Isolation Of Antibody Fragments Directed Against  
Polypeptide(s) From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against polypeptide(s) of the invention to which the donor may or may not have been exposed (see e.g., U.S. Patent 10 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library.

A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, 15 approximately 10<sup>9</sup> E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10<sup>8</sup> TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 20 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 ug/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage 25 does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III

particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10<sup>13</sup> transducing units/ml (ampicillin-resistant clones).

#### Panning of the Library.

Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10<sup>13</sup> TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection.

This process is then repeated for a total of 4 rounds of affinity purification with tube-

washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

#### Characterization of Binders.

Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

#### 15 **Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation**

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-

superfamily. Within this family CD40, CD27, and CD30 along with their respective ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added  $10^5$  B-cells suspended in culture medium (RPMI 1640 containing 10% FBS,  $5 \times 10^{-5}$ M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and  $10^{-5}$  dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse



(1uCi/well) with 3H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

**Example 33: T Cell Proliferation Assay**

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of  $^3\text{H}$ -thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100  $\mu\text{l}$ /well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control mAb (B33.1) overnight at 4 degrees C (1  $\mu\text{g}/\text{ml}$  in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells ( $5 \times 10^4/\text{well}$ ) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of polypeptides of the invention (total volume 200  $\mu\text{l}$ ). Relevant protein buffer and medium alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100  $\mu\text{l}$  of supernatant is removed and stored  $-20$  degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100  $\mu\text{l}$  of medium containing 0.5  $\mu\text{Ci}$  of  $^3\text{H}$ -thymidine and cultured at 37 degrees C for 18-24 hr. Wells are harvested and incorporation of  $^3\text{H}$ -thymidine used as a measure of proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of polypeptides of the invention.

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

**Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells**

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- $\alpha$ , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC $\gamma$ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

**Effect on the production of cytokines.** Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to measure the IL-12 release as follows. Dendritic cells ( $10^6$ /ml) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for

IL-12 content using commercial ELISA kit (e.g., R & D Systems (Minneapolis, MN)).

The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules.

- 5 Three major families of cell surface antigens can be identified on monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with
- 10 improved monocyte cytotoxic activity, cytokine release and phagocytosis.

- FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal
- 15 antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

- Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or
- 20 alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American
- 25 Red Cross, Baltimore, MD) by centrifugation through a Histopaque gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of  $2 \times 10^6$ /ml in PBS containing PI at a final concentration of 5  $\mu$ g/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA fragmentation in this experimental paradigm.

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of  $5 \times 10^5$  cells/ml with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g., R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at  $2 \times 10^5$  cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20  $\mu$ l 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of H<sub>2</sub>O<sub>2</sub> produced by the macrophages, a standard curve of a H<sub>2</sub>O<sub>2</sub> solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

### **Example 35: Biological Effects of Polypeptides of the Invention**

#### **Astrocyte and Neuronal Assays:**

Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

#### Fibroblast and endothelial cell assays

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE<sub>2</sub> assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or

without IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for PGE<sub>2</sub> by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

#### Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP<sup>+</sup>) and released. Subsequently, MPP<sup>+</sup> is actively accumulated in dopaminergic neurons by the high-affinity reuptake transporter for dopamine. MPP<sup>+</sup> is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989).



Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J. Neuroscience, 1990).

5           Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic  
10 neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm<sup>2</sup> on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde  
15 after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

          Since the dopaminergic neurons are isolated from animals at gestation day 14, a  
20 developmental time which is past the stage when the dopaminergic precursor cells are proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

25           The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to

test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 36: The Effect of Polypeptides of the Invention on the Growth of**

**5 Vascular Endothelial Cells**

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at  $2.5 \times 10^4$  cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16 units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8  
10 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the  
15 invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20

**Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells**

For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was  
25 performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000

cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight. After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF<sub>165</sub> or a polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al.* *In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell**

##### **Proliferation Stimulatory Effect**

HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6 mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for

individual cells by the concomitant use of bright field illumination and dark field-UV fluorescent illumination. See, Hayashida et al., J. Biol. Chem. 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 39: Stimulation of Endothelial Migration**

This example will be used to explore the possibility that a polypeptide of the invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 um (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25 ul of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber,  $2.5 \times 10^5$  cells suspended in 50 ul M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO<sub>2</sub> to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by

counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.


The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells**

Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of  $\text{KNO}_2$  (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and  $\text{H}_2\text{SO}_4$ . The specificity of the Iso-NO electrode to NO is previously determined by

measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C.

5 The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions.

S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per  $1 \times 10^6$  endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See,

10 Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

15

**Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis**

Another step in angiogenesis is cord formation, marked by differentiation of endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

20

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 µl/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then

25

replaced with 300 mg Cell Applications' Chord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control. b-esteradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also utilized as a control.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane**

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese quail (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old quail embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cellotape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the

inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

5           The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### 10   **Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse**

*In vivo* angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After  
15   7 days, the solid "plug" of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold  
20   3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde,  
25   embedded in paraffin and used to produce sections for histological examination after



staining with Masson's Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

5        The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### 10    **Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al.* *Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al.* *J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these

rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

10           The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.

#### **Example 45: Effect of Polypeptides of the Invention on Vasodilation**

15           Since dilation of vascular endothelium is important in reducing blood pressure, the ability of polypeptides of the invention to affect the blood pressure in spontaneously hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900 mg/kg) of the polypeptides of the invention are administered to 13-14 week old spontaneously hypertensive rats (SHR). Data are expressed as the mean +/- SEM.

20           Statistical analysis are performed with a paired t-test and statistical significance is defined as  $p < 0.05$  vs. the response to buffer alone.

          The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

25

**Example 46: Rat Ischemic Skin Flap Model**

The evaluation parameters include skin blood flow, skin temperature, and factor VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of polypeptides of the invention, during the skin ischemia, is studied using in situ

5 hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- b) Ischemic skin wounds
- c) Normal wounds

10 The experimental protocol includes:

a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).

b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).

c) Topical treatment with a polypeptide of the invention of the excisional wounds  
15 (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.

d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
20 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 47: Peripheral Arterial Disease Model**

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

- a) One side of the femoral artery is ligated to create ischemic muscle of  
5 the hindlimb, the other side of hindlimb serves as a control.
- b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.
- c) The ischemic muscle tissue is collected after ligation of the femoral  
10 artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
15 test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 48: Ischemic Myocardial Disease Model**

20 A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

- a) The heart is exposed through a left-side thoracotomy in the rat. Immediately,  
25 the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.

c) Thirty days after the surgery, the heart is removed and cross-sectioned  
5 for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10

#### **Example 49: Rat Corneal Wound Healing Model**

This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

15 a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.

b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.

c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).

20 d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.

e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the  
25 invention. However, one skilled in the art could easily modify the exemplified studies to

test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing**

**5 Models**

***A. Diabetic db+/db+ Mouse Model.***

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is dependent on formation of granulation tissue and re-epithelialization rather than contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

15 The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria.

20 Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration

25 abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*,

*Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model  
5 may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study.

10 Animals are individually housed and received food and water ad libitum. All manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

15 Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and  
20 iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to  
25 treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the



healing process and the morphologic appearance of the repaired skin is altered by treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

### ***B. Steroid Impaired Rat Model***

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahlet *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular

permeability (Ebert *et al.*, *An. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors*. 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", *In: Antiinflammatory Steroid Action: Basic and Clinical Aspects*, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth Factors*. 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", *In: Antiinflammatory Steroid Action: Basic and Clinical Aspects*, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).

To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

The wounding protocol is followed according to section A, above. On the day of wounding, animals are anesthetized with an intramuscular injection of ketamine (50

mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8).

The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch.

Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

5

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the healing process and the morphologic appearance of the repaired skin is improved by treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

10

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

15

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

20

#### **Example 51: Lymphadema Animal Model**

The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and

25

histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

Prior to beginning surgery, blood sample is drawn for protein concentration analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital.

- 5 Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's
- 10 Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

- Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are used to dissect and separate the skin flaps. After locating the femoral vessels, the
- 15 lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

- Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are
- 20 then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

- Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving
- 25 a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and  $\text{Ca}^{2+}$  comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for tissue collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

5           The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10   **Example 52: Suppression of TNF alpha-induced adhesion molecule expression by a Polypeptide of the Invention**

          The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both  
15   normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local vasculature and  
20   extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

          Tumor necrosis factor alpha (TNF-a), a potent proinflammatory cytokine, is a stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of  
25   inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- $\alpha$  induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- $\alpha$  treated ECs when co-stimulated with a member of the FGF family of proteins.

- 5           To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO<sub>2</sub>. HUVECs are seeded in 96-well plates at concentrations of  $1 \times 10^4$  cells/well in EGM
- 10           medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

- 15           Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90  $\mu$ l of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are
- 20           aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca<sup>++</sup> and Mg<sup>++</sup>) is added to each well. Plates are held at 4°C for 30 min.

- Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10  $\mu$ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-
- 25           1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution



of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

Then add 20  $\mu$ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with

- 5 PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100  $\mu$ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer:  $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$ . 5  $\mu$ l of each dilution is added to triplicate wells and the resulting AP content in each well is
- 10 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100  $\mu$ l of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50  $\mu$ l of 3M NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [
- 15 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

- The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the
- 20 invention.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

- 25 The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other

disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

395

Applicant's or agent's file reference number	P5547PCT	International application No.	UNASSIGNED
---	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>81</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 26 April 1999	Accession Number 203959
C. ADDITIONAL INDICATIONS (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input type="checkbox"/></span>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
Europe  In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC).	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

<p style="text-align: center;">For receiving Office use only</p> <p><input type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer</p>	<p style="text-align: center;">For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
---	--

**ATCC Deposit No. 203959****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: 203959**

## **DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

## **SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

## **NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

***What Is Claimed Is:***

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group

5 consisting of:

(a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

10 (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;

(e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,  
20 having biological activity;

(f) a polynucleotide which is a variant of SEQ ID NO:X;

(g) a polynucleotide which is an allelic variant of SEQ ID NO:X;

(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;

(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

5

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

10

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

15

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

20

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

25

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

5 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

10 10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence  
15 included in ATCC Deposit No:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

20 (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in  
25 ATCC Deposit No:Z;

(g) a variant of SEQ ID NO:Y;



(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

10 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

20 17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

25 18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

5

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

10 (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

15 (a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

20

22. A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

25 (c) detecting an activity in a biological assay; and

(d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

<120> 48 Human Secreted Proteins

<130> PS547PCT

<140> Unassigned

<141> 2000-04-06

<150> 60/128,701

<151> 1999-04-09

<150> 60/177,166

<151> 2000-01-20

<160> 154

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

gggatccgga	gcccaaattct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccagcacctg	60
aattcgaggg	tgacaccgtca	gtcttcctct	tcccccaaaa	acccaaggac	accctcatga	120
tctcccgga	tcctgaggtc	acatgcgtgg	tggtggacgt	aagccacgaa	gaccctgagg	180
tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	aagccgcggg	240
aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	caccaggact	300
ggctgaatgg	caaggagtac	aagtgcgaag	tctccaacaa	agccctccca	accccatcgc	360
agaaaacat	ctccaaagcc	aaagggcagc	cccagagaacc	acaggtgtac	accctgcccc	420
catcccgga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	aaaggcttct	480
atccaagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccggagAAC	aactacaaga	540
ccacgcctcc	cgtgctggac	tccgacggct	ccttcttcct	ctacagcaag	ctcaccgtgg	600
acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	gaggctctgc	660
acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaatgagtg	cgacggccgc	720
gactctagag	gat					733

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 2

Trp Ser Xaa Trp Ser

1 5

&lt;210&gt; 3

&lt;211&gt; 86

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 3

gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60  
cccgaatat ctgccatctc aattag 86

&lt;210&gt; 4

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 4

gcggcaagct ttttgcaaag cctaggc 27

&lt;210&gt; 5

&lt;211&gt; 271

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 5

ctcgagattt cccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60  
aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120  
gccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat 180  
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240  
ttttggaggc ctaggctttt gcaaaaagct t 271

&lt;210&gt; 6

&lt;211&gt; 32

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 6

gcgctcgagg gatgacagcg atagaacccc gg 32

&lt;210&gt; 7

&lt;211&gt; 31

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<400> 7  
gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8  
<211> 12  
<212> DNA  
<213> Homo sapiens

<400> 8  
ggggactttc cc 12

<210> 9  
<211> 73  
<212> DNA  
<213> Homo sapiens

<400> 9  
gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60  
ccatctcaat tag 73

<210> 10  
<211> 256  
<212> DNA  
<213> Homo sapiens

<400> 10  
ctcgagggga ctttcccggg gaatttccgg ggactttccg ggactttcca tctgccatct 60  
caattagtca gcaaccatag tcccggccct aactccgccc atcccgcccc taactccgcc 120  
cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180  
ggcgcctcgc gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240  
cttttgcaaa aagctt 256

<210> 11  
<211> 979  
<212> DNA  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (9)  
<223> n equals a,t,g, or c

<220>  
<221> SITE  
<222> (23)  
<223> n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (976)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 11

gaactcccnt	gaacaaattc	tnagctcca	ccgcggtggc	ggccgctcta	gaactagtgg	60
atcccccg	ctgcaggaat	tcggcacgag	gtaaattcca	aaaaaattcc	taaaagaaat	120
gttcccgtgc	ccctgccacc	ctcactcact	aggaatgcaa	caatgcattg	gacaggagg	180
tctcggcaat	cggtttggga	cccacactgt	ctaggaaaga	aacttctggt	ttccatgtgc	240
tgactgagca	acaacccctt	ggaagaaatc	cttgaaaaac	tgggatgttc	tatggaggga	300
agctactcat	gagttgtgta	acttaggcaa	aggcattcac	cttttctgag	actcagtttt	360
cttcttatca	ataaaatgga	gctaacaata	ggcaccttca	gaattatgat	gattaattgg	420
ctcgtgtttt	ctcaacactg	tcaattgttc	ttgaggtcac	tattgttacc	cctacttcta	480
tgcacccacc	atgtatgcat	ggaatgtgct	agaaggggaa	gaggtagtgg	gaggtgatcc	540
tggggcaaat	acagctaaga	cctcccccca	tcctacatgc	actcattctt	ctctttcctc	600
tgktagtctg	gaaggggttg	gggctgttgg	aagaaaagga	acataaagca	gagagaagga	660
tgcagtgagg	gtgtctggga	ctgttggcag	gcarcagtcg	ggtttggggg	ctacagggct	720
ctgcaattga	ggaagccaga	ggtggatgaa	gagttggcca	cacctctccc	ctaaagctgc	780
agaatcttct	gactataaaa	agagctggtg	cattcagaat	cctctacaac	cagtccttcc	840
cctgaccttc	ccagaagctt	cgaaccctca	gtgctgagct	gccaagacga	gctgggtgac	900
taacatagcc	attctccagt	ttggggatgt	cagaatgtcc	accccttccc	cacktctggg	960
ggcggaccga	acccgngcg					979

&lt;210&gt; 12

&lt;211&gt; 2952

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1145)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 12

atttacagag	acaactgaag	taaggaaaac	taaaatcaga	aatggaatat	cattttacaat	60
ttgggatcga	tggaccgtac	atggaaaaga	agatttcacc	ctcttggatt	tcataaatgc	120
agtcaaagag	aagtatggaa	ttgagccaac	aatggtggta	cagggagtca	aaatgcttta	180
tgttcctgta	atgcctggtc	atgcaaaaag	attgaagtta	acaatgcata	aacttgtaaa	240
acctactact	gaaaagaaat	atgtggatct	tactgtgtca	tttgctccag	acattgatgg	300
agatgaagat	ttgccgggac	ctccagtaag	atactacttc	agtcatgaca	ctgattaata	360
caagtgtgtc	taacgttact	ccaggaccac	ttgattttgg	gaaagagtgc	acttaattca	420
gaagctaaag	aaaatcagtt	cataatacta	tggattttct	tttcattaag	ccttaatttt	480
aagggaaca	tcagtaagaa	actgcactga	agaattataa	aacatttttg	ggcatagcat	540
acacttgtct	aacggttcac	acgtggctat	gatcacaaag	aactttgaac	tggaatgctr	600
tttacaaaag	ttttgtgtat	taatctgtgt	attaatctct	ctggataaaa	agaaggaaaa	660
aatatgtatg	accagaacag	atatggatga	agaaattgaa	agcaacgaat	gcaactattc	720
aaaaagttta	attttatgaa	tttctttttt	gtttagtctt	gaagactgat	tttctatgca	780
aatagtgttt	ggcatcctgc	acctctgata	tgattttggc	ttgagattta	taccatggga	840
agaatatgta	tggtggatga	aggtggatat	tttaaatgtg	gcagttacag	tttactgtcc	900

tattacctct	gctcgtttaa	ccagtttggt	atatcactgt	gtcccaaaa	tcaggatttt	960
tggtgatagc	atcagtgttg	taggagcaat	aggtcagatg	agacatatta	acttagacta	1020
aacgtgaaca	gtattatatg	gactctcaca	acgctcttag	agaatccgtg	aatgtgaaca	1080
gacaaatgtg	gctaaccatt	tgattcttca	gtatgccttc	taatgtggct	attttattta	1140
tgtgnagact	ctaaacctga	ttgtccta	atataaaact	aaaagatttt	gtaaagggag	1200
tgctcttaga	aatagatgaa	atgtagaatg	ttaaaaatta	ttgctagggg	agtctttttt	1260
ttttccagaa	acctaattag	ggattataat	tttgtgtttt	ttttgttttt	tttttttaaa	1320
cagaagcatg	ttatttcatt	cccattccca	gaaagggagt	taatgaagat	aaaaatttat	1380
tttttaaggt	ctttattgag	agaaactttg	ttttctgata	tgaactattg	cagatgtttt	1440
tataaatact	ttcattaaaa	tgatgtaaac	agtagtacc	aacactgtaa	actcagttaa	1500
aatagtaaat	gattctttta	ttactaagac	tgtyatgcat	tctgaagcag	ttggcttttt	1560
tttaaccata	ggaagtcatt	tccctctagc	tccttccctt	ctactctcct	gctcagacca	1620
ttagtaggta	ctttgttaaa	taaaaaacta	gattaacatc	aatattactc	caatttggtta	1680
tcttttacac	tatgtattat	acctaacttt	tttttatttc	atttacaat	agtttaaat	1740
actttatcaa	ccagctgtat	tgtttccctc	ttgtaaaagt	accatcaagt	ggggaaaatg	1800
tatgtggaag	tgagagtgga	atttgtatga	ctaaaggata	atctgtacat	ggggaagtgg	1860
gcaaaagtgg	ataggatgaa	tttaaagaaa	atgactacct	ttggaaaaaa	gaaattaaat	1920
tttgttcaca	tatcctaccc	tttcccatgg	tgcatatccc	aagtgtcata	tttaaaacta	1980
aggttactta	aaacagaatc	caggaatatc	aaggctctgt	ggcttggaat	tttagaggat	2040
aggactaata	aaaggacttt	tgcaagaag	gcttttttcc	acgttcactt	tgttttgtgt	2100
tctttgaaag	taactgatac	ttttcgggta	gttaattcag	cagtccataa	atatgatcca	2160
gtaacttgct	tatatattat	tgaagtctcg	acagctcttc	agaagtaaat	ttagaacgat	2220
gctgtcagtt	catatttata	gatattagtg	ttttagcaga	taaaacaaaa	tcaacaaaaa	2280
ttaaagttcat	tttgtgatta	aacctgcaac	cattttttcca	ttactttttt	tctatagtta	2340
atgggttattg	ccatgatttc	ttctgtttgg	ttctactaag	ctagaaagcc	aggggtgaagt	2400
taatgataat	tcccattatt	ttatttctgt	accatgagat	tgctgttgat	gactgaaata	2460
ccagggtgcaa	aaattaatga	tttgattttt	gtacagtttc	aatgagtatt	ttttacttat	2520
taaaaataaa	ttaagaaatg	taagaatatc	tttgtaaata	atgtttcata	agttgactcc	2580
agagattctg	attttgctgt	ttattttgtg	agtaatgttg	ctttgggtgt	tcctgatttt	2640
caagtttgca	atcatggaga	tacagcagtt	attaggtgtg	gaaggacatt	acctcaaatg	2700
tcctcagatg	gctccaggaa	attcttttaa	aacagttgga	gagaaatagt	cgtgaccatg	2760
taaaacctag	aggatctggg	aaatcccata	ctactgggta	gggatttgta	aagtccattt	2820
cttttttagag	ttcaaagcag	ttctgttact	tgtccataag	ttcctcataa	attgtcccaa	2880
aggtaggaca	tggaataaaa	tgtatatctt	tattttttta	tctactatgt	cacactctgg	2940
tgatattcat	gg					2952

&lt;210&gt; 13

&lt;211&gt; 1117

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (35)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (36)

&lt;223&gt; n equals a,t,g, or c



&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1096)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1114)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 13

gggacttttt	actggtaaag	ctcacaaaag	ctggnngetc	caccgcggtg	gcggccgctc	60
tagaactagt	ggatcccccg	ggctgcagga	attcggcacg	aggagactat	cagcggcagc	120
attctccagg	gaagacccat	cccctagtgc	cagagcttgc	atcctggaga	ctaaagattg	180
cacttttttg	tagttttttg	tccaaatgca	atccccattc	tgtgcctctt	agcatgcagt	240
tagatttgga	caaacaagat	tcctaaggaa	tgactttatt	aactataata	tggttacagc	300
tattatataa	atatatatcc	tggttatagt	tctaatatgg	agatgttgtg	tgcaatgctg	360
gcctgtggtg	gtctgtgtaa	tgctttaact	tgtatggagg	aggccaggct	cagagctgag	420
atgtggcctg	aaccttcctt	gtatcgatcc	tttaatttag	aactgtcaag	atgtcacttt	480
ctccccctct	gccttttagt	ggtatctgac	atatactcaa	aacagtaatt	tcctggtcac	540
atcattaact	gctaattctg	tattttataa	gaattttcag	atggacatgt	acaaatttga	600
actcaaacca	tccccagtc	agatacagg	cagcgtgtag	gtgaccacac	cagagcctca	660
gcctcgggtc	ttctcagccg	tcgggatagg	atccaggcat	ttctttttaa	tctcagaggt	720
agcagtaaac	ttttcagtat	tgctgttagc	aagtgtgtgt	ttgccaatag	ataccatta	780
tactaatgtg	ccaagtaaat	gttcattgca	catctgcttc	cactgtgttc	ccacgggtgc	840
catgaagtgt	gtgaggagcc	cctcatctgg	agggatgagt	gctgcgttga	ctactgctat	900
caggattgtg	ttgtgtggaa	tattcatcta	cataaatttt	atatgcacag	taatttccct	960
ttttatatgt	caagtaacta	tttgtaaaag	ttatactcac	aaattattat	aatgattact	1020
aatatatatt	ttccatgttt	cattgcctga	ataaaaactg	tttaccactg	ttaaaaaaaa	1080
aaaaaaaaaa	actcgnnggg	ggrmcggaa	ccngntt			1117

&lt;210&gt; 14

&lt;211&gt; 1073

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (694)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1050)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1056)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1067)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (1072)

<223> n equals a,t,g, or c

<400> 14

agctccaccg	cggtggcggc	cgctctagaa	ctagtggatc	ccccgggctg	caggaattcg	60
gcacgagaaa	aaacagatga	gagcctactc	actccaaggg	gatggtttta	agccactcat	120
gggttttaag	ctcccatgat	ccaaacacct	cccaccaggc	cccacctctt	aacactaggc	180
tggagtactt	gctttctagt	gtggtctcat	gagattcgga	caggggcaca	tatccaaacc	240
atgtcacata	caattcaaag	aattatagca	atgtgtaagt	aaaaagatct	taatcttttg	300
tagtaaaaac	agaatgaaga	agtataaatg	gtgaattttc	atcttggagg	acaggagcta	360
tataaaaacc	catcatgaaa	agtctcagct	ttgtatctgg	gagaaacaca	tgatgaaaac	420
gagcttgtaa	tggtttttgt	tctctkgtag	gcctagtcat	tcattttgsa	tgagttctaa	480
gccctggtaa	acaatctccc	ttggtttctt	ctgtagctct	tattatacca	cactagaaaa	540
gcaagtactc	cagcccagtt	cccttacttt	ctaagtcttt	ttccattttc	aagccatgtg	600
tgktatgtgc	tgattttgga	atgggtctga	atgctctctt	cttaacctca	acctctctga	660
gaccttacca	atccgcagag	tccactggag	tctnacctyc	aagataactt	ccccaacctc	720
tctgagacct	tacccatccg	cagagtccac	tggagtctca	cctccaagat	aacttcccca	780
gccacctaaa	ccaagcccca	gcacccccag	catcactcta	gtgcttagtt	attattcggg	840
gatgaggtga	gggggttgcta	gatccacatg	aaaactctac	atgctgtgaa	gtgcagtaca	900
gatgtgagag	ggcaacactg	ttttccttgc	attattattt	ttgttttacc	tgttatgtgt	960
ttgtcctgtc	atcccccttc	cccacattat	gacctccta	gaggtcaaaa	gctttatgtt	1020
tcttaaccga	tccccaagtg	cagaaaaggn	aggggnaccg	aaccngtgc	gna	1073

<210> 15

<211> 1030

<212> DNA

<213> Homo sapiens

<400> 15

aagctggtac	gcctgcaggt	accggtccgg	aattccccgg	tcgacccacg	cgtccgctcg	60
ggagccgcaa	cctagaagcc	agaattgtgt	atcagattca	actaggagaa	aatcccacct	120
ccaggctcca	ttaatccttc	caatggagtg	gaagtctctc	tcacagagaa	actagtaagg	180
ggatccaatg	ggaaaagaac	gttcacacgg	actagaagac	gaaaccaatg	gaatggaaaa	240
ttgtcctcgc	gttggtagaa	gcagccaatg	agatgaaaag	agcccgctc	caaagtggct	300
gcagaggcaa	tggggtgaat	cgtgctcaga	ggcgcgctcc	aatggggtag	cagggctcgc	360
ccggccgcca	ctaccccgct	tccccgcgcc	cggagtcccc	acccacggcc	ggccgcggag	420
ccgagtgtcg	acccgggtcc	gaggagtgc	aggtgtgact	gatgggaatg	aagtggccaa	480
ggcccagcag	gcaactcctg	ggggagcagc	cccaaccatc	ttctcccga	tcctggacaa	540
gagcctccca	gctgacattc	tctatgagga	ccagcagtgt	cttgtgttcc	gtgatgtggc	600
ccctcaggct	cctgtgcact	tcctggtcat	tcctaagaag	cccattcctc	ggattagcca	660
ggctgaagaa	gaagaccagc	agcttctagc	acacctactc	cttgtggcca	agcagacagc	720

aaaggctgag	ggcctgggag	atggataccg	acttgtgac	aacgatggga	agctgggtgc	780
acaatctgtg	tatcatctgc	acattcatgt	acttgggggc	cggcagctcc	agtggcctcc	840
aggttgaacc	tgccaactga	ttaaaggaca	ccagactctg	gatgcttgga	tggaaaggga	900
aaaatggacc	ctgtgatgct	aataaaactg	ttctccctta	aaaaaaaaaa	aaaaaaaaaa	960
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaagg	cggccgctct	agaggatcca	1020
agcttacgta						1030

&lt;210&gt; 16

&lt;211&gt; 1164

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

ccacgcgtcc	gcccacgcgt	ccgcacgaga	aacagtgagg	ctgaaagggg	gggctatgga	60
agagcggtag	ggagtccacg	gagaagatgc	agtgaatgct	tgcattgcatt	cacacgtgtg	120
tgtgtccag	ctagttcact	cctttcgccg	tgcgtgggtg	aggctggcct	ctctggctgg	180
gtgcagtga	tggccagcgg	gtttcttttc	tgctgggcca	aggcgctttg	ggggtggagg	240
gggtggtgct	ggtgctgcac	tgggctgact	gcggcgctga	cgcagcgttt	ccccccatcc	300
ctgttgccctg	tgtgttgtgt	ggatctgttc	ctagtatagg	caacataatg	agatactgtg	360
cttccacact	ccccttcagt	tcagagccaa	aatgggtcta	gaatctggca	ctttactcat	420
ttcctttgat	aaattgtact	atgcagagct	gtcaggaacc	ttcagatagc	agtagaggac	480
tgcagctgtc	taggtctgcg	gccacatctt	ggggacacac	tggactgttc	ccatgtgcag	540
ggttcagcag	ttatgtggga	gtgctagggg	ttaggctttt	gagcttgaac	gcctgcgtgt	600
gaacagatga	aaaatccttc	agtacccaag	tcccagctctg	tcctatgggg	agcagtttgg	660
gggcggccgg	cagcaggagc	ctgggaaaga	ggccctcgcc	aggtgatggc	agggccaggg	720
tggcctgggg	cacccagcgg	aatgtgctta	gtatttggtc	accagccgtc	atcctgggct	780
tttctactg	tgtcttggtt	caaggcctca	gcaatccaca	gaactctctc	tccttccttc	840
cacctgtcag	cttctctgct	tctgagataa	gaaccatttg	tgtaacacca	acacttaact	900
tcagaaagac	atgcattatg	tgggtgaatc	aaacccgatg	ctttcagatg	acctacttac	960
atcttcaatg	tggataagat	aaagaacaaa	acacatgcat	ctaaactgct	gggcaatcca	1020
gttgactttt	aaatgtaaga	atggaattcc	aaacacttaa	cacattcagc	tatatgacag	1080
aaagtaaata	tatggatatg	gtattttgtg	aatgatcttt	taaataaaa	aaaaccttac	1140
gtaatatatta	aaaaaaaaaa	aaaa				1164

&lt;210&gt; 17

&lt;211&gt; 871

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (555)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (585)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (744)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (837)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (843)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (847)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 17

gaaatacata	cctttatatg	catatactat	atacatat	atatgcatat	acatttagaa	60
ataaaaacac	cactatttcta	caaggggagt	tttattttca	ccatttcata	gatgcggaac	120
caatgctccc	tgattttcaa	taacttgatc	tttgatcggt	agggtatgac	cagcatgtta	180
ctcctgggtcc	gctggatccc	aaagctcttg	ctccttttat	tatcctgcat	ggccccctgga	240
tactggggca	gaagccttct	cttcctgatc	ttaaaggctg	gtctgtagaa	cctgatcatc	300
tttcttctag	gtaaggagca	tcctggagcc	aaacttcaga	taccctgga	gcattccctt	360
caccctcaaa	cctgagctcc	tcgccccact	ccagagttag	ggtttgcca	tcacctatgg	420
cctgctggag	gagtggtggc	ttaggacgga	gctggataac	cccaggtcaa	cctgggatgt	480
agaagcaaag	atgccccgtg	ctgccctcta	tgggactctc	tcgktgctgc	agcarctggc	540
tgaggctaag	ccctnccctga	tgggcagcag	tccagagatg	ctggncctcg	sccagctatg	600
ctgtgagtgt	ccytatgggt	gcaagarata	gggctgkgcc	tctctgcgtt	tccaggtgga	660
gtagagacag	taatgggtag	agacttttag	aaatgttttg	gggtggtgga	atactctata	720
tattgacaag	agtttatata	ttgncaagag	tttatatatt	tgtcaaaact	cctcaaatag	780
tatgttaaag	acgtaagcgt	ttcactatgt	ataaatttta	cttcaaaata	ataaaancaa	840
atnctgnctc	taaaaaaaaa	aaaaaaaggg	c			871

&lt;210&gt; 18

&lt;211&gt; 1497

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 18

ccacgcgtcc	ggatcctgag	aaagtgactt	tatctctcag	agccatcggt	tccttatgtg	60
taaaacagag	atgaagaatg	accacctgga	aggattgtcc	catgtgaaag	tgctgcctc	120
ttccagcagc	tgacaggtag	taggaactca	ctgtgggtag	tagctgatgg	cgggtggcacc	180
agcttatgta	agcccacaag	actcaagcag	gattctcttt	ttacagagga	aactccaggc	240
tacgttcatt	tcttactgtc	cctcatgtag	aaaggtaaac	ttgggtcata	cctggatact	300
gtctctcatc	tttttctttt	gctctgagca	agtagctccc	atgtatccaa	tatgaatctt	360
ggtccataaa	ttcaagcatt	tgagaaataa	aatttc aaat	atatacttga	aatgcttcaa	420

gtgtatctga	gaaattcttg	gtatgtccac	acagtgaat	attactcagt	cataaaaagg	480
agtaagtact	gtacatacta	cgacatggat	gaacctagaa	aacatgcact	aagtgaaca	540
aaccagatgc	aaaagaccac	atatcataag	acttcattta	tatgaattgt	ccagaataag	600
caaaccata	aagacaaaa	gtagatgact	ggttgccaga	ggataagggg	agggagaatg	660
gagagtgtt	gctaataagg	atagggtttc	tttttgagc	gatgaaaata	ttctgggatc	720
agatagttgt	gatggttaca	tacttagtga	gtatagtaaa	agccgctgaa	gggtattctt	780
taaaatgttg	agtttacgtt	acatgaatta	cagctcaaga	aaaaaagtaa	aatcactgc	840
caaacctatg	gacattgaaa	agataataaa	ggaatattat	gaacaactct	atgcccacca	900
atttgctaac	ttagatgaaa	tgaataaatt	tcttatttct	attaaaactc	atacaaatag	960
aagaccctat	ggagctttaa	tttattaatg	caaacagtac	ctaacaaacc	cacaggtcct	1020
aaactaccaa	actgcattaa	aaatttcggg	tggggcgacc	tcggagcaga	acccaacctc	1080
cgagcagtac	atgctaagac	ttcaccagtc	aaagcgaact	actatactca	attgatccaa	1140
taacttgacc	aacggaacaa	gttaccctag	ggataacagc	gcaatcctat	tctagagtcc	1200
atatcaccaa	tagggtttac	gacctcgatg	ttggatcagg	acatcccgat	gggtgcagccg	1260
ctattaaagg	ttcgtttgtt	caacgattaa	agtcctacgt	gatctgagtt	cagaccggag	1320
taatccaggt	cggtttctat	ctacttcaaa	ttcctccctg	tacgaaagga	caagagaaat	1380
aaggcctact	tcacaaagcg	ccttcccccg	taaatgatat	catctcaact	tagtattata	1440
cccacacca	cccaagaaca	gggtttaaca	aaaaaaaaa	aaaaaaaaa	aaaaaaa	1497

&lt;210&gt; 19

&lt;211&gt; 1161

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (899)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 19

nggccccccc	cggggtcgacc	cacgcgtccg	gttcattccc	acttcacacc	ttggtcctgc	60
tgattagaga	gctcatcaga	ggggcctgga	aaggctgagc	aagtaccagt	gacaatggcc	120
atttaagaat	tctcaggccc	catgtgccag	ccttcttgga	aactgagctg	gctttctggg	180
ttttctcatg	cctggtctta	ctgcttcttc	ctcagggtcc	ttgttctccc	agaagcctca	240
gggtaatgtg	ttgggttagca	cgtaactact	aggattgggg	ccctagggat	tatagccagg	300
actctaactc	gcctaccatg	ccatttaaca	agagatcccc	ctctccagct	gccttggtgc	360
cctaggggtc	tggccatgtg	tttagtgtgc	taaactttct	cctttgttct	caggccttcc	420
aggtagtccc	cttcctggac	ttaagagtgc	aaactcttct	ctgtggttct	agccttgggc	480
agaattatat	cccagagacc	acagagcaac	tgtcaagctg	cttaccacct	caccaggggc	540
tacagcctgt	gccagccct	ctaatttgtg	cctctcttgt	gttgggggtg	gtgggggtta	600
ttcctttccc	tttctgtctc	tggcctcctt	gaaagtccag	agtaccagct	acaagtcagc	660
tttaaagtac	agcttttagt	gtttcctggg	ttgtttctct	ggggctttag	tgaggggacct	720
ttgccctctg	gtttttcttg	cctcctgggt	tagggagcat	ctcacacttg	ttagtatctg	780
gttggtgggc	cagccgtgcc	tcctctagat	ctggagccag	gccaggcagg	ggcmacgtgt	840
gggcmagtca	gccactacaa	gatttttgct	aagctttggg	ctgttggcag	catcttggnc	900

11

ctcatgcctg	ggcctgaatg	aggetctttc	ttaagtgttt	ttacaagttt	gtgtttttatt	960
tatggagtga	cttatccctt	ccattcagag	cagccccacc	cagccaccat	gctgacgggt	1020
atttttcctc	ataaagttta	taaccagtta	tttatatgaa	tctttgttat	gtccattttgt	1080
ttgtattgcg	tattttgatt	ataaaataaa	gtatcttaac	agacaaaaaa	aaaaaaaaaa	1140
aaaaaaaaaa	aggcgggccg	c				1161

&lt;210&gt; 20

&lt;211&gt; 1462

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

ccacgcgtcc	ggcggcgggc	gcggcgggcag	cgccaggagc	tgctacagca	gaggcgagg	60
ttgtcctgt	acgcgtacgg	gccgctcggc	cggagccgca	gcccggaggc	gccgggcgggt	120
gcgctgggag	ctgctggtgc	tgetgctgct	gctgctgccc	accctccgcc	gcccgggccc	180
ccgctgccgc	ccggggcccc	gctgccgtct	gcgcccccg	cgaccccgcc	cgcgagtgcg	240
ccccagccag	gacgcgcgcc	ccggccgggt	ctccacttct	tgccgcacc	ttccatgaca	300
gcgcccgcga	gaagatggct	gcgaaggcg	cgacggctc	ctacctgaag	gtggagagcg	360
agctggagcg	ctgcgcgcgc	agggccactg	ggaccgcag	ccggagctgg	tccggcagct	420
gcagacgctg	agcatgcccc	gcggcgagg	taacaggcga	ggcagcccga	gcgcagcggt	480
cacctttccg	gacaccgatg	actttgggaa	attgctgctg	gctgaggccc	tcctggagca	540
gtgtttgaag	gagaaccatg	ccaaaataaa	agactccatg	cctttgctgg	agaagaatga	600
gccgaagatg	agtgaagcca	aaaattatct	aagcagtatc	cttaaccatg	ggaggctctc	660
ggtaagtcgt	cagccttcaa	gcctgagacc	tcctctcctc	gtctgtcttg	cctcgcatct	720
gtccagtcct	ccctgagtca	tttggtcacc	tgagcaacaa	gtctctctta	caagctgccc	780
ttgcacttac	agtagccact	ggctgcacat	ggccccttga	gcacttgag	tatggctagt	840
ccacattgag	atgtgctgta	agtataaagc	atacacaaag	tttcaaagac	ttagtacaaa	900
acaaagaata	gaaaagagca	gtaacttttt	atgttgatta	catgttcaga	tggtatatatt	960
tgatatatt	gggttaaata	aaacatgtta	ttaaaattaa	tttcaccttt	tacctttttc	1020
agtgtgacta	aaaaaaatct	tagtagaaat	ttttaaatta	cacatgtgg	tcacattttgt	1080
ggcttacatc	atattttttt	ggacagtgt	tggttgactt	aatatgtgcc	tggccctttg	1140
ggctccttgg	gtcagggggc	tctcaggaaa	ataaaacctc	agtgaacctg	tgacctagtt	1200
agaaacaggc	aaacatgcag	agttggctag	ggacagaaga	gctccataac	agggcaagcc	1260
catttaagtc	cacgtgtatt	tatcaagcac	ctactgagta	caagacactg	agggaggtag	1320
aggaccacc	tctccctccc	agaaggagta	tggtcacaa	tttctctgga	ctttgctgct	1380
caaatgtgg	tccaccacc	agcagtgtag	gcatcattgg	ggagctgggt	agaaatgcaa	1440
ttaagagaaa	aaaaaaaaaa	aa				1462

&lt;210&gt; 21

&lt;211&gt; 1579

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1522)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

<221> SITE  
 <222> (1537)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1541)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1563)  
 <223> n equals a,t,g, or c

<400> 21

ttgaaggtac	gcctgcaggt	accggtccgg	aattcgcggc	cgcgctcgacc	acagacagga	60
cgcakgggta	ctagtatttt	ggattgactg	cagattttga	actgtctgcc	tagatgaact	120
ataccatgtc	cctagggcca	agtcccatgt	gcattttgtg	gctactagac	cctcttcaga	180
aatcaaacac	aaaatagctc	tggcctgtaa	agaaaacaaa	cttcaccagt	aaaattgttt	240
cctgttccta	tccaccaatg	tgcatagcac	agtgtgtagt	ctgggtaata	cggtttgcat	300
aattttttga	taatgttcta	cttaaaaagg	gcagtgtatt	tatatattac	ttatgtaatt	360
aaaaaaaaaa	ttcttctggc	tgggattaca	ggcgtgagct	gccgcgcccc	gccgtgactg	420
ggctctttca	cttagcgtgg	tgttttcaga	gttcatccag	aagaggatgy	tatttaaaac	480
tagttttgca	gatgctgttc	cttacggcat	gactcttacc	tcttccatgg	tcattgggaa	540
gaaattccat	ctgggtgcag	cgtgacggga	atgttttctg	ttttctttta	gggtttgtca	600
catggaggat	gtgtacatat	ggattctcta	aattggatcg	cgctatacat	attttttttt	660
tttattttct	tagctattct	ctattctaga	ttatgytttg	aattagcttt	tccagtttta	720
tagaaaaatc	tttttgagat	ttttgatttc	gggagaattg	acagttttac	agagcccagg	780
aaaatggtgt	ttctccttgt	ttgttaagct	cttcctgttc	ttcagtgaag	tctcacggct	840
ttcttcgtgt	cgtctgggct	cattcttagt	cctggagtgc	ttggctcttg	cgttcttaca	900
ttccatagca	gtctgcagat	tcctatgaac	agaagagcct	ctgaatctca	gattaggctg	960
tgtttcgatc	tgacagggaa	gctggttccc	tgataaaaaag	tccagaaatg	cccgtcagc	1020
tcagctactc	ctgaggtcac	cagggccttc	tgtgcactcc	acgctgctgt	ttttgctcag	1080
gtttttgcct	cgagggttca	cagtggctgc	cagagctctg	aacatcactg	acacattcat	1140
ggcaggcacc	aggaagcctc	cggagaaggg	acctttgctt	tccatggatc	tgktggctga	1200
tccgcagcag	caagagccat	gtctcccaga	agactgctcc	ctctgketca	tgagccagcc	1260
tggctgctct	gctacaggac	actccttggt	tttatgtctc	tctgtgtatt	ccagtgggat	1320
ttggggaaag	agaggcatcg	ggtgcaggga	ctcagtgtgc	cttcttgaaa	ccagaaacct	1380
ctcacgctct	ctgggcctgt	ttccacttct	gttgatgtgg	tttttactcc	gttgatatgcc	1440
gttgctctgt	cttcacacgg	gcagccacac	cggtcgacgc	ggccgcgaat	tcccgggtcg	1500
acgagctcac	tagtcggcga	cnactctaga	ggatccntcg	nggggcccac	gettacgcgt	1560
gcnggcgggt	gtccttaaa					1579

<210> 22  
 <211> 1135  
 <212> DNA  
 <213> Homo sapiens

<400> 22

ccacgcgtcc	gcttttgtat	ctcaagaatt	gagggttttg	ttttctgata	tcaggtttta	60
------------	------------	------------	------------	------------	------------	----

ttattggtgg	gagcctgtgt	ttcttcctgg	gtagaattga	ataagatttt	ccaggaaagg	120	
catttggtga	gctaattaca	gattatgggt	caaagtatgt	ctcatattcc	tccccctaac	180	
cccagcta	at	tgctgtatac	ttgacagttt	atttcaatat	tgtattaaga	cattgggttt	240
gtgctggaca	gagtaaaagg	gagatgggtat	ttttttttaa	aagaacaatt	tatttcataa	300	
ttaagtatct	aaatacttgg	ttgggaataa	atgactaatt	agaacagtac	ctttagggtat	360	
tctgatacct	ctacttagaa	atgccttttc	ttttcttgca	aaaattactt	ggcagatttg	420	
atgaaaaaga	aaatgtgtcc	aactgcatcc	agttgaaaac	ttcagttatt	aagggtatta	480	
agaatcaatt	gatagagcaa	tttccaggta	ttgaaccatg	gcttaatcaa	atcatgccta	540	
agaaagatcc	tgtcaaaaata	gtccgatgcc	atgaacatat	agaaatcctt	acagtaaagt	600	
gagaatactc	tttttagaca	aagagaaggg	cttttttatcc	aaccctaaga	ttacttcaca	660	
aatatccttt	atcctgccac	accagcaggt	tgataaagga	gccatcaaat	ttgtactcag	720	
tggagcaaat	atcatgtgtc	caggcttaac	ttctcctgga	gctaagcttt	accctgctgc	780	
agtagatacc	attgttgcta	tcatggcaga	aggaaaacag	catgctctat	gtgttggagt	840	
catgaagatg	tctgcagaag	acattgagaa	agtcaacaaa	ggaattggca	ttgaaaatat	900	
ccattattta	aatgatgggc	tgtggcatat	gaagacatat	aaatgagcct	cagaagggaat	960	
gcacttgggc	taaatatgga	tattggctgt	atctgtgttt	gtgtctgtgt	gtgacagcat	1020	
gaagataatg	cctgtggtat	gctgaataaa	ttcaccagat	gctaaaattc	aaaaaaaaaa	1080	
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaa	1135	

&lt;210&gt; 23

&lt;211&gt; 1225

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1214)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 23

ggcacgagcc	gggtcggcgc	tcctgcctcc	ctgcagggag	ctgcttatgg	gacaccgctt	60	
cctgcgcggc	ctcttaacgc	tgtgtgtgcc	gccgccaccc	ctgtataccc	ggcacccgat	120	
gctcgggtcca	gagtccgtcc	cgcccccaaa	acgatcccgc	agcaaaactca	tggcacccgcc	180	
ccgaatcggg	acgcacaatg	gcaccttcca	ctgcgacgag	gcaactggcat	gcgcactgct	240	
tcgcctcctg	ccggagtacc	gggatgcaga	gattgtgcgg	acccgggatc	ccgaaaaact	300	
cgttctctgt	gacatcgtgg	tggacgtggg	gggcgagtac	gaccctcgga	gacaccgata	360	
tgaccatcac	cagaggtctt	tcacagagac	catgagctcc	ctgtcccctg	ggaagccgtg	420	
gcagaccaag	ctgagcagtg	cgggactcat	ctatctgcac	ttcgggcaca	agctgctggc	480	
ccagttgctg	ggcactagtg	aagaggacag	catggtgggc	accctctatg	acaagatgta	540	
tgagaacttt	gtggaggagg	tggatgctgt	ggacaatggg	atctcccagt	gggcagaggg	600	
ggagcctcga	tatgcactga	ccactaccct	gagtgcacga	gttgctcgac	ttaatcctac	660	
ctggaaccac	cccagaccaag	acactgaggc	agggttcaag	cgtgcaatgg	atctggttca	720	
agaggagt	tt	ctgcagagat	tagatttcta	ccaacacagc	tggctgccag	cccgggcctt	780
ggtggaagag	gcccttgccc	agcgattcca	ggtggaccca	agtggagaga	ttgtggaact	840	
ggcgaaagg	gcatgtccct	ggaaggagca	tctctaccac	ctggaatctg	ggctgtcccc	900	
tccagtggcc	atcttctttg	ttatctacac	tgaccagget	ggacagtggc	gaatacagt	960	
tgtgcccagg	gagccccact	cattccaaag	ccggctgccc	ctgccagagc	catggcgggg	1020	
tcttcgggac	gaggccctgg	accaggtcag	tgggatccct	ggctgcatct	tcgtccatgc	1080	
aagcggcttc	attggcggtc	amcgcacccg	agagggtgcc	ttgagcatgg	cccgtgccac	1140	
cttggccag	cgctcatacc	tcccacaaat	ctcctagtct	aataaaacct	tccatctcat	1200	



aaaaaaaaaa aaanaaaaaa cttga

1225

&lt;210&gt; 24

&lt;211&gt; 1324

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (4)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1241)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1288)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1323)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 24

gcncccgga	attcccggt	cgaccacgc	gttcgcccac	gcgtccgttc	acaggtacag	60
tctctataac	tataaaatcc	aggaaatgag	agtcccatta	gggtttaaat	cactatttga	120
ttaaattgtt	caatcaaacc	cattttgtaa	tgttttatat	gcacacttac	ctaaaatgta	180
gtattattca	agagctatga	ttgctgtatg	taatgtaatt	tagttaaaat	ggatgcaa	240
tcatatgatt	ccagttacat	atgaacttaa	aattagatgt	ctgctgcttt	ttgtatcatt	300
ttccagaaaa	atgagtcaac	aaccaattag	gaaactgtac	cagtcaactc	ttgattacaa	360
attgacagaa	accattaata	acaaagcaac	acagtatgag	tataatacac	caaaaggga	420
ataggtagt	tactactggg	cttgtttttc	agctgaggcc	tcaatggaac	tttgtgagtc	480
tcctcctcta	cttcacttcc	tttgccttca	gtttgaatct	cactgggtca	gagtcaggga	540
tttgaacccc	tcgtggccct	cctgaatcag	gttcgagtat	aatttcgttg	acactttctc	600
ccaatcccca	agtatagcaa	taactctact	ttcccccaag	aggaacaaga	aaacacaata	660
acacattaac	aacagtgaac	atctttttat	ttccctgktt	acttacggca	ttaaaactcc	720
aaactcgtac	agccttaatt	tccaartcaa	tgcaatatta	ctgtgtctct	tggtagagaa	780
ttcccccttt	cttggtgcta	tgctatcaga	gtccaaaatc	aaaaggacag	aaagcagaca	840
attagaatgt	gtcaataagt	gtaatctcaa	aggcttgcat	cccagtttcc	agtcctagga	900
ctccagacgc	atatatttta	gctaaggggg	taaaagaatg	ccatgtggta	gtcacttatt	960
cagaacataa	actgtattct	gcaggacagt	acctcaaatt	tgcaagctat	tgactctgaa	1020

tgaagctcat	ctgagttttc	atggagtatg	caatacccac	aaatcccttg	aacattagct	1080
cattgctttg	tttctctata	aagttatttc	ctttaaactg	aagcaacttt	gtgtgggata	1140
ccatgccctt	gcataatgta	gacaatctat	agatagagca	aggacagaga	aaaatgatca	1200
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaagggcggc	nactatagag	gatccctcga	1260
ggggcccaag	cttacgcgtg	catgcgngt	gtttacctca	aatcaactat	agagagtgtc	1320
ccnt						1324

&lt;210&gt; 25

&lt;211&gt; 1782

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

cccagccccg	gactgtccgc	gctccatctg	gtatcttggc	ctcagctgtc	cttgaagtca	60
ccatggcgtg	gtccccacca	gccaccctct	ttctgttcc	gctgctgcta	ggccagcccc	120
ctcccagcag	gccacagtca	ctgggcacca	ctaagctccg	gctggtgggc	ccagagagca	180
agccagagga	gggccgcctg	gaggtgctgc	accagggcca	gtggggcacc	gtgtgtgatg	240
acaactttgc	tatccaggag	gccacagtgg	cttgccgcca	gctgggcttc	gaagctgcct	300
tgacctgggc	ccacagtgcc	aagtacggcc	aaagggaggg	acccatctgg	ctggacaatg	360
tgcgctgtgt	gggcacagag	agctccttgg	accagtgcgg	gtctaattgg	tggggagtca	420
gtgactgcag	tcactcagaa	gacgtagggg	tgatatgcc	cccccgccgc	catcgtggct	480
acctttctga	aactgtctcc	aatgcccttg	ggccccaggc	cggcggctgg	aggaggtcgg	540
ctcaagccca	tccttgccag	tgccaagcag	catagcccag	tgaccgaggg	agccgtggag	600
gtgaagtatg	agggccactg	gcggcagggt	tgtgaccagg	gctggacat	gaacaacagc	660
aggggtggtg	gcgggatgct	gggcttcccc	agcgagggtc	ctgtcgacag	ccactactac	720
aggaaagtct	gggatctgaa	gatgagggac	cctaagtcta	ggctgaagag	cctgacgaat	780
aagaactcct	tctggatcca	ccaggtcacc	tgcttgggga	cagagcccca	catggccaac	840
tgccagggtc	aggtggctcc	agcccggggc	aaagctgcgg	cagcctgccc	aggtggcatg	900
cacgctgtgg	tcagctgtgt	ggcagggcct	cacttccgcc	caccgaagac	aaagccacaa	960
cgcaaagggt	cctgggcaga	ggagccgagg	gtgcgcctgc	gctccggggc	ccagggtggc	1020
gagggccggg	tggaagtgtc	catgaaccgc	cagtggggca	cggtctgtga	ccacagggtg	1080
aacctcatct	ctgccagtgt	cgtgtgtcgt	cagctgggct	ttggctctgc	tcgggaggcc	1140
ctctttgggg	cccggctggg	ccaagggcta	gggcccattc	acctgagtga	ggtgcgctgc	1200
aggggatatg	agcggaccct	cagcgactgc	cctgccctgg	aagggtccca	gaatggttgc	1260
caacatgaga	atgatgctgc	tgtcagggtc	aatgtcccta	acatgggctt	tcagaatcag	1320
gtgcgcttgg	ctggtgggcg	tatccctgaa	gaggggctat	tggaggtgca	ggtggaggtg	1380
aacgggggtc	cacgctgggg	gagcgtgtgc	agtgaaaact	gggggctcac	cgaagccatg	1440
gtggcctgcc	gacagctcgg	cctgggtttt	gccatccatg	cctacaagga	aacctggttc	1500
tggtcgggga	cgccaagggc	ccaggaggtg	gtgatgagtg	gggtgcgctg	ctcaggcaca	1560
gagctggccc	tgcagcagtg	ccagaggcac	gggccgggtc	actgctccca	cgggtggcggg	1620
cgcttctctg	ctggagtctc	ctgcatggac	agtgcaccag	acctggtgat	gaacgcccag	1680
ctagtgcagg	agacggccta	cttgagggac	cgcccgccta	gccagctgta	ttgtgcccac	1740
gaggagaact	gcctctccaa	gtctgcgggc	gacgcggccg	cg		1782

&lt;210&gt; 26

&lt;211&gt; 849

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

tcgacccacg	cgtcgaaaag	aatcttcctc	ttgtctctct	tttctttcct	acccctcaact	60
tcattctgttt	ccctgatttt	tgactctccc	ctttccagtc	atttctttcc	cacccatccg	120
cagtcctgga	aacattttatt	ttttcttttg	cccactgttt	tcatttgctc	attaaattaa	180
aatgactgct	cggtccattg	ggaatccaca	tccccaggtt	agactgggga	tatgctctct	240
gtactgtctc	cttctatgga	attccacccc	accagagag	agatgacttc	acagtttggt	300
catatgagca	tcattcccatg	tcgtcccca	cccagggtg	gtaggtgcta	cagcttgctc	360
ttcatgctgc	tcctgtggcc	cctattccta	cccagctcag	agctttgcag	ggctactgc	420
agacaatcag	aagtcagttt	ctaacaaata	gcaacagcca	caaactctct	cctccttcct	480
ctctgacatt	accctgtgca	acttttctca	aagtctgttg	caccactcag	caaagcaagt	540
tgcaccagct	atatcagaat	cacctggggc	agcctattaa	aaatgcagac	tgttgagacc	600
atcctggcta	acacgggtgaa	accctgtctc	tactaaaaat	acaaaaaatt	agccggccgt	660
gggtggcgggc	agctactcgg	gaggctgagg	caggagaatg	acctgaacct	gggaggcaga	720
gcttgacagt	agctgagatt	gtgccactgc	actccagcct	gggtgacaga	gcaagactcc	780
gtctcaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	840
aaaaaaaaaa						849

&lt;210&gt; 27

&lt;211&gt; 1147

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (5)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (6)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (11)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (12)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (19)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1145)

<223> n equals a,t,g, or c

<400> 27

cgcanccac nnggtggang ccgctctaga atatggatcc cccgggactg cagggagtcc	60
aaggtacagt cgccgcgtgc ggagcttggt actggttact tggcctcatg gcggtccgag	120
cttcgttcga gaacaactgt gagatcggt gctttgccaa gtcaccaac acctactgtc	180
tggtagcgat cggaggtca gagaacttct acagtgtgtt cgaggcgag ctctccgata	240
ccatccccgt ggtgcacgcg tctatcgccg gctgccgcac catcgggcgc atgtgtgtgg	300
ggaacaggca cgggtctcctg gtaccaaca ataccaccga ccaggagctg caacacattc	360
gcaacagcct ccagacaca gtgcagatta ggcgggtgga ggagcggctc tcagccttgg	420
gcaatgtcac cacctgcaat gactacgtgg ccttggtcca ccagacttg gacagggaga	480
cagaagaaat tctggcagat gtgctcaagg tggaggtctt cagacagaca gtggccgacc	540
aggtgctagt aggaagctac tgtgtcttca gcaatcaggg agggctggtg catcccaaga	600
cttcaattga agaccaggat gagctgtcct ctcttcttca agtccccctt gtggcgggga	660
ctgtgaaccg aggcagttag gtgattgctg ctgggatggt ggtgaatgac tgggtgtgct	720
tctgtggcct ggacacaacc agcacagagc tgtcagtggg ggagagtgtc ttcaagctga	780
atgaagccca gcctagcacc attgccacca gcatgcggga ttccctcatt gacagcctca	840
cctgagtcac cttccaagtt gttccatggg ctccctggctc tggactgtgg ccaaccttct	900
ccacattccg cccaatctgt accggatgct ggcaggaggg tggcagagag ctactggga	960
ctgaggggct gggcacccaa cccttttcca cctgtgctta tcgcctggat ctatcattac	1020
tgcaaaaacc tgctctgttg tgctggctgg caggccctgt ggctgctggc tgagggttct	1080
gctgtcctgt gccaccccat taaagtgcag ttccctccgg aaaaaaaaaa aaaaaagg	1140
cggnac	1147

<210> 28

<211> 781

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (751)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (762)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (764)

<223> n equals a,t,g, or c

<400> 28

cccggaattc	ccgggtcgac	ccacgcgttc	ggcncagtga	cagaggcacc	cagggctcag	60
caagctcatg	gcccagcttg	ttggactcag	agggcagaag	aatcacattc	taaacatgat	120
aaggtatagc	cagcaggagg	cagattccca	gattgattct	ccagagcctt	gtagggtcca	180
agggtgccta	tgacaccaat	gggaatctga	accaacacag	acagcacagt	cttcttagga	240
gaccctagtg	cagcagcgct	ggcctcctcc	tgagcgtgca	cgcttatatg	gcttctgagc	300
tggtccaggt	acttcatgca	tttggtttaa	tggttcctcg	taaggcagga	gaatcttctt	360
gaacttgtag	ttgggtctgt	ggtccattgg	tcagtacttt	gttcagaggc	actgaggggtg	420
ggaaggtcca	tggtgctgga	ttctgctgct	gggaagctgg	gtgggccttg	tttgtgggcc	480
tcaggttcag	gactgaatga	gagtcctctt	gttgcgagtt	gaggggtgtac	tctgggcatg	540
ccatgccctt	ttttgtact	aagagggtag	aaaagcaaag	accagactag	ttggcaaatt	600
ggaacccaac	taccagttt	atttatttct	targcgtaga	aggaataatt	tagggggaac	660
tgaagagcca	acctaaagga	aaaaaaaaaa	aaaagggcgg	ccctatagag	gatccctcga	720
ggggcccaag	cttacgcgtg	catgcgggcg	ngttacctca	antnaaatat	agagagttcc	780
c						781

&lt;210&gt; 29

&lt;211&gt; 552

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (3)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (69)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (128)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (164)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (198)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 29

cancttccgc	cccattgacg	caaattggcg	gtaggcgtgt	acggtggaag	gtctatataa	60
gcagagctng	tttagtgaac	cgtcagatcg	cctggagacg	ccatccacgc	tgttttgacc	120
tccatagnag	acaccgggac	cgatccagcc	tccggactct	agcntaggcc	gcgggacggg	180
ataacaattt	cacacagnaa	acagctatga	ccactaggct	tttgcaaaaa	gctatttagg	240

tgacactata gaaggtacsc ctgcmggtac cggtcggaa ttcccgggtc gactgcgccc	300
cgggcgcccw ttcccacgat tgccacgat ctgtccacgc tgatgaacct cgccctgccg	360
ctgacccggc tgcacatgcc cgcgggagcc ggcgatgctg atggcctcgg cgctgagccg	420
ctgcgcgggg gcggccgtgc tgggtgctgct gctgtggctg gcggtggact gggcgctgat	480
gtgagcgctc cggtgccggc gggcggcgtg ctgctgaggc tggatcggct gacgctcgcg	540
cgaggcggcc gc	552

<210> 30  
 <211> 451  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (6)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (27)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (34)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (434)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (437)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (447)  
 <223> n equals a,t,g, or c

<400> 30	
tcacancaca ctcccctctt taaagtnaac aaangctgca gctcgcgcgc ctgcaggctc	60
acactagtgg atccaaagaa ttcttttttt ttttttttt taactttaag ttctgggata	120
tatgtgcaga acgtgcaggc ttgttacgtt ggtatacatg tgccatgggtg gtttggtgca	180
cctatcaacc catcatctaa gttttaagct ctgcatgcaa taggtatttg tcctaatacct	240
ctccctcccc ttgaccacct cccaccagct ggcccaggta tgttatgctc cattccctgt	300
gtccatgtgt tctcattgtt caactccaaa aaaaaaaaaa aaaaaaaaaa aattcaaaaa	360
gcttctcgag agtacttctá gagcgaccgc gggcccatcg attttccacc cgggtggggg	420

accgggtaag tggncanttt tcgcggnaagt a

451

&lt;210&gt; 31

&lt;211&gt; 1558

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (13)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1557)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1558)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 31

gcggacgcgt	gtncggacgc	gtgggtcgcg	gagccggggc	gcacccgccg	agccgtcttg	60
atactgatgg	acattgtgtg	ggccagaggg	agggatgggt	ggctatgacc	ccaaaccaga	120
tggcaggaat	aacaccaagt	tccaggtggc	agtggctggg	tctgtgtctg	gacttggtac	180
tcgggcgctg	atcagtcctt	tcgacgtcat	caagatccgt	ttccagcttc	agcatgagcg	240
cctgtytcgc	agtgacccca	gcgcaaagta	ccatggcatc	ctccaggcct	ctaggcagat	300
tctgcaggag	gagggtccga	cagctttctg	gaaaggacac	gtcccagctc	agattctctc	360
cataggctat	ggagctgtcc	aattcttctg	atttgaaatg	ctgacggagc	tgggtccacag	420
aggcagcgtg	tacgacgccc	gggaattctc	agtgcacttt	gtatgtgggtg	gcctggctgc	480
ctgtatggcc	accctcactg	tgacccccgt	ggatgttctg	cgcacccgct	ttgcagctca	540
gggtgagccc	aaggtctata	atacgtcgcg	ccacgccgtg	gggaccatgt	ataggagcga	600
aggcccccag	gttttctaca	aaggettggc	tcccaccttg	atcgccatct	tcccctacgc	660
cgggctgcag	ttctcttgct	acagctcctt	gaagcacctg	tacaagtggg	ccataccagc	720
cgaaggaaag	aaaaatgaga	acctccaaaa	cctgctttgt	ggcagtgagg	ctgggtgtcat	780
cagcaagacc	ctgacatata	cgtctggacct	cttcaagaag	cggctacagg	ttggagggtt	840
tgagcatgcc	agagctgcct	ttggccaggt	acggagatac	aagggcctca	tggactgtgc	900
caagcaggtg	ctacaaaagg	aaggcgccct	gggcttcttc	aagggcctgt	ccccagctt	960
gctgaagget	gccctctcca	caggettcat	gttcttctcg	tatgaattct	tctgtaatgt	1020
cttccactgc	atgaacagga	cagccagcca	gcgctgagcg	caggaaggac	cccaggtctt	1080
ccctggaggc	agcctcctga	aggaagggaag	attcagtctc	cactgagagg	tgccgtctgg	1140
cccttccctg	caggccagct	gccccaaagc	gggtagcagc	cttgaaccca	cccagctggg	1200
acaccaccag	aaggtccagg	gctctcccca	tgagagaatc	agagggaatg	caggacgtgg	1260
tctatggtga	gccaacgaca	cagtgagaag	gagcaggaag	ttgctgtttc	tcctctgacc	1320
agcccacact	scaaaggaaa	cagacgccat	cctacacctc	tcagccctgc	ctgccaggag	1380
aacagaacac	actcctggtc	tggatggggc	tgctgcttga	gtgcagaggg	ctgcggtagg	1440
ccctttgcag	gagtcaggtc	cctacacttg	gcctgttttt	ccaacctatt	taatagacat	1500
taaagctaaa	cacacatawm	aaaaaaaaaa	aaaaaaactc	gagggggggc	ccggtann	1558

<210> 32  
 <211> 1501  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (795)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (796)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (823)  
 <223> n equals a,t,g, or c

<400> 32  
 gactaacagg gactataatc ttgcagcacc atgccgagct aatttttattt ttgtagaga 60  
 tgagctctca ctatgtcacc cagggttcgtc tcaaaactcct gaaccctagt aattctccta 120  
 tctcagcctc ccaaagtgtc agggttacag acatgagcca ctgtgcctgt ctagacttgt 180  
 actttcaact gtccatttct ccctgtctgt cccatgggca ctcatgaaaa aacagaatgc 240  
 toccaacttt attcatcttc caagcctgta gctcttggt tactcactgt tgcaagtcag 300  
 aagcttgatt tcatcattga tgtttttctc acgtttcaca tctcactcat caccaagtca 360  
 tgttggtgtt aatttctgat taacccttga atttaccgtc ttctcatcct ctgtacaaaa 420  
 gcctcaagtg aggggtcaaat tcaacattat cctgatctag acagccccc tctcfaatcc 480  
 acccttttcc aagttgattg cccaaggact tctaacaata aactctcttt tgcaccacag 540  
 acttctttga aaatatacat gctgttgacc ctctctgtag aaaaccgcac acataaaaact 600  
 taccaacaga ttctattggt tcttggttcc tcccgaagcc tatccatggt ttatagatta 660  
 agaattgatg aggtagctgg gcacagtggc tcacacctac gatcacagca cttcgggagg 720  
 ctgaagcaag cagatcactt gaggtcagga gtttgagacc agcctggcca acatggtgaa 780  
 accctgtctc tactnnaaat acaaaaagta gccagccgtg atnacaggca cctgtaatcc 840  
 cagctactcg ggaggctgag gcatgagaat tgccttgagcc cgggaggcgg aggttgcggt 900  
 gagcctggat catgccactg cactccaacc tgggcagcag agcaagactc tgtctcaaaa 960  
 ggggaaaaaa aaaattgctg atgtgaccca tgaagggaac tcattttcct cgtaattttg 1020  
 gactgccaca cattggtacc tttagttctc tgaaggccca cgtttttatc attaagacct 1080  
 atttgttagc tagtagagct ttatgttcgc tgtccatgaa accttctgta accacagtga 1140  
 ctacaagtag ttctttctct attgaattat taggtccaga atagaagatg tcattgtaca 1200  
 ctttatttcc ctcacactgt gttatgctct gatgtgctat gcttagctat ctgtcagaga 1260  
 ttagtaaaatt ataaaactca tgtgtactac ttaagtttat atcttatgct agttttataag 1320  
 aacaattaaa aggacttaga agattaactt tggtttcatg gtctctgaag tcaactgactg 1380  
 ctatttcagc ttgtttaccc ttacctagca ttaagactcc atctacttct gtacagtata 1440  
 tgaaaatttt taaactttca ttttagactgg tgggataggg ctgaccatta caaattgtcg 1500  
 t 1501

<210> 33



<211> 1880  
 <212> DNA  
 <213> Homo sapiens

<400> 33  
 ggcacgagag acgccagagg tgcagctcca gcagcaatgg cagtgcgggc gttggcgggc 60  
 cggacgtggc ttggcgtgtg gggcgtgagg accatgcaag cccgaggctt cggctcggat 120  
 cagtccgaga atgtcgaccg gggcgcgggc tccatccggg aagccggtgg ggccttcgga 180  
 aagagagagc aggctgaaga ggaacgatat ttccggtgag gctcaccggg tcccaagtcc 240  
 agccctggat ctcccaatgg ccttccaatc cttaaactgc caatcgcccc acccgttcct 300  
 acctggtgcc ttgggcgccc catcccccaa cagaactccc gggccccaat ccagtatacc 360  
 ctaacccttg atgtcccgcg cggtgccacg tatagggcac tcccagttac ctgcacaaca 420  
 gtttcaggcc cccaaaccgt ttccaccggc gggctctcaa aacaaccacac ggtcaactc 480  
 ctcttttacc attaccatct ccgcggtgga gttctctca ggtcgtgcga aacacccct 540  
 agattcttcg cacagtgtct agatccgacc gcccaacgtt tgcctcccag cctgactccc 600  
 tcggccctta cccacctgtc accccctcta cgctctcctt cctcgccagc acgccttagc 660  
 tttgcaagcc tgcattgcatt caggcttctc aggtgtttct agacccccga ctccgcaaga 720  
 gtgaggatga tgggagctgg tcatgggagc tacttatggt tggacaccat cttctaaagg 780  
 cttttgccct actcagccca acctagacct gtagatttcc ctctcctgct taggagtatg 840  
 gagtgggctg ggctccctt tgccagcctt gagtatatct taactgactt ctgtccactc 900  
 tggagagcag tgaggaatta atcttgcttt tgcttgcctt ttggcctttc acttctgcct 960  
 tctgttgaga attatcacca tgacacctgc cataccgtat agagagccaa ggtacagccg 1020  
 ttagagacta tctaattgag cccctacatt ttgtagttaa ggaaaactga ggcctaaatg 1080  
 tgaccaaacc aacattgtaa tccagtccct tcttggaacc taaattgaac tgccaagtac 1140  
 tgcgcatgca agagaccctt tattggcctt acagtgggac attcatttct ataggcaaag 1200  
 aaagctctag acagattgga ataggaaatg gatatttgcc ttttagctac acccctttgt 1260  
 ctgtcttctc cattttgttc cttttttttt ccctaaaggg gagtcaagtt ccctgggttg 1320  
 ttccctcat aaggtattag ggacttgtgt caaatctttc tggagttttc tattttaaag 1380  
 aggaatctga aagcaataag ctctttggtc ttcttaagat ggctacacct caatttaaga 1440  
 tgggggtattc ttctactagt tgaggagtag aagaggatga ccagctagac tcccatggaa 1500  
 ttggaactcc tattccttgc ttagacatta cagggtatgc tttgagatct ctttggggtg 1560  
 aaggattgaa attaaaccct gagccaccgt gtccttgtag agcacagagt agagaacaac 1620  
 tggcagcttt gaaaaaacac catgaagaag aaatcgttca tcataagaag gagattgagc 1680  
 gtctgcagaa agaaattgag cgccataagc agaagatcaa aatgctaaaa catgatgatt 1740  
 aagtgcacac cgtgtgccat agaatggcac atgtcattgc ccacttctgt gtagacatgg 1800  
 ttctggttta actaatattt gtctgtgtgc tactaacaga ttataataaa ttgtcatcag 1860  
 tgaaaaaaaa aaaaaaaaaa 1880

<210> 34  
 <211> 2904  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (2899)  
 <223> n equals a,t,g, or c

<400> 34  
 ggcgtcttgt gatagagaaa tttcagaaag caccttttga agaaatagca gcacagtgtg 60

aatccaaagc	aaatttgctt	catgatagac	ttgcccaaat	attggaactc	accatacgtc	120
ctcctccag	tccatcagga	acactgacca	ttacttctgg	gcatgcccaa	taccaatctg	180
tcacagtcta	tgagatgaag	tttccagatc	tgtgtgtgta	ctgatcggcg	catgaagacc	240
tcagcatatg	atttgtaaag	cctaaaaaatt	aaggccaagc	tgagctttca	gggtttactt	300
aatgtgtatt	aacatacttc	ttgaaaataa	tgatggaaca	tatctttaac	caaagtgttg	360
gcataccata	ttagaagttt	tggagctata	tataatttcg	agtactttca	aagatagatt	420
tatgccatgt	taatttgctt	tgaggttcct	gttgcccttt	taagtgaac	atgttttggt	480
ttcactttat	tccactgtta	agtagtatgt	tttaaacttt	tcacaaatgt	aatgtttttt	540
aaaaagtaag	ccttcagagg	attgaaactg	tataaattgt	ttatctctta	aacatctaca	600
cagccgctta	gatgtagaat	ttttgttggt	gttttctgca	aaggcagata	catttaaata	660
tattcctagt	cctggggctg	caaaactggt	cgggtgcttt	ttgtcccat	gctttagata	720
agctgggata	ggcaccttgc	tattcagtta	ctataataat	atgtgatagg	cattcctcat	780
cttcttcaca	ataataggac	atctgttgaa	tagcattcct	cgaatataac	cctaaaaacg	840
ccatacttta	aattgtctgg	ttcttgtaat	attgtgtttc	ctgccaaagag	tttgaccatt	900
ctgcttgaga	agtgtagagc	ttactcttgg	agtaccaaac	tgtgcaatat	ttttacatca	960
taagatgtat	tagtttacag	gctgtgcttt	gaaattatag	tagtattttg	ctgtggctcc	1020
attaattaaa	tgagatatat	atttagtgca	gaaaaagac	atttaaaaca	gctattagtt	1080
cacctgtgaa	gagtctgtac	attttgattt	ctattaagag	cacatttatt	tacatttgta	1140
tattatttta	aatcctcata	gtcaaaaaat	tctccagatg	gacttttaat	ttgtaagatt	1200
tgaactgtga	cttgataaca	tctgtttaga	atcaattata	tttgaaaagc	tgctgtgttt	1260
ttaacagtca	agtgtgctaa	agtttgtaa	tttaagctgc	ttttgatttc	agctaccaag	1320
atcacagggtg	cactctacac	ataacactga	cagaccata	acattacata	catcttagtg	1380
aattctatca	catggtaaaa	tgaacagctt	tctttgtaac	tcataaaatt	ctcttaggac	1440
atttttataa	agtcacctgt	ttatagttct	atcttttcag	attccatttc	tttttacata	1500
aaacagcata	catatcaaaa	actgtagcct	agaatacagt	ttaatttttg	gcttttggtt	1560
ttgtttaaaa	aattgcagtg	aagaatggga	tgtttggtgt	tatggctatt	tgggcacctt	1620
tagtagaaac	agacaaaagt	aaggaaacga	taataggaca	agcatacttg	aaaatttctg	1680
aatacttaaa	caaaagcgca	acatcttgaa	aaccagctta	gtcattgaaa	cctatgaaat	1740
gacactgaaa	gatcctgggc	tgcttcttaa	ataagtagat	cagcaagact	tgtttcagag	1800
tgacagtgga	gtcggtaccg	ctggaggact	aaaggccct	gtggcagctg	tcactggaac	1860
tttgccctctt	gatcaggaaa	aatgcttcac	cagtcctgta	agccaagttg	tatttttttw	1920
attgcccttt	tttccctctg	tatttttaaa	gaaggatgtt	aatttttgac	tatatatttt	1980
aaaaaaatct	aagcaggggg	acatgcaaaa	acaatcatca	tccacttggg	tgctatttta	2040
tagattaaca	ctgtgtgctt	ttgtatggaa	aaaatatata	taatttaata	gtataaaaaa	2100
taaaatatat	attcatttgc	acttacgtga	aacacaaact	ttgctctaca	aaatttcgtg	2160
tttcttagtg	attttaaaa	gcatgtattg	catgtaaagg	aaaaccatta	caattaatgt	2220
ttatcacacc	tttatcttgg	tctttgttga	tttgggtttt	gttgggggtt	ttgttactgt	2280
ttttaaatta	cagtaggctt	ctatatatcc	tggatttctg	aactggctct	gttgacaagg	2340
attcccaaga	aatggatctt	ttcactggct	gactctccca	tatctgcaag	agattctgca	2400
ggaactgggt	gtgcacacgg	tggtgtagcc	agttcaggta	ctgaatattt	aggatttggt	2460
gaagttcact	gtattgctat	atttttgtag	ataaataaaa	ctcaataaat	tgtaaatcat	2520
tctctttttg	ctgtatagaa	ttgcttatat	cactctttct	ttcatgacat	tggttaacat	2580
ttaaagtgtc	ctcctgtact	tggtgtgtct	gtgaccgctt	atagagtttt	attgttattg	2640
gtgtttacct	gaatacctat	gcgtacacac	acacataatt	ccttaataact	tctgaactca	2700
ttatctttta	gaataataat	actactacac	tttaccagca	attaacttct	ccctacccaa	2760
aatgtttttc	ttcctgtctg	aaaatggaac	taatttgtct	tattcgtgct	tatatctgta	2820
ttaaagtcaa	taaagttagt	ttttgaaatg	taaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2880
aaaaaaaaaa	agggggggnc	cccc				2904

&lt;211&gt; 2637

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

acgagaacga	gagccccatc	ccctgcttcc	tgcccgggga	ccaccgcgcc	aacgagcagc	60
tgggcctgac	cagcatgcac	acgctgtggt	tccgcgagca	caaccgcatt	gccacggagc	120
tgctcaagct	gaaccgcac	tgggacggcg	acaccatcta	ctatgagacc	aggaagatcg	180
tggtgcgga	gatccagcac	atcacctacc	agcactggct	cccgaagatc	ctgggggagg	240
tgggcatgag	gacgctggga	gagtaccacg	gctacgaccc	cgcatcaat	gctggcatct	300
tcaacgcctt	cgccaccgcg	gccttcaggt	ttggccacac	gcttgtaaac	ccactgcttt	360
accggctgga	cgagaacttc	cagccattg	cacaagatca	cctccccctt	cacaaagctt	420
tcttctctcc	cttcgggatt	gtgaatgagg	gcggcatcga	tccgcttctc	agggggctgt	480
tcgggggtggc	ggggaaaatg	cgtgtgccct	cgcagctgct	gaacacggag	ctcacggagc	540
ggctgttctc	catggcacac	acggtggctc	tggaacctggc	ggccatcaac	atccagcggg	600
gccgggacca	cgggatccca	ccctaccacg	actacagggt	ctactgcaat	ctatcggcgg	660
cacacacgtt	cgaggacctg	aaaaatgaga	ttaaaaaccc	tgagatccgg	gagaaactga	720
aaaggttgta	tggtctgaca	ctcaacatcg	acctgtttcc	ggcgctcgtg	gtggaggacc	780
tggtgcctgg	cagccggctg	ggccccaccc	tgatgtgtct	tctcagcaca	cagttcaagc	840
gcctgcgaga	tggggacagg	ttgtggtatg	agaaccttgg	ggtgttctcc	ccggcccagc	900
tgactcagat	caagcagacg	tcgctggcca	ggatcctatg	cgacaacgcg	gacaacatca	960
cccggtgca	gagcgacgtg	ttcagggtgg	cggagtctcc	tcacggctac	ggcagctgtg	1020
acgagatccc	cagggtggac	ctccgggtgt	ggcaggactg	ctgtgaagac	tgtaggacca	1080
gggggcagtt	caatgccttt	tcctatcatt	tccgaggcag	acggtctctt	gagttcagct	1140
accaggagga	caagccgacc	aagaaaacaa	gaccacggaa	aatacccagt	gttgggagac	1200
agggggaaca	tctcagcaac	agcacctcag	ccttcagcac	acgctcagat	gcactctggga	1260
caaatgactt	cagagagttt	gttctggaaa	tgcagaagac	catcacagac	ctcagaacac	1320
agataaagaa	acttgaatca	cggctcagta	ccacagagtg	cgtggatgcc	gggggcgaat	1380
ctcacgccaa	caacaccaag	tggaaaaaag	atgcatgcac	catttgtgaa	tgcaaagacg	1440
ggcaggtcac	ctgcttcgtg	gaagcttgcc	cccctgccac	ctgtgctgtc	cccgtgaaca	1500
tcccaggggc	ctgctgtcca	gtctgcttac	agaagagggc	ggaggaaaag	ccctaggctc	1560
ctgggaggtc	cctcagagtt	tgtctgctgt	gccatcgtga	gatcgggtgg	ccgatggcag	1620
ggagctgcgg	actgcagacc	aggaaacacc	cagaactcgt	gacatttcat	gacaacgtcc	1680
agctggtgct	gttacagaag	gcagtgacag	aggcttccaa	ccagagcatc	tgccggagaag	1740
gaggcacagc	aggtgcctga	agggaagcag	gcaggagtcc	tagcttcacg	ttagacttct	1800
caggttttta	tttaattctt	ttaaaatgaa	aaattgggtgc	tactattaaa	ttgcacagtt	1860
gaatcattta	ggcgccataa	ttgattttgc	ctcccaacac	catttctttt	taaataaagc	1920
aggatacctc	tatatgtcag	ccttgccctg	ttcagatgcc	aggagccggc	agacctgtca	1980
cccgagtggt	ggtgagctct	ggagctgcca	gaggggctca	ccgaaatcgg	ggttccatca	2040
caagctatgt	ttaaaaagaa	aattgggtgt	tggaacacgg	aacagaacct	ttgatgagag	2100
cgttcacagg	gacactgtct	gggggtgcag	tgcaagcccc	cggcctcttc	cctgggaacc	2160
tctgaactcc	tccttctctc	gggtctctct	taacatttca	ccacacgtca	gcacttaatc	2220
ccaagacaaa	cattcccgtc	gctcgaagca	gctgtatagc	ctgtgactct	ccgtgtgtca	2280
gctccttcca	cacctgatta	gaacattcat	aagccacatt	tagaaacagr	tttgctttca	2340
gctgtcactt	gcacacatac	tgcttagttg	tgaaccaaatt	gtgaaaaaac	ctccttcac	2400
ccattgtgta	tctgatacct	gccgagggcc	aagggtgtgt	gttgacaacg	ccgctcccag	2460
ccggccctgg	ttgcgtccac	gtcctgaaca	agagccgctt	ccggtgggct	cttcccaagg	2520
gaggaggagc	tcaagtgtcg	ggaactgtct	aacttcaggt	tgtgtgagtg	cgtaaaaaaa	2580
aaaaaaaaaa	gtcgacgcgg	ccgcgaatcc	ggaccggtac	ctgcaggcgt	accttct	2637

25

<210> 36  
 <211> 1260  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (15)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (37)  
 <223> n equals a,t,g, or c

<400> 36  
 cccgggttttt agaactaag gggattcccc cccgggnctg ccaggaattt cgggcaccga 60  
 agtgagaaaa gagcctggca acaagatgaa gcaagccaag tctgtgggtg acctcgcccc 120  
 acctgaatgg gactggagga gtaagggggc tgtcacaaaa gtcaaagacc agggcatgtg 180  
 tggctcctgc tgggccttct cagtcacagg caatgtggag ggccagtggg ttctcaacca 240  
 ggggaccctg ctctccctct ctgaacagga gctcttggac tgtgacaaga tggacaaggc 300  
 ctgcatgggc ggcttgccct ccaatgccta ctcgccata agaatttgg gagggctgga 360  
 gacagaggat gactacagct accaggttca catgcagtc tgcaacttct cagcagagaa 420  
 ggccaaggtc tacatcaatg actccgtgga gctgagccag aacgagcaga agctggcagc 480  
 ctggctggcc aagagaggcc caatctccgt ggccatcaat gcctttggca tgcagtttta 540  
 ccgccacggg atctcccgcc ctctccggcc cctctgcagc ccttggctca ttgaccatgc 600  
 ggtgttgctt gtgggctacg gcaaccgctc tgacgttccc ttttgggcca tcaagaacag 660  
 ctggggcact gactgggggtg agaaggggta ctactacttg catcgygggt ccgggggcctg 720  
 tggcgtgaac accatggcca gctcggcggg ggtggactga agaggggccc ccagctcggg 780  
 acctggtgct gatcagagtg gctgctgccc cagcctgaca tgtgtccagg cccctccccg 840  
 ggaggtacag ctggcagagg gaaaggcact gggtagctca gggtagcag agggcactgg 900  
 gctggggcac agcccctgct tccctgcacc ccattcccac cctgaagtgc tgcacctgca 960  
 cctttgttga attgtggtag cttaggagga tgtcgggggtg aagggtggta tcttggcagt 1020  
 tgaagctggg gcaagaactc tgggcttggg taatgagcag gaagaaaatt ttctgatctt 1080  
 aagcccagct ctgttctgcc cccgctttcc tctgtttgat actataaatt ttctggttcc 1140  
 cttggattta gggatagtgt cccyctccat gtccaggaaa cttgtaacca cctttttcta 1200  
 acagcaataa agaggtgtcc ttgtaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1260

<210> 37  
 <211> 927  
 <212> DNA  
 <213> Homo sapiens

<400> 37  
 ggaattcggc acgagcactt ttagtacagc atttccagga actatgtatc agcatataaa 60  
 aatgcacaga aggattctcg gacatctatc tgcgttttac tgtgtagcat ttgataggac 120  
 aggacataga atctttacag gttcagatga ctgtttggta aagatttggg caacacataa 180  
 tggccgcttg ttatctacat taagaggtca ttctgcagaa atttcagata tggcagtaaa 240  
 ctatgagaat acaatgattg ctgcggggag ctgtgattaa aattattaga gtgtggtgct 300  
 tgagaacttg tgccccagtt gctgtgctcc aaggacacac aggatcaatt acatctttac 360

aggtaaaactt	gtagcttagt	gggcacattc	cctatatgta	ttttcacctt	tttcttttaa	420
acagtttctt	tggaattga	gaaatagtaa	gatgtgtatt	agttatgttt	taagtaagag	480
aagtgataat	cattcataca	aatcatacaa	atcatggaag	gctgatgaaa	tgaagatcta	540
atgcatattt	acatgaaggc	ttattgatat	tttggggtta	tggttgaact	ggatgagtgt	600
caattagaaa	ctggtgatag	attaattatt	tttcaacttt	aaaacttggt	gattttgcta	660
agttgatttt	tttttttttt	ttgagactga	gtcttgttct	gttcccagg	ctggagtga	720
gtggtgtgat	ctcagctcgc	tgcaacctct	gcctcctggg	ttcaagcgat	tcttgtgcct	780
cagcctccc	agtagtctcg	gtactcctga	ggttgaggga	ggattgcttg	agccaggagg	840
ttgaggctgc	agtgaaccgt	tatcgcacca	gtgcattcca	gcctgggtga	caaagtgaga	900
ctgcctcaaa	aaaaaaaaaa	aaaaaac				927

&lt;210&gt; 38

&lt;211&gt; 1874

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1593)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 38

ggcgcgactt	tttgaaagcc	aggagggttc	gaattgcaac	ggcagctgcc	gggcgtatgt	60
gttgggtgcta	gaggcagctg	cagggtctcg	ctgggggccg	ctcgggacca	atthttgaaga	120
ggtagcttggc	cacgacttat	tttcacctcc	gacctttcct	tccaggcggg	gagactctgg	180
actgagagtgt	gctttcacaa	tggaagggat	cagtaatttc	aagacaccaa	gcaaattatc	240
agaaaaaaag	aaatctgtat	tatgttcaac	tccaactata	aatatcccgg	cctctccgtt	300
tatgcagaag	cttggtcttg	gtactggggt	aaatgtgtac	ctaataaaaa	gatctccaag	360
aggtttgtct	cattctcctt	gggtctgtaa	aaagattaat	cctatatgta	atgatcatta	420
tcgaagtgtg	tatcmaaaga	gactaatgga	tgaagctaag	atthttgaaa	gccttcatca	480
tccaaacatt	gttggttatc	gtgcttttac	tgaagccagt	gatggcagtc	tgtgtcttgc	540
tatggaatat	ggagggtgaa	agtctctaaa	tgacttaata	gaagaacgat	ataaagccag	600
ccaagatcct	tttccagcag	ccataattht	aaaagttgct	ttgaatatgg	caagagggtt	660
aaagtatctg	caccaagaaa	agaaactgct	tcattggagac	ataaagtctt	caaagtgtgt	720
aattaaaggc	gattttgaaa	caattaaaat	ctgtgatgta	ggagtctctc	taccactgga	780
tgaaaatatg	actgtgactg	accctgaggg	ttgttacatt	ggcacagagc	catggaaacc	840
caaagaagct	gtggaggaga	atggtgttat	tactgacaag	gcagacatat	ttgccttttg	900
ccttactttg	tgggaaatga	tgactttatc	gattccacac	attaatcttt	caaagtatga	960
tgatgatgaa	gataaaactt	ttgatgaaag	tgattttgat	gatgaagcat	actatgcagc	1020
gttgggaact	aggccacctt	ttaatatgga	agaactggat	gaatcatacc	agaaagtaat	1080
tgaactcttc	tctgtatgca	ctaatagaag	ccctaaagat	cgtccttctg	ctgcacacat	1140
tggtgaagct	ctggaaacag	atgtctagtgt	atcatctcag	ctgaagtgtg	gcttgcgtaa	1200
ataactgttt	attccaaaat	atttacatag	ttactatcag	tagttattag	actctaaaaat	1260
tggcataatth	gaggaccata	gtttcttggt	aacatatgga	taactatttc	taatatgaaa	1320
tatgcttata	ttggctataa	gcacttgga	ttgtactggg	ttttctgtaa	agtttttagaa	1380
actagctaca	taagtactth	gatactgctc	atgctgactt	aaaacactag	cagtaaaacg	1440
ctgtaaaactg	taacattaaa	ttgaatgacc	attactthta	ttaatgatct	ttcttaataa	1500
ttctataatth	taatggatct	actgacatta	gcactttgta	cagtacaaaa	taaagtctac	1560
atthgtthta	aacactgaac	ctthtgctga	tgngkgttht	caaagtataa	ctggaagctg	1620
aggagaatat	gcctcaaaaa	gagtagctyc	ttggataact	cagactctgg	ktacagattg	1680

kcttgatctc	ttggatctcc	tcagatcttt	ggtttttgct	ttaatttatt	aaatgtattt	1740
tccatactga	gtttaaaatt	tattaatttg	taccttaagc	atttcccagc	tgtgtaaaaa	1800
caataaaact	caaataggat	gataaagaat	aaaggacact	ttgggtaaaa	aaaaaaaaaa	1860
aaaaaaaaaa	aaaa					1874

<210> 39  
 <211> 1345  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (1324)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1326)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1338)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1344)  
 <223> n equals a,t,g, or c

<400> 39	
ctccagggat	gtgatccggc atccttgagt ttgctcacag tgcctgtgca ccattcgaga 60
agcccagccc	ctytccctca ccaccaaacc agaaaccggg gccagctgg ctctccactc 120
tgcgccttcm	tgtcggctaa ggctgcagcc tcctcytctg ggcagatggg cagccagcyt 180
ccccctctgt	cccgcccyt ccccttgagg tccatgccc cagctctgct ggctctccc 240
ccgtccttcc	ccgccacgct ccatgccac caggccctcc cgggtctaca ggcccagcct 300
ctttccctgg	tcaccaagtc tgcccactaa gctccccccg acccctgcag gctgtcacat 360
gactcattga	gtagtaatga ttcagaagaa aaagaaaaag gagactttat tgggtcaatat 420
ttgaccactc	tggactgttc tgtaaagtgg ctggttaaaa cagcaacttta cagttttag 480
atgtaaccag	tagctgatct taaggctttt ttaaaaaaca aaacaaaaca aaaaaaaaaa 540
atctttataa	gaaagagaac tgaaaagtag cgtgctattc gtcctgtagg tgctgtggtg 600
gatggacctg	ggcagagggc acttctctct cttacctctc ttgcaacttc tgtctcctgt 660
ctcttctcgc	ccctgccgcc tgccccagct tccccgactc catctgcagc tctgccattg 720
tgacatttcc	tgttaccag cccaagtttt catcgtctgc tcaataccgt gggttcttct 780
tcgtcctctg	tcctctgccc agtgtgaggc catcaccatg tgagaagaca tcttggcctg 840
atttgctgcc	accagcgtcc cctccctcag tgggcccga ctcgccagcc ccagctttca 900
gtggagaaag	cggctcctctg aaatggtttc ctcccaacc cgcatttaa agggactcaa 960
gggtgcctgcc	acttccctcag cgaagaagtc tgtgttctc cccgtccttg ccagtggcga 1020
tcaccccttc	acaatcccag agtggcaggc gggaccrgcc ccattggtctg gctcctgtca 1080
cctgggtccg	tgccagcaca atctgccaaa gttctagaga ccctgttccc tccccatca 1140

cctcacatgc	ttcttctgtg	tgtatttctt	tttgttttta	tggttttttg	agcaatttaa	1200
actcccagtt	gtttattttc	acaaaagaaa	ataaaattgc	agttgcaaaa	aaaaaaaaaa	1260
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1320
aaancnsggg	gggggggncc	gttnc				1345

&lt;210&gt; 40

&lt;211&gt; 1246

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 40

ggcacgagct	cgtgccgaat	tcggcagagg	tcaccttctc	ctcctttccc	tgctgggggt	60
ggcaggggtc	cctttacccc	ctcattcttg	acccttctcc	agggatgctt	gtgacctcct	120
tacccacccc	cccatcacct	ctctgtcctg	aagtgagggg	ttgtcacctg	ccatggcaag	180
gtgtggtgtc	tggtaggctc	tatgacctgc	cttctctcag	ggtgtttatt	ctgcagcaga	240
gaggggtctg	cggctctgagt	gtaatggtgg	aaatccaggc	ttccttccat	ggcccaagga	300
ggcctttccg	gagcaacagg	gttttctctg	gactcagcct	ggcttttggt	aaggcagggtc	360
ccggatttac	tcagaagatg	ggccccagag	aggaggagag	gaaaggaata	cctgtcagtc	420
aaacgtgaag	ccactgatg	acactgcctg	gcagagctgc	ctccggctcag	cagtgaccct	480
tcacccccca	gtctccaagt	cctcttctctg	agggagctgg	tccggcttta	tggaaggctc	540
cgcctgtgtt	ccccactgg	gtccctgggtc	cctcacctgt	cacgtggggc	gatggtcacc	600
ctccctccct	gcctgccctg	aaggatacac	tgagatgaag	gtcaggaaat	ctgctggctg	660
cagaaccagg	ggccatgcag	gagtgaggga	tggtctgggtc	aagttgaggc	tctgccccag	720
cctcagtttc	cccacacagg	catgagactg	tcttctctgac	tttcagagga	cagggtctgag	780
atgggatgag	ggaacacagg	gaaagcgttt	agcacctctg	agtgtgtgtg	ggatgcgacc	840
tggggggtcc	tggcctccac	tctttaattc	tatctggact	gtgtgccctc	ctacctccag	900
tttccctgcg	ggggcctttc	acagggcctg	gcttgcggtg	acggggtttg	gcgtagggca	960
gtgcttctca	aatgggaagg	cgcaactggga	ttcttcagggt	tggggtgggg	cctgagggttc	1020
tgcatcttcta	atcagttgcc	taggactggc	tctaattctt	gttgaattta	caatcacttg	1080
tgaggttaag	aaaaacatac	tgggccttgg	ttgggtgtgg	tggctcacac	ctgtaatccc	1140
agcacttttg	gaggccaagg	tgggcagatc	atgaggtcga	gagattgaga	ccatcctggc	1200
caacatggtg	aaaccttgct	tctactaaaa	aaaaaaaaaa	aaaaaa		1246

&lt;210&gt; 41

&lt;211&gt; 2174

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

ggaattcccc	gggggaatgg	gccactgatt	catttcgtgg	ttaactggaa	tactgctttt	60
taattgatac	ccagctgtat	ctaaatcatt	acaatactgg	acagatagtg	tagtgcagag	120
tatttgaaat	gcagtgcttt	gtttggcaaa	gatttattta	atggtttcat	tttctctgca	180
agaagaaaaa	aagcagatca	tcgaagctct	tattatttgc	actgtggcag	attcacttga	240
gttcagaagc	ctagggaaaa	ggtgggactt	ttgaaactag	ggcagtaggt	aaatgtggac	300
acaccttcgt	ttgtatttga	ttagggatct	gacagcgtgc	atatgtgtac	aggtttgcac	360
gtgtgcatac	acacatatac	aaatcataga	aaaccatagg	tggtctgtga	gagagaaaat	420
tttgctactt	aaatacagcg	tgaattctca	tcctgatagt	tgagaaaaat	atttctttta	480
aaatggagat	taatgtctaa	ttccatataa	agaagattat	aggaaagggtg	atttaaactg	540
taagtagctt	tggtcactaa	aacgctagat	ttatttgaaa	cagtgtttta	tttcttttgg	600

aaggcagaca	actagtttaa	tagtgtacat	atgaaacgct	aatttggctt	gttaattgga	660
tgcaattaaa	ttgaggttat	tttatactgc	ttaattgtta	gaaaattaca	tgcggttgcca	720
tgctgtgtga	atgtgaagca	aaagcgaagg	gtatagcagg	agtgggggtg	ggagggacgc	780
aagatctagt	cctgtctttg	caattaactt	tctgtgaaaa	cttggaacaa	agtcattcgaa	840
gctcttttga	cctcatttgg	aaatggaaga	gattggaaca	gatggctcct	aaagcttctt	900
ccagctcata	ttctatcagt	ttataaattc	tactttgtag	ttgtagagaa	tgcaatgtca	960
ttatattctg	taattatggt	attacaagga	tgaactaaac	acttaaaaaa	atcagcacag	1020
tgccaattta	gcaaatccgt	tagaaggaag	gcaatttagg	cttaaagagc	actcacctgt	1080
gccaggctcc	atcccaggct	ctctctccac	attacgtcac	ttagccctca	caaccaacct	1140
gagaagattt	agttttttat	cttgatgtgt	atacttaaa	aaacttccat	tcggaaaagg	1200
tttgtgggga	tgctttgcta	gtcattgggtg	aagcaggatt	cgaactcagg	gttctttggc	1260
tccgaaaatg	ctttgtcttt	ttaccattt	cacgcagtat	aagcaattgt	ttacacatca	1320
aaattatttc	aaatatttaa	aaaaggccaa	ccatatttat	cacttagcac	aatgtttccc	1380
cttagtagta	tatggataaa	caggtagccc	acgggattaa	gaacctcgat	ttgaagtcag	1440
acagaatagg	gcaaatccca	gtccaccac	cacctggggg	aatttgggta	tgttacttaa	1500
cctccctgag	gttacaaaat	gaggataata	cccattcaag	agtcattggg	aaatttttat	1560
gagaatgttt	gtaccatct	caatgagcac	atagtaaacg	tttaatacct	ggtagctatg	1620
ggttattatt	aacaagggtat	tagactataa	gaaaaacata	ggacaattca	aattgttgtg	1680
acagtaaaat	attaaatatt	ttcaaagtgt	ccattaaact	cttgactgaa	atggtttaag	1740
aaacaatggt	agaatgacat	ggtttcacat	ttaacagtta	acaaatggaa	atatcaatta	1800
aaatctgggg	tggtttctcac	tgagctcagc	cagtgtctatg	ccaatgaagt	gaactaaatt	1860
ctctgggttct	ttgtggaaaa	tcattctgaa	gtttttgctc	taaaaatagc	ttttggggcc	1920
tgaattaccc	cttaccaccac	tcgaacttct	gtgcaagagc	cagaggacca	gtgattactc	1980
gtggggccct	tgggcctact	taagagactc	aacttgggtg	ttcacaggac	tggtgacttt	2040
aattctaaaa	aaatttatta	attcaacaga	gatttattaa	gcacctgctc	tgggaaaggg	2100
ctgttctaga	cactggagat	ccatcaatag	acaaaaatag	taaaaaaaaa	aaaaaaaaac	2160
tcgagggggg	gccc					2174

&lt;210&gt; 42

&lt;211&gt; 854

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

ggcagcagcc	agcaacatca	ttgatgtgtc	tgctgcagac	tcacagggca	tgagcagca	60
tgagtacatg	gaccgtgcca	ggcagtagac	caccgcgttg	gctgtgctga	gcagcagcct	120
gaaccatttg	gaagaagctg	ccaccgctgc	cgtctcttac	cagccagccc	caccaagtgc	180
tggccagtga	gccccatccc	ttctctgatt	tgacgcaggt	ctccaggata	gctgcttatg	240
cctacagtgc	actttctcag	atccgtgtgg	acgcaaaaga	ggagctgggt	gtacagtttg	300
ggatcccatg	aagagagggg	tccttggaca	gctcttctcc	tctcttcac	ccatctctac	360
cccacccctt	tggccccag	cctcactgcg	gcttatacag	taccctaacc	tgctactaat	420
cacagagaaa	aatgtgaaga	aggaggagaa	gaggaaggct	agaagcctga	gcaagtgagg	480
gtagaacctt	ttgggactgg	cctttgaagc	tctggccagg	gatgggggtg	gggcaaaaag	540
gacagagcct	ggtatgtctt	catagtcatt	gagaatgtgg	agataccagt	ttgggtgggg	600
ggtgatcacc	aggggacctt	gggagatccc	cttcccaccc	tctctgttgg	cctcagagtc	660
actcctgccc	cctctccctg	acttgggtgt	cacatgcacc	tcactagggg	ttgtgaccag	720
ggtctggatg	agcttgaatt	tgaatgaatt	gagtttgtat	ttctagaacc	ctgggttttt	780
acatgttttg	tctttttttg	ttttggtttg	tcaccctcga	taaaggaagt	atattcaaaa	840
aaaaaaaaaa	aaaa					854



<210> 43  
 <211> 776  
 <212> DNA  
 <213> Homo sapiens

<400> 43  
 ggcacgagtg aagtagaaca tgcattgagaa agaattgcaga aatcatgaat aaacagctcc 60  
 agaaagggat cagcggccaa taaccagcac ccgaattcag agcccaccag cccccgggat 120  
 cccggccacg tccactctga ccccatgcct gcaaggatag ggtctctatc gtgacttcta 180  
 accccaccag gtacttttgc ctcttttttag aaatggaatc atacagtctg tactcttttg 240  
 tgcctgggtt gttttgggta acattgcgtc tgggagtttt atctctgtcc aggggtggcg 300  
 aacccagct tacaagccaa atctggctct ttgcctgttt tcatatggcc tgtgagctaa 360  
 ggatggattt tatgttttta aatagttgcg ggggggggag ggggggggag gaaagaatga 420  
 tattttgtga cgcgtgaaaa ttatatgaaa ttcaaatgtg tgtccacaaa ttgactgggc 480  
 atggtggctc atgcctgtaa tcccagcact ttgtggggcc gaggtgggtg ggtcacttgg 540  
 ggccagaagt ttgctaccag cctgaccaac atggttgaac cccatctct actaaaagg 600  
 acaaaaaaat agctgggtgt ggtggttga gcctgtaatc ccagctactc aggtggctga 660  
 ggcaggagaa tcacttgaac ccgggaggca gagattgcac tgagccaaga ttgtgccact 720  
 gtacttcagc ctggatgaca gagtaacact gtatctcaaa aaaaaaaaaa aaaaaa 776

<210> 44  
 <211> 1733  
 <212> DNA  
 <213> Homo sapiens

<400> 44  
 aattcggcac gagtggacaa cactatgaag ctgtggctag aaagggactg tcatgtccca 60  
 tcctttggcc agattgactg gggatgtccg gacagatgcc tgcattgggtg gtgagggcca 120  
 catctgcaca cgagccagtg gctgcttga gttcactgct gtgatgccag agtgtgttca 180  
 aaggtgactc tcctgctctt ctggactctt ctctcaggca agaaaggctg caggctgcct 240  
 gctatgtgat gcctgagcac aaagccaagg aactgaacta agtctttctg ttaagtcctg 300  
 agtttgtcat tggcagggtt acttgtggcc agctctctct gcccttgggt gtctgagcag 360  
 gcagaccaga agaccaggca ctggacctgc atgccaagg gactggtcat ctctgagga 420  
 cctgtaaatg accctgtgga ctgttccgca cgatccggaa cccacttttt attcactccc 480  
 catgtctttg gccttctctt tctttctctt tccctctgcc atcctgacac tgatagtttg 540  
 tcatataaat tccccgggtt gtgttttttt ttctagaaaa aaattaaaag ggaaaacaaa 600  
 accaaaaaaa ccagaaacca cgaataagaa tggaaatgac aatggctgcc tgtcattttt 660  
 ctgtcacgat ttccctgatt tggtttggtc cctttgtctc agagaagcag gagatgttga 720  
 tgaggctgta tttttttttt tttttctgtt ttttgagaca agagtctcgc tctgtcaccc 780  
 gggctggagt gtaacgtggc atgatctcag ctactgcaa cctctgcctc ctgggttcaa 840  
 gcgattatcc tgcctcagcc tcctgagtag ctgggattac aggcattgct cactatgcc 900  
 agataatttt tttgtatttt tagtagagac agggtttcac catgttggcc aggtggtct 960  
 ggaactccta acctcagggt atccaccac cttggcctcc caaagtgtg ggattatagg 1020  
 catgaaccac cgtgcctggc caaagatgta atttaaaata gttagaaggg acttggcatg 1080  
 ggccagctcc gtgcattgca ttttcacccc cagagcttcc taatcctgtt ttcacacagg 1140  
 aagtttctag gtctttctag aacagctaga aatagtagct gactcccgcc caaggcccaa 1200  
 ccttcaaacc ctgagctctt caggctgcat cctctggtga gctatagagg agaactggc 1260  
 tcctaaactc tagccatcct gtgggaggaa atagacttct ttgggctgtg gcttgcagaa 1320  
 caaactacac tttttttccc tctattgttt aaattttatt taataatttg tgtgtttttc 1380

tgtctttatt	ttctgtattt	cacgtgttcc	ttcactccct	agaaactgca	ctttctttga	1440
aaccataggt	aatgaatctt	actaggagag	gcatggggat	agagacagtt	ctgggagtgt	1500
gacctgtaag	cctcctgtag	ggcagtgcc	ggccttgatt	gccacagttc	tctccgttcc	1560
ttcttccttc	atacatttga	tcacacagcc	tacacccagc	cccagagtgtg	catcacggta	1620
aaagagctga	gggctctctt	cagggagcag	cccatttagg	tctcttttgt	tggtgttagg	1680
gagaatacac	atctttcttg	gaaaaaaaa	aaaaaaaaa	ctcgaggggg	ggc	1733

&lt;210&gt; 45

&lt;211&gt; 1918

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (9)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (28)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 45

taacgcctnc	cttgacggcc	tccacaangc	actcttcgcc	actcagcgca	gcttgaggca	60
gcaccagcgg	ctcttccaca	gcctctttgg	gaacttccaa	gggcwcatgg	aagccaacgt	120
cagcctggac	ctggggaagc	tgcagaccat	gctgagcagg	aaagggaaga	agcagcagaa	180
agacctggaa	gctccccgga	agagggacaa	gaaggaaagc	gagcctttgg	tgacatacag	240
ggtcacaggg	cctgtgccag	gtgccttggg	cgcggcgctc	tgggaggcag	gatccccctgt	300
ggccttctat	gccagctttt	cagaagggac	ggctgccctg	cagacagtga	agttcaacac	360
cacatacatc	aacattggca	gcagctactt	ccctgaacat	ggctacttcc	gagccccctga	420
gcgtggtgtc	tacctgtttg	cagtgagcgt	tgaatttggc	ccagggycag	gcaccgggca	480
gctggtgttt	ggaggtcacc	atcggactcc	agtctgtacc	actgggcagg	ggagtgggaag	540
cacagcaacg	gtctttgcc	tggctgagct	gcagaagggt	gagcgagtat	ggtttgagtt	600
aaccacaggga	tcaataacaa	agagaagcct	gtcgggcact	gcatttgggg	gcttccctgat	660
gtttaagacc	tgaacccag	ccccaatctg	atcagacatc	atggactcgc	ccagctctcc	720
tcggcctggg	gctctggcca	aggatgggct	ggaggtcatt	cagttggtct	gtctcttccc	780
tggaacacct	ctgcaaagat	ggtgtggtgt	acgtggcttc	cctgtaacca	catggggcct	840
ggccatttct	ccatgatgag	aaggactgga	atgcttctcc	gggcaggaca	tggtcctagg	900
aagcctgaac	cttggtcttg	catgccttct	cagacagcac	ggcctgggct	ccaactcttc	960
accacaccct	gtattctaca	acttcttttg	tgttttgctc	ctcctgtggt	tggaacttc	1020
tgtacaacac	tttaaacttt	tctcttgctt	cctcttctct	tctcccttat	cgtatgatag	1080
aaagacattc	ttccccagga	ggaatgttta	aaatggaggc	aacatttttg	ccaacattgg	1140
aaagcactag	agggcaatgg	gattaaacca	acctgcttgg	tctctattag	tcagtaatga	1200
agacgacagc	ctggccaacc	aagggaagg	aaattagtat	ctttagtctc	agtcattcct	1260
tgtaggatat	ggtttagctg	tgccccacc	taaaatatca	tcttgaattg	taatccctat	1320
aatccccaca	tcaagggaga	gatcaggtgg	aggtaattgg	atcttggggg	cggttcccc	1380
atgctgttct	tgtgatagtt	ctcacgagat	ctgatgatgt	tataagtttg	atagttcctc	1440
ctgtgttcat	tctccttctc	gccaccttgt	gaagatgcct	tggttcctct	tcactgtctg	1500
ccatgattgt	aagtttctctg	aggcctcccc	agccatgtgg	aacagtgagt	caattaaacc	1560
tctttccttt	ataaattatc	cagtcttggg	caattcttga	tagcagtgtg	aaaatggact	1620

aatacacttg	tgtttatctg	taattttaat	ttcatgtctt	tttctccttg	ccttacatag	1680
ggtaaagacc	aagaaatgcc	aaacgtgaac	taaaatatgt	agggccttca	acttttttac	1740
ttcctccagt	atcttaggac	catcgtaatt	cttgtagca	tctctaacca	ggaggcagct	1800
gagggaggag	ggaaagaaga	ctgtaaaaat	ccccctcact	aatgatcaac	tttgaataa	1860
agtgatgcc	ttcaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaactcga	1918

&lt;210&gt; 46

&lt;211&gt; 1610

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 46

ggcacgagtc	aaaacaagta	tggattttga	atgtgaatat	tttaaaagat	atattgaaat	60
tacttagagt	agccctggat	atatgttcat	tatggcattt	atcttgtaa	taagtttcta	120
catgctcatt	ttaattttcca	gtagcatgag	caagtaactt	atatttcatt	cccagaaaa	180
taaaagaatc	tgcttaaaga	gtatgaaaat	tgccattaaa	tctgtattgt	ctactttctg	240
gatgggtata	tcattatagt	tctctgctct	tccacacatt	tttgggctgc	tatcagtttg	300
taagtaatca	ttatacaaac	taaattttaa	aattttaaaca	agataatttt	atattacttg	360
gatcagggaa	aaaatgcagt	tgctgaagg	ggtttcatag	ctaaatataa	gcaattattt	420
tgttttttct	acttttttgg	attttatcat	cttttccctt	ttagtaatag	agtaatacag	480
gtaggaatta	acttagcact	gccaaattaa	tagtaatat	agaactgtgt	acacagcaca	540
gggttaaggt	tatatagaaa	aatgtotcat	ccatgtttaa	tttggctgac	cagcccagtt	600
gattagccaa	ttttattgtt	ttgttaaatt	aaaattctaa	atatagttgt	ccattgttaa	660
aataagttag	taggggttaa	atagagaatt	gataaaaaata	aagccttaaa	aatcttttag	720
ctaaagtagc	aggcttcaag	tgaaattcag	ttttgggtctc	ctttacagga	atagctattc	780
agtcagacag	aaccacttat	cacgttttgc	agtatctcct	gaggaagtca	gaattctgag	840
ccagcatgaa	gacggaatct	tgtctttgat	ctgatttgca	aaccgtactt	ttattctaata	900
catgtgcaag	gtggagggtta	tagcgtggga	actaaaatct	tagtaagtgt	ggtttttatt	960
ttagctatta	agtagtatac	tttcttatag	tgattttttt	ttcttcttag	cagagttcac	1020
actataaata	gtgtatggac	ttggcaggca	ggaacataat	acagtatact	tcaaaagtga	1080
aagatttagg	ccaggcgtgg	tggttcatgc	ctgtaatcct	agcactttgg	gaggtcgagg	1140
tgggtggatc	acgaggctag	gagttcatca	agagaagccc	ggccaagatg	ctgaagccct	1200
atctctacta	aagggtacaaa	aatttagccgg	gcattggtggc	atgcgcctgt	agtctcggct	1260
acttgggagg	ctgaggcagg	agaatcgctt	gagcctgggg	ggtggagggt	gcagtgagct	1320
tagattgcac	cactccactg	cattccggcc	tgggcaaaac	atagcgagac	tccatctcaa	1380
aaaaacaaaa	atgaaaacaa	caacaacaaa	aaaacaaaca	aacaaaagat	ttaaccctct	1440
aggttcagga	aaaatccctg	agaaagagag	agcaaaagctt	ctatactctg	cctaggattt	1500
ctttctcttt	ccgggtgaaa	aataggcggt	gggatgatac	tgagttgata	aaagtattag	1560
gaaaagtggc	cagtgtctaa	attcaagcca	ttaaaaaaa	aaaaaaaaaa		1610

&lt;210&gt; 47

&lt;211&gt; 879

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 47

ggcacgagaa	attacagcag	tgcaaagcag	agctaaactc	taccactgaa	gagttgcata	60
agtatcagaa	aatgttagaa	ccaccaccct	cagccaagcc	cttcaccatt	gatgtggaca	120
agaagttaga	agagggccag	aagaatataa	ggctgttgcg	gacagagctt	cagaaacttg	180

gtgagtctct	ccaatcagca	gagagagctt	gttgccacag	cactggggca	ggaaaacttc	240
gtcaagcctt	gaccacttgt	gatgacatct	taatcaaaca	ggaccagact	ctggctgaac	300
tgcagaacaa	catggtgcta	gtgaaactgg	accttcggaa	gaaggcagca	tgtattgctg	360
agcagtatca	tactgtgttg	aaactccaag	gccaggtttc	tgccaaaaag	cgccttggtg	420
ccaaccagga	aaatcagcaa	ccaaaccaac	aaccaccagg	gaagaaacca	ttccttcgaa	480
atttacttcc	ccgaacacca	acctgccaaa	gctcaacaga	ctgcagccct	tatgcccgga	540
tcctacgctc	acggcggttc	cctttactca	aatctgggcc	ttttggcaaa	aagtactaag	600
gctgtgggga	aagagaagag	cagtcatggc	cctgagggtg	gtcagctact	ctcctgaaga	660
aataggtctc	ttttatgctt	taccatatat	caggaattat	atccaggatg	caatactcag	720
acactagctt	ttttctcact	tttgtattat	aaccacctat	gtaatctcat	gttggtgttt	780
ttttttattt	acttatatga	tttctatgca	cacaaaaaca	gttatattaa	agatattatt	840
gttcacaaaa	aaaaaaaaata	aaaaaaaaaa	aaaaaaaaaa			879

&lt;210&gt; 48

&lt;211&gt; 1330

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 48

gtcctgagtc	cccagccagc	cttcagggtc	cccttggtat	gtgtagatgc	agtctagcgg	60
ggggccggag	aagggctcag	gtgggagggg	cctcagcagg	ctcccagctc	aggggctggc	120
ctggggggaa	ccctgggagc	caggggctga	ctccagcaac	actggcctgt	ctgcctgttc	180
tgggagggct	gtgaggatgt	cttgccagatg	ctctggattt	ctgcggaggc	acctccattc	240
ctttctggct	ttttttgcgg	gggagggcct	tgggcctctt	tctttgaggg	aacaccgtca	300
aagaaagcct	gggagatcga	ggcttcagtg	agccaggatg	gaaacgcgtg	tcccaagtgt	360
ccggagcagg	cggcagaggc	ctcagtgcgg	caaacacagc	cccagagcct	gtgtggcacc	420
agcagcatct	tagagcccca	ggtatatgct	gagatcttat	ctcacgctgt	cctccagtgt	480
ctggggggcc	caaatgatgg	cacaggggca	agttgggctt	gaagggcgca	gatgcctgtg	540
ttcaaggaag	gtggccacca	tgggcccagg	tctcaccag	gaccccttgc	tctgctcctc	600
agccttgcat	tcacggcagc	actatggtgg	actgcccatg	gccgtgtgac	tttgggggca	660
agtgggaggg	cgccttgaat	aatgattgca	aggacaacag	gcagaggcta	ccctagagca	720
ggacacaggg	tgtggtactg	acaaccctag	tgtcacctca	aatccatgtc	cccacactct	780
gggcatgggt	gggacttgtg	accctaccct	gtcaggcgga	ccagtggccc	aggagccatg	840
aggacagttg	tgtgccactg	gaagagaaac	tttttgaaaa	accctaaatc	aggtagagaa	900
agcaaaaaat	ctctggccgt	aaaccgtgct	ctctaattta	tcggcagctt	ctgtggatga	960
cctctgatga	gcccgggctg	cgtccacgcc	ctgggcagg	aggcgggagc	ttccctgcgt	1020
gggcctcatt	tcttgctgca	gagaatcttt	tgactaagt	catgctgttt	cctcaaagaa	1080
gctttgtttt	ttgttaacgt	attactcaga	gtcacccaag	cctcttggtt	gaggggtgaag	1140
gtgggacggg	aggcgggagg	gggctggtgg	tggcgctcgt	gcggtgtcaa	cgctgcaggg	1200
agttgtggca	ccttggtgcc	ctctgagcac	ctggccgcct	gctgtccccg	gtgcctgtga	1260
aattcgtcat	gccatgacct	acctgcatta	aacctatttt	tttaatgtgt	aaaaaaaaaa	1320
aaaaaaaaac						1330

&lt;210&gt; 49

&lt;211&gt; 1100

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 49

```

ggcacgaggg ccaactgtgtc ctgggacgtc ccagaaggca acatcgtcat tggctactcc      60
atttcccagc aacggcagaa tggccccggg cagcgtgtga ttcgggaggt gaacaccacc      120
acccgggcct gtgccctctg gggcctggct gaagacagt actacacagt gcaggtcagg      180
agcatcgccc ttcggggaga gagtcccca gggccccggg tgcacttccg aactctcaag      240
ggttctgacc ggctaccttc aaacagttca agcccagggt acatcacagt ggaagggtctg      300
gatggagagc ggccactgca gactggggaa gtggtcatca ttgtgggtggg gttgctcatg      360
tgggctgctg taattgggct gttctgccgt cagtatgaca tcatcaagga caatgactcc      420
aacaacaatc ccaaggagaa gggaaagggg ccggaacaga gtcctcaggg aaggccagtg      480
gggacaagac agaaaaagtc accatctatc aacaccatcg acgtttgagt gaagaaacac      540
accagaaga gagatgcact aacaactggg gatagggatg gggtcagggg gagccaaga      600
tgggtgatctg cccgagactc ccagagggta atgccactcc cacaatctca ggctggtac      660
ccatcctctt tccactgtga gcagagccag aaggtaggtc tgttcagagt ctgtgccct      720
ggacctgggg agtggatatc agatgggata tctccttcca tccccgggc caggggagag      780
tactagttag taccctactc cattaggtcc caaatggggg ccccatctca cctgtatcag      840
gactctgagc atccccagct gcccacatc ttgcctctgg ccctcagaga ggggtgtttc      900
tgtgggtact cctcttaccg cagcaaataa aaggaattgt ctgacctag aggcagatgc      960
tgcactgcac tactccaatg tcttccatgg agcctcagggt gctccccctc tcacctggca     1020
gcccttctag ctgctagtga tatcacttgt tggacatttt tccaataaag gttcttggac     1080
aaaaaaaaaa aaaaaaaaaa                                     1100

```

&lt;210&gt; 50

&lt;211&gt; 890

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

```

ggcacaggaa atgaggcatc tgttggtggc ttccctgtgg agtttgtgtc cctccctgag      60
ctccgcctc tgtggggcca gcccagtggt ggacttgtgg cccctgtgtc tgctgggcct      120
caggtttggg tctgcgaggt acatgggtgt gagtgtctctg accactggac tcttaaaaca      180
tgcagccctc tttgactgtg acaactggaca tgtgcaaagc ttggggactg atcaaaaagt      240
ataaagaggc cattgaaaaa gaccttgact cctgcaccca gaggtagcac caagaacatg      300
gcatgcattt catctccacg tctcccttct ctcttctct cccctgttca ttcattcagc      360
caatctatca gccaacctg aagcaactcac ggacaccac gtgcgcagggt gccatggagg      420
cagccgagtg tggggactgc tgtggc aaag ctggcagcct tgtgtgtctc ctgcacttgt      480
gacattttat tgcagccagt gcctgtgcca ttaagcattc cttgaaaata aaatcttttt      540
tggctgtacg atgtttcttc gtgtagacat accaaaagta aactcttggc cggctgcggt      600
ggctcatgcc tgtaacccta gcactttggg aggetgagac ggggtggattg cctgagctca      660
ggagttcgga ccagcctggg caacacgggtg aaaccccgtc tctactaaaa taaaaaaat      720
tagttgggag tgggtggtgtg tgccctgtagt cccacctact caggaggctg aggcaggaga      780
atcgcttgaa cccgggagac aaagggttgc gtgagcctag atcacacatc tgcactccag      840
cctgggcgac agcgaactcc gtctccaaaa aaaaaaaaaa aaaactcgag      890

```

&lt;210&gt; 51

&lt;211&gt; 1523

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 51

```

ggcacgaggt tgtcttccat ggctgttttc tctgtgtgtc tgggtgagtg agcctgcaac      60

```

gcaatgccca	tgagagtaaa	tgccctcctga	cctaccctgc	tcagcaactgt	tctagtgtct	120
tgcccttgaa	agaaaagcct	gacttcctgc	tgacacatgt	ggtaggggca	tggcagctat	180
gaggcacctc	ctacgtctgt	tttctggctg	tggtgacttg	ggatttttaa	ccttatatat	240
ctttttcctt	tactcaaaac	aaaacaattt	ttagcacact	gaaaaaaaaa	aaaagccaaa	300
tgttttgtgc	ctttctaagg	cagcaactgta	tcccaggctg	catttttagga	cttaatatgg	360
aaataccaga	gtctgagctc	ctctaccttg	agtttcatta	gtccttagtg	tctaggagac	420
aggaaagaat	gctctctgtg	actggagagg	tgacatgcag	gtgcagtgtg	tctggagtcc	480
ctttcccctg	ctgtgagact	tcagtggagg	agagaagcat	tgtaccctgg	gatcatttgg	540
ttggttccaa	tcacaagctt	agttatcagg	ttgcatgcct	tgtctcctgc	aaaagacaga	600
atgtttcaca	attcccaggt	aaactctgga	ccattccaag	tgtcctagcc	ttctgatgac	660
attaattacc	tagttgtgtc	gaggagtata	ggatggactc	tcctgagaag	gggagggttg	720
tggtttgtgc	ttttcttttt	gctggatcct	gaactggtct	agacctcctg	ccccacccc	780
ccagccccc	tcagatgtgg	ctggcccttc	atttgaaggc	ttcagactta	aagcattaag	840
cagctagtgc	cctctgcagg	gcctggtttc	cccagggaag	ggcagcaagg	aacatgggac	900
cagaagcctg	tcctcagtaa	tgtgactata	gtgagcttta	gcaaaagttt	ttctatataa	960
tgacatctta	cttatctttt	accctttcct	cagttttccc	ctgcctttaa	ctaataaaga	1020
attggggagac	agaaatttta	aagtcctcct	tattcaagat	tttgaatttc	ttagcctggg	1080
agtgtgtggag	agaacctgat	gctttctcca	gaatgaagag	tcccaatttg	tatatcagtg	1140
ttaagaagaa	aacaaaacaa	acacataggt	gagattttcg	tggactattt	taaaaatgtg	1200
tcattaatat	aaaaaattta	tattagcagt	atttaatcat	tctcacctgt	aaagaataag	1260
aaaaacagaa	ggtaaataat	cttacagaga	atagcagagc	tttaagattc	attttcattt	1320
taagtccatt	ttattttgcc	agtgtattaa	tgtttagaag	tctgttttac	taatgttatt	1380
tattaatttt	ttttcatttc	catacacagt	tagttaacta	aagagctttt	tcaagcacc	1440
atgtctgtaa	aaaaatattt	ttaaataaag	tttcttttgt	tgtagcagaa	aaaaaaaaaa	1500
aaaaaaaaaa	aaaaaaaaaa	aaa				1523

&lt;210&gt; 52

&lt;211&gt; 2078

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 52

aattcggcac	gagcccacac	ctgtctgccc	ccaccccggc	agcacctttc	cctgcccagg	60
cttcagagtg	ccctgttgct	gctgccactg	ccccccacac	tccaggggcca	tgtcagagct	120
cccattctacc	ctccaccagc	atgccgctcc	tgaagatgcc	cccaccattc	tcgggggtgca	180
gccacccctg	cagcggggcac	tgtggtgggc	actgcagtgg	gcctctcctc	ccacccccga	240
gctctcagcc	actccctagc	actcacaggg	atcccggtg	caagggggcac	aagtttgcac	300
acagtggcct	ggcttgccag	ctgccccagc	cctgcgaggg	agatgagggg	ctgggtgagg	360
aagaggatag	cagctctgag	cgaagtcctg	cacctcatcc	tccaccacc	agagagatgg	420
gaagtctctg	gactgctgct	actgtgagtt	cttcggccac	aatgcggaaa	aggagaaggc	480
ccagttggca	gcagaagctc	taaagcaggc	aaatcgtgtt	tctggaagcc	gggagccaag	540
gcctgccagg	gagaggctct	tggaagtggc	ccgaaccggg	aactggatcg	ggtcaacagc	600
ttcctgagca	gcgctctgca	ggagatcaaa	aacactgtca	aagactccat	ccgtgccagc	660
ttcagtgtgt	gtgagctcag	catggacagc	aatggcttct	ctaaggaggg	ggctgctgag	720
cctgagcctc	agagtctacc	cccctcaaac	ctcagtggct	cctcagagca	gcagcctgac	780
atcaaccttg	acctgtcccc	tttgactttg	ggctccccctc	agaaccacac	gttacaagct	840
ccaggcgagc	cagccccacc	atgggcagaa	atgagaggcc	cccaccacc	atggacagag	900
gtgagggggc	cccctcccg	tatcgtcccc	gagaacgggc	tcgtgaggag	actcaacacc	960
gtgcccgaac	tatcccggt	gatctgggtc	aagacaccca	agccgggcta	ccccagctcc	1020
gaggagccaa	gctcaaagga	agttcccagt	tgcaagcagg	agctgcctga	gcctgtgtcc	1080

tcaggtggga	agccacagaa	gggcaagagg	cagggcagtc	aggccaagaa	gagcgaggca	1140
agcccagccc	cccgccccc	agccagccta	gaggttccca	gtgccaaggg	ccaggtcgct	1200
ggccccaagc	agccaggcag	ggtcctagag	cttcccaaag	taggcagctg	tgctgaggct	1260
tggaagaggg	gaagccgggg	gaagccggcc	aggaccaggt	tgggctggca	gtcccaaaac	1320
tgagaaggag	aagggcagct	cctggcgaaa	ctggccaggc	gaggccaagg	cacgggcctc	1380
aggagcagga	gtctgtgcag	ccccagggcc	cagcaaggcc	acagagcttg	ccccagggca	1440
agggccgcag	ccgccggagc	cgcaacaagc	aggagaagcc	agcctcctcc	ttggacgatg	1500
tgttcctgcc	caaggacatg	gacggggtgg	agatggatga	gactgaccga	gaggtggagt	1560
actttaagag	gttctgtttg	gattctgcaa	agcagactcg	tcagaaagtt	gctgtgaact	1620
ggaccaactt	cagcctcaag	aaaaccactc	ctagcacagc	tcagtgaggc	cctgcccagg	1680
ctgagctgct	tcagggcacg	ctgaggccct	gactgccagc	tgaaggcgta	taatttttcc	1740
ctccgtgtgc	cccacctacc	cgtccaagac	cctctgtgct	ccccaccatc	ctggaccaac	1800
caaaagctga	acggatgccca	cactgtgctg	gggccccttg	acctcagcag	agccgcttcc	1860
tggtgctacg	cagcctccac	actcagagcc	cgtggactgg	gctggcctaa	gggccagggc	1920
tgatggtact	gctggcccaa	cactgctctc	tttgtgtttg	gtttttttgt	ttttgttttt	1980
attttgtttt	tttccaattc	tttacttttg	atactgtgaa	gatctttcgt	gccgaaagat	2040
aaagcaacat	ttggacacag	aaaaaaaaaa	aaaaaaaaaa			2078

<210> 53

<211> 903

<212> DNA

<213> Homo sapiens

<220>

<221> SITE

<222> (18)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (27)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (56)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (94)

<223> n equals a,t,g, or c

<220>

<221> SITE

<222> (889)

<223> n equals a,t,g, or c

<220>

<221> SITE

&lt;222&gt; (898)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (900)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 53

tgttaccggt	tcgccggnag	ccggaancgg	accgaaccgc	aagcgaattc	attgancgag	60
gaaccggaag	gagcgcccaa	atacgcaaac	cgctctctcc	ccgcgcgttg	ccgattcatt	120
aatgcagctg	gcacgacagg	tttcccgact	ggaaagcggg	cagtgcgcgc	aacgcaatta	180
atgtgagtta	gctcactcat	taggcacccc	aggctttaca	ctttatgctt	ccggctcgta	240
tgttgtgtgg	aattgtgagc	ggataacaat	ttcacacagg	aaacagctat	gaccatgatt	300
acgccaaagt	cgaaattaac	cctcactaaa	gggaacaaaa	gctggagctc	caccgcgggtg	360
gcggccgctc	tagaactagt	ggatcccccg	ggctgcagga	attcggcacg	agacgacacg	420
ataaataaaa	gcagatgttc	aaatgggaga	cacctgaaga	gacaagttag	tccaatggat	480
aggagcgaag	gaaactgccc	ctttgtaaag	attgaggaaa	agagtgtaaa	attatgctct	540
cattacactc	atgctgttac	taaggcctac	agagagaagg	tattgagagg	tgacaacatg	600
ctggcagccc	tcgcttgctc	ttggcgccctc	ctcagcctcg	gtgcccactc	tggccgtgct	660
tgaggagccc	ttcagcccg	cgcttcactg	tgggagtccc	tctctgggct	ggccgaggtc	720
aaagccagct	ccctctgctt	gcagggaggt	gtggagggag	aggtgcgggc	aggaactggg	780
gctgcgcgcg	gcacttgtgg	gccagctcga	rgggggggccc	ggtacccaat	tcgccctata	840
gtgagtagta	ttacaattca	ctggccgctc	ttttacaacg	tcgtgactng	gaaaaccngn	900
aaa						903

&lt;210&gt; 54

&lt;211&gt; 1104

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 54

tgcaggaatt	cggcagcagc	ttcacatttt	tctattccac	tcccagccca	aaaataactaa	60
aaacagaaag	aacaaagtcc	atacaaagag	tatttcatga	aaaatttaac	ccactttttt	120
ctttcgtttt	cttccctctc	ctcttttctt	tttcttgtct	cctcttcttt	ctcacgcagg	180
gcagggccgg	gccaggggta	gcgggccagg	gtaaggctcg	agctgctcca	acttctgggtg	240
tgtacttggt	agtctttatg	atattcttgt	agattcaatc	atgaaacatg	agtttgatgc	300
tggtgtgatt	gtaggtggtc	ttgcagtcag	gtgaacagtt	gctcccaaag	agaactgacg	360
gctcagcctc	agcctggagg	ggatgtagac	ctctcgtgac	ataactcagt	gctgggaggg	420
aagtcaacag	agtgaatcaa	ggacagaacc	aacactcaaa	atgatggcaa	gagttgcagc	480
caaagccagc	cagatgacac	accaacaaaa	tacagtaaag	cccataaagg	tcagtccttg	540
gcttcagaga	aaaccatagt	gggcagtgat	gcatttgga	aatatctgga	aaccttgcc	600
gctggcagac	actgtgggtt	atctatggga	tccagctgct	aactccatca	atgtgacctt	660
acacttcatt	aatggaagt	tctacctaac	tggatgtaac	agcctcctca	ctaacttata	720
tttacagtgc	tgcctctgag	tcagcagtaa	aagttcaaat	tatattcaga	atcttctgct	780
taataaatta	gaaaagtgtc	ggccaggcgc	ggtggctcat	gcctgtaatc	ccagcacttt	840
gggaggccga	ggctgggtga	tcacttgagg	tcgggggttc	gagaccagcc	tggccgacat	900
ggtgaaaccc	cgtctctgct	agggatacaa	gggttggtg	ggcgtggtgg	cgggcacctg	960
tggtcccagc	tactcgggag	gctgaggcag	gagaattgct	caaaccaggg	aggtggaggt	1020
tgcagttagt	cgagatcgcg	ccactgcact	ccagcctggt	gatacagcga	gactccatct	1080



caaaaaaaaaa aaaaaaaaaac tcga

1104

&lt;210&gt; 55

&lt;211&gt; 692

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 55

tgcaggaatt	cggcacgagt	gagcttcacg	gggctgagt	atgagctgct	gcacctcctg	60
ctgcccagcc	tgtgggcgct	gccccgcctc	acccagctcc	tgctcaacgg	caaccgactg	120
acgcgggcca	ctgcccgcaa	gctcactgat	gccatcaagg	acaccaccaa	gttccctgct	180
ttggcttggg	tggacctggg	caacaacgtg	gatgtggctt	ccctgcccc	gcccctgctg	240
gtcggcctgc	gccggcggct	gagccagcgc	acctcactcc	ccaccatcta	cgagggcctg	300
gaccttgagc	ctgagggcag	tgcggccggg	gccaccaccc	ctgcctccac	ctgggactcc	360
acagctgctg	ggctgggacc	cgagccccag	gcctgctgtg	ccagggtgacc	caccacccac	420
ctggctcatt	gctactgact	tgtgatgctc	tcaagcacat	gatagtgggc	gatgaaggtc	480
aaggaggact	cacaggcccc	cagaaatcca	gtgtaaattg	tcagcctgag	attaaggggg	540
cagaagaatg	gactcatagg	tggccagggt	gccagccctg	gctagagggt	cagccttccc	600
tcagtgggag	gggccccagc	acccacagtg	tggaccccg	aataaagagt	gacacccgcc	660
tctgcttttc	tgcaaaaaaa	aaaaaaaaaa	ac			692

&lt;210&gt; 56

&lt;211&gt; 789

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (15)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (47)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 56

cgtatgttgt	gtggnattgt	gagcggataa	caatttcaca	caggaancag	ttatgaccat	60
gattacgcca	agtctaatac	gactcactat	agggaaagct	ggtacgcctg	caggtaccgg	120
tccggaattc	ccgggtcgac	ccacgcgtcc	gctcttatat	taaaataata	cctggccggg	180
agcagtggct	cacacctgta	atcctagcac	ctttggaggc	cagggtgggc	agatcgcttg	240
aggtcaggag	tttgagagca	gcctggccaa	catggcgaaa	ccccgtctcc	gcaaataata	300
caaaaaatga	gccgagcgtg	gtggcacacg	cctgtattct	cagcctcctg	agtgcctggg	360
accacagtca	tgccccacca	cacctggcta	atatTTTTTg	TTTTTgtaga	gatgaggttt	420
cgctatgctg	cgcgggctgc	gtcgaactcc	tgccctcaag	caaacctcct	acctcagcgt	480
cccgaaggct	gggatttatg	gtgcacgcca	ctgcactctg	cccttttgta	ggtatttttt	540
ccccctttct	ctgattgtac	ctattgattt	ttctcccttt	ctctgattgt	acctattgat	600
tgtttagagt	ctctgaaaaa	tcacactctt	attggctaag	tcttcacccc	ataaatcttt	660
cctaataaat	gtcatttcag	actctcagaa	ctttcagcat	taaagagttt	tctattcatg	720

ccctcaattc ctcccataag aactaaagtg atcttttgca aagtaaaaaa aaaaaaaaag 780  
ggcgccgc 789

<210> 57

<211> 1236

<212> DNA

<213> Homo sapiens

<400> 57

ccacgcgtcc gagacaacat ccggcccagc agctctgggg ggtactgggt gggcatgtcg 60  
accatccgcc ctaaccctgg gttttccatg ctggatttct tatctgagag accctggatt 120  
aaaaggatga tttttaagct cttagtcaa gagacggtga tgaagtttgt gccgcgtac 180  
agcctcgtcc tagaactcag cgacagcggg gccttccgga gaagcctgca tgatcccgat 240  
gggctggtgg ccacctacat cagcgagggt cacgaacacg atgggcacct gtacctgggc 300  
tctttcaggt ccccttcct ctgcagactc agcctccagg ctgttttagcc ctcccagata 360  
gctgcccctg ccacgcaggc caggagtctt cactctcagg caccaggcct ggtccaggag 420  
gagctgtgga cacagtcgtg gttcaagtgt ccacatgcac ctgttagtcc ctgagagggtg 480  
gtgggaatgg ctgcttcatt cctcgaggat gcccgggccc cactgggct tgtctttctg 540  
tttagaggga agtgaacat atctgccatg aggaacataa attcatgtaa agccattttc 600  
tcttaacaa aacaaaactt tctaagtaca gtcatctctt aggatttggg aagctccttg 660  
cacttggaac agggtcagg tgggtggagc agtaaggcac taccagaga gcttgctgct 720  
gcggccctgt cctgcggcct caaagttctt cttactata tataacgtgc ggtcatacct 780  
ttcttcgttg tggtggggat ggaagagcag agggagcatg gccaggggt gttgaggcca 840  
gcggtgagag ccgtgttagc caagacatgg aactgtgttc tcaagggtta tgtggggcgt 900  
gggctctcca tagtgtgtat gaaaaagctt gttgactcta gcggctcaga gaggacttg 960  
ctgggtttct ttctgtgaat atctccgtgc tgaccatgct ggaattggat gattctgcaa 1020  
ttcgggacct actgcagggg tccgtttagt aacgtcttgt ctgtgatctt tgttcttgac 1080  
ctctagacct caagatgtga acagtgcacg tgtaaatgtc atctttgtct atgtgttata 1140  
agccccaagt tgctgtatat ttccacaagt atgtctacac actggtcatg attttgataa 1200  
taaataacga taaatcgaaa aaaaaaaaaa aagggc 1236

<210> 58

<211> 1065

<212> DNA

<213> Homo sapiens

<400> 58

gccacgcgt ccgcccacgc gtccgcccac gcgtccgctt tttaaaaaat atctgaaaaa 60  
agcttcatat ctttacaac tcataaaata gctgattggg ccatggagga gatgaggctg 120  
tttagaactg gttttgtttc aagtttgta attttccctg tatgagaact tgggtaaagc 180  
acaaagaaac atacagtgt agtaacaggt ctctgcgcc ctggaactaa gtgtttggag 240  
gaaggactaa accccggggg aggtgagtat aaaataattc cactaagatc acctcctcag 300  
tccccagaag gctgatggtg gatcctctgg ccctctctg tggggtctta ctgctcctct 360  
gccatttctc tatgcctgaa gacacgaaga tgatatcaag gcagagctac catatcgag 420  
ccagtctcta ggctactgct gtgcagtggc tcccactttc taatgctttt ttgtttttgc 480  
tttttctaac aaaacaatct tttttcaaaa tgaattccaa cccctgctag cttccttccc 540  
cgctccata ctgttttagg cagcaccgtt tatgtgatag agtccgtgtt tctcaaatgc 600  
atggtgttcc tcagggtggag agtgggcaga agtttttgca acactttttt ttttaagttat 660  
tggtgtcaaa atcccaaacc aggatatgtg tatgtctgtg tgtttatgtt ttttatttga 720

40

```

ccctcccctc tttcaaccta cccccccttta tatctaattgt agaaaaagcg aaattgaatc      780
tggaagcaaa actgttgtat atagttgctg taacaatcat gaagagagag ccgggctgtc      840
ccctcagtaa ttcattttta ataacaaatt atttaaaaaa aaaattcatg ccagagccag      900
ctgaagaggc cttccttcat caccactgag gccaccccca atctgggccc tctgtccatc      960
tggcattgtc cctcccagca agattcatct gttcaatgcc atttgcgttt caataaagtt    1020
atctcctgta ctgtcaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa                    1065

```

&lt;210&gt; 59

&lt;211&gt; 54

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (54)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 59

```

Met Glu Leu Thr Ile Gly Thr Phe Arg Ile Met Met Ile Asn Trp Leu
  1             5             10             15

```

```

Val Phe Ser Gln His Cys Gln Leu Phe Leu Arg Ser Leu Leu Leu Pro
      20             25             30

```

```

Leu Leu Leu Cys Thr His His Val Cys Met Glu Cys Ala Arg Arg Gly
      35             40             45

```

```

Arg Gly Ser Gly Arg Xaa
      50

```

&lt;210&gt; 60

&lt;211&gt; 19

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (9)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (19)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 60

```

Met Ile Leu Leu Leu Leu Arg Leu Xaa Cys Ile Leu Lys Gln Leu Ala
  1             5             10             15

```

41

Phe Phe Xaa

&lt;210&gt; 61

&lt;211&gt; 62

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (62)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 61

Met Leu Cys Ala Met Leu Ala Cys Gly Gly Leu Cys Asn Ala Leu Thr  
1 5 10 15

Cys Met Glu Glu Ala Arg Leu Arg Ala Glu Met Trp Pro Glu Pro Ser  
20 25 30

Leu Tyr Arg Ser Phe Asn Leu Glu Leu Ser Arg Cys His Phe Leu Pro  
35 40 45

Leu Cys Leu Leu Val Val Ser Asp Ile Tyr Ser Lys Gln Xaa  
50 55 60

&lt;210&gt; 62

&lt;211&gt;

49MIQTPTTRPHLLTLGWSTCFLVWSHEIRTGAHIQTMSHTIQRRIAMCK\*KDLNLL\*\*KQNEEV\*MVNFHLGGQ  
ELYKNPS\*KVSALYLGETHDENELVMFFVLX\*A\*SFILKEF\*ALVNNLPWFLL\*LLLYHTRKASTPAQFPYFLSL  
FPFSSHVXYVLILEWSGMLSS\*PQPL\*DLTNQSPLESXLQDNFPNLSETLPIRR VHWSLTSKITSPAT\*TKPQH  
PQHHSSA\*LLFGDEVRCG\*IHMKTLHAVKSTDVRGQHCFFCIIIFVLPVMCLSCHPLPPHYDPPRGQKLYVS\*P  
IPKCRKGRGTEPXS

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (49)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 62

Met Ile Gln Thr Pro Pro Thr Arg Pro His Leu Leu Thr Leu Gly Trp  
1 5 10 15

Ser Thr Cys Phe Leu Val Trp Ser His Glu Ile Arg Thr Gly Ala His  
20 25 30

Ile Gln Thr Met Ser His Thr Ile Gln Arg Ile Ile Ala Met Cys Lys

42

35

40

45

Xaa

&lt;210&gt; 63

&lt;211&gt; 32

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (32)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 63

Met Trp Pro Leu Arg Leu Leu Cys Thr Ser Trp Ser Phe Leu Arg Ser  
1 5 10 15

Pro Phe Leu Gly Leu Ala Arg Leu Lys Lys Lys Thr Ser Ser Phe Xaa  
20 25 30

&lt;210&gt; 64

&lt;211&gt; 50

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (50)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 64

Met Ala Ser Gly Phe Leu Phe Cys Trp Ala Lys Ala Leu Trp Gly Trp  
1 5 10 15

Arg Gly Trp Cys Trp Cys Cys Thr Gly Leu Thr Ala Ala Leu Thr Gln  
20 25 30

Arg Phe Pro Pro Ser Leu Leu Pro Val Cys Cys Val Asp Leu Phe Leu  
35 40 45

Val Xaa

50

43

<210> 65  
<211> 41  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (41)  
<223> Xaa equals stop translation

<400> 65  
Met Thr Ser Met Leu Leu Leu Val Arg Trp Ile Pro Lys Leu Leu Leu  
1 5 10 15  
Leu Leu Leu Ser Cys Met Ala Pro Gly Tyr Trp Gly Arg Ser Leu Leu  
20 25 30  
Phe Leu Ile Leu Lys Ala Gly Leu Xaa  
35 40

<210> 66  
<211> 4  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (4)  
<223> Xaa equals stop translation

<400> 66  
Val Glu Arg Xaa  
1

<210> 67  
<211> 16  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (16)  
<223> Xaa equals stop translation

<400> 67  
Met Pro Phe Asn Lys Arg Ser His Ser Pro Ala Ala Leu Cys Pro Xaa  
1 5 10 15

44

<210> 68  
<211> 63  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (63)  
<223> Xaa equals stop translation

<400> 68  
Arg Arg Ala Val Arg Trp Glu Leu Leu Val Leu Leu Leu Leu Leu  
1 5 10 15  
Pro Thr Leu Arg Arg Pro Gly Pro Arg Cys Arg Pro Gly Pro Gly Cys  
20 25 30  
Arg Leu Arg Pro Arg Arg Pro Arg Pro Arg Val Arg Pro Ser Gln Asp  
35 40 45  
Ala Ala Pro Gly Arg Val Ser Thr Ser Trp Pro His Leu Pro Xaa  
50 55 60

<210> 69  
<211> 24  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (24)  
<223> Xaa equals stop translation

<400> 69  
Met Ser Leu Gly Pro Ser Pro Met Cys Ile Leu Trp Leu Leu Asp Pro  
1 5 10 15  
Leu Gln Lys Ser Asn Thr Lys Xaa  
20

<210> 70  
<211> 45  
<212> PRT  
<213> Homo sapiens

<220>

45

&lt;221&gt; SITE

&lt;222&gt; (45)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 70

Ile Cys Val Ala Asn Tyr Arg Leu Trp Cys Lys Val Cys Leu Ile Phe  
1 5 10 15

Leu Pro Leu Thr Pro Ala Asn Cys Cys Ile Leu Asp Ser Leu Phe Gln  
20 25 30

Tyr Cys Ile Lys Thr Leu Val Leu Cys Trp Thr Glu Xaa  
35 40 45

&lt;210&gt; 71

&lt;211&gt;

66MAPSTATRHWHAHCFASCRSTGMQRLCGPGIPKNSLPVTSWWTWGASTTLGDTDMTITRGLSQRP\*APCPLGS  
RGRPS\*AVRDSSICTSGTSCWPCWALVKRTAWWAPSMTRCMTLWRRWMLWTMGSPSGQRGSLDMH\*PLP\*VHE  
LLDLILPGTTPTKTLRQGSSVQWIWFKRSFCRD\*ISTNTAGCQPGPWWKRPLPSDSRWTQVERLWNWRKVHVPGR  
SISTTWNLGCPLQWPSSLLSTLRLDSGEYSVCPRSPTHSKAGCPCQSHGGVFGTRPWTRSVGSLAASSSMQAAS  
LAVXAPERVP\*AWPVPPWPSAHTSHKSPSLIKPSIS\*KKKXKKL

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (66)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 71

Met Ala Pro Ser Thr Ala Thr Arg His Trp His Ala His Cys Phe Ala  
1 5 10 15

Ser Cys Arg Ser Thr Gly Met Gln Arg Leu Cys Gly Pro Gly Ile Pro  
20 25 30

Lys Asn Ser Leu Pro Val Thr Ser Trp Trp Thr Trp Gly Ala Ser Thr  
35 40 45

Thr Leu Gly Asp Thr Asp Met Thr Ile Thr Arg Gly Leu Ser Gln Arg  
50 55 60

Pro Xaa  
65

&lt;210&gt; 72

&lt;211&gt;

64MQIHMIPTVYELKIRCLLLFVSFSRKMSQQPIRKLYQSTLDYKLTETINNKAQYQYNTPKGT\*VVYYWACFS  
AEASMELCESPLLHFLCLQFESHWVRVRLNPSWPS\*IRLQYNFVDTFSSQSPSIAITLLSPKRKNKKTQ\*HINNS



DNLFISLXTYGIKTPNSYSLNFQXNAILLCLLVENSFPLGAMLSESKIKRTESRQLECVNKC�LKGHLHPSFQS\*D  
 SRRIYFS\*GGKRMPCGSHLFRT\*TVFCRTVPQICKLLTLNEAHL SFHGVCNTHKSLEH\*LIALFLYKVISFKLKQ  
 LCVGYHALAYGRQSIDRARTKNDQKKKKKKKKKKGGXYRGSLEGPKLTRACGVFTSNQL\*RVSX

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (64)

<223> Xaa equals stop translation

<400> 72

Met	Gln	Ile	His	Met	Ile	Pro	Val	Thr	Tyr	Glu	Leu	Lys	Ile	Arg	Cys
1				5					10					15	

Leu	Leu	Leu	Phe	Val	Ser	Phe	Ser	Arg	Lys	Met	Ser	Gln	Gln	Pro	Ile
			20					25					30		

Arg	Lys	Leu	Tyr	Gln	Ser	Thr	Leu	Asp	Tyr	Lys	Leu	Thr	Glu	Thr	Ile
	35						40					45			

Asn	Asn	Lys	Ala	Thr	Gln	Tyr	Glu	Tyr	Asn	Thr	Pro	Lys	Gly	Thr	Xaa
	50					55					60				

<210> 73

<211> 171

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (171)

<223> Xaa equals stop translation

<400> 73

Met	Ala	Trp	Ser	Pro	Pro	Ala	Thr	Leu	Phe	Leu	Phe	Leu	Leu	Leu	Leu
1				5				10					15		

Gly	Gln	Pro	Pro	Pro	Ser	Arg	Pro	Gln	Ser	Leu	Gly	Thr	Thr	Lys	Leu
			20					25					30		

Arg	Leu	Val	Gly	Pro	Glu	Ser	Lys	Pro	Glu	Glu	Gly	Arg	Leu	Glu	Val
		35					40					45			

Leu	His	Gln	Gly	Gln	Trp	Gly	Thr	Val	Cys	Asp	Asp	Asn	Phe	Ala	Ile
	50					55						60			

47

Gln Glu Ala Thr Val Ala Cys Arg Gln Leu Gly Phe Glu Ala Ala Leu  
65 70 75 80

Thr Trp Ala His Ser Ala Lys Tyr Gly Gln Gly Glu Gly Pro Ile Trp  
85 90 95

Leu Asp Asn Val Arg Cys Val Gly Thr Glu Ser Ser Leu Asp Gln Cys  
100 105 110

Gly Ser Asn Gly Trp Gly Val Ser Asp Cys Ser His Ser Glu Asp Val  
115 120 125

Gly Val Ile Cys His Pro Arg Arg His Arg Gly Tyr Leu Ser Glu Thr  
130 135 140

Val Ser Asn Ala Leu Gly Pro Gln Ala Gly Gly Trp Arg Arg Ser Ala  
145 150 155 160

Gln Ala His Pro Cys Gln Cys Gln Ala Ala Xaa  
165 170

&lt;210&gt; 74

&lt;211&gt; 47

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (47)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 74

Met Ser Ile Ile Pro Cys Arg Pro Gln Pro Arg Ala Gly Arg Cys Tyr  
1 5 10 15

Ser Leu Cys Phe Met Leu Leu Leu Trp Pro Leu Phe Leu Pro Ser Ser  
20 25 30

Glu Leu Cys Arg Val Tyr Cys Arg Gln Ser Glu Val Ser Phe Xaa  
35 40 45

&lt;210&gt; 75

&lt;211&gt;

33MGSWLWTVANLLHIPPNNLYRMLAGRWQRAHWD\*GAGHPTLFHLCCLSPGSIITAKTCSVVLAGRPCGCWLRVLL  
SCATPLKCSSLRKKKKKKGGX

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

48

&lt;221&gt; SITE

&lt;222&gt; (33)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 75

Met Gly Ser Trp Leu Trp Thr Val Ala Asn Leu Leu His Ile Pro Pro

1

5

10

15

Asn Leu Tyr Arg Met Leu Ala Gly Arg Trp Gln Arg Ala His Trp Asp

20

25

30

Xaa

&lt;210&gt; 76

&lt;211&gt;

25MASELARLLHAFGLMGPRKAGESS\*TWSWVCGLVSTLFRGTEGGKAHGAGFCCWEAGWALFVGLRFRTE\*ES  
SCCEL RVYSGHAMPFFCTKRVEKQRPD\*LANWNPTTQFIYFLXVEGII\*GELKSQPKGKKKKKGGPIEDPSRGPS  
LRVHAGXLPQXKYREF

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (25)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 76

Met Ala Ser Glu Leu Ala Arg Leu Leu His Ala Phe Gly Leu Met Gly

1

5

10

15

Pro Arg Lys Ala Gly Glu Ser Ser Xaa

20

25

&lt;210&gt; 77

&lt;211&gt; 30

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (30)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 77

Met Leu Met Ala Ser Ala Leu Ser Arg Cys Ala Gly Ala Ala Val Leu

1

5

10

15

Val Leu Leu Leu Trp Leu Ala Val Asp Trp Ala Leu Met Xaa

49

20

25

30

&lt;210&gt; 78

&lt;211&gt; 22

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (22)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 78

Met Cys His Gly Gly Leu Val His Leu Ser Thr His His Leu Ser Phe  
1 5 10 15

Lys Leu Cys Met Gln Xaa  
20

&lt;210&gt; 79

&lt;211&gt;

29MTPNQAGITPSSRWQWLGLCLDLLGR\*SVPSTSSRSVSSFSMSACKAVTPAQSTMASRRPLGRFCRRVRQ  
LSGKDTSQLRFSP\*AMELSNSCHLKC\*RSWSTEAACTTPGNSQCTLYVVAWLVPVWPPSLCTPWMFCAPALQLRVS  
PRSIIRC ATPWGPCIGAKAPRFSTKAWLPP\*SPSSPTPGCSSLATAP\*STCTSGPYQPKERKMRTSKTCFVAVEL  
VSSARP\*HIRWTSSRSGYRLEGLSMPELPLARYGDTRASWTVPSRCYKRKAPWASSRACPPAC\*RLPSPQASCSS  
RMNSSVMSSTA\*TGQPASAERRKDPRSSLEAAS\*RKEDSVSTERCRLALPCRPAAPSGVAALNPPSWDTTTRSRA  
LPMRESEGMQDVVYGEPTTQ\*EGAGSCCFSSDQPTLQRKQTPSYTYQPCLPGEQNTLLVWMGLLLECRGLR\*ALC  
RSQVPTLGLFFQPI\*\*TLKLNTHXKKKKKNSRGGPV

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (29)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 79

Met Thr Pro Asn Gln Met Ala Gly Ile Thr Pro Ser Ser Arg Trp Gln  
1 5 10 15

Trp Leu Gly Leu Cys Leu Asp Leu Leu Leu Gly Arg Xaa  
20 25

&lt;210&gt; 80

&lt;211&gt; 39

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

50

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (39)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 80

Glu Pro Leu Cys Leu Ser Arg Leu Val Leu Ser Thr Val His Phe Ser  
1 5 10 15

Leu Ser Val Pro Trp Ala Leu Met Lys Lys Gln Asn Ala Pro Asn Phe  
20 25 30

Ile His Leu Pro Ser Leu Xaa  
35

&lt;210&gt; 81

&lt;211&gt; 61

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (61)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 81

Met Ala Val Thr Ala Leu Ala Ala Arg Thr Trp Leu Gly Val Trp Gly  
1 5 10 15

Val Arg Thr Met Gln Ala Arg Gly Phe Gly Ser Asp Gln Ser Glu Asn  
20 25 30

Val Asp Arg Gly Ala Gly Ser Ile Arg Glu Ala Gly Gly Ala Phe Gly  
35 40 45

Lys Arg Glu Gln Ala Glu Glu Glu Arg Tyr Phe Arg Xaa  
50 55 60

&lt;210&gt; 82

&lt;211&gt; 35

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (35)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 82

51

Met Phe Ile Thr Pro Leu Ser Trp Ser Leu Leu Ile Trp Val Leu Leu  
1 5 10 15

Gly Phe Leu Leu Leu Phe Leu Asn Tyr Ser Arg Leu Leu Tyr Ile Leu  
20 25 30

Asp Phe Xaa  
35

<210> 83  
<211> 28  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (28)  
<223> Xaa equals stop translation

<400> 83  
Met Ala Arg His Ser Thr Ser Thr Cys Phe Arg Arg Ser Trp Trp Arg  
1 5 10 15

Thr Trp Cys Leu Ala Ala Gly Trp Ala Pro Pro Xaa  
20 25

<210> 84  
<211> 195  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (195)  
<223> Xaa equals stop translation

<400> 84  
Met Cys Gly Ser Cys Trp Ala Phe Ser Val Thr Gly Asn Val Glu Gly  
1 5 10 15

Gln Trp Phe Leu Asn Gln Gly Thr Leu Leu Ser Leu Ser Glu Gln Glu  
20 25 30

Leu Leu Asp Cys Asp Lys Met Asp Lys Ala Cys Met Gly Gly Leu Pro  
35 40 45

Ser Asn Ala Tyr Ser Ala Ile Lys Asn Leu Gly Gly Leu Glu Thr Glu  
50 55 60

52

Asp Asp Tyr Ser Tyr Gln Gly His Met Gln Ser Cys Asn Phe Ser Ala  
 65 70 75 80  
 Glu Lys Ala Lys Val Tyr Ile Asn Asp Ser Val Glu Leu Ser Gln Asn  
 85 90 95  
 Glu Gln Lys Leu Ala Ala Trp Leu Ala Lys Arg Gly Pro Ile Ser Val  
 100 105 110  
 Ala Ile Asn Ala Phe Gly Met Gln Phe Tyr Arg His Gly Ile Ser Arg  
 115 120 125  
 Pro Leu Arg Pro Leu Cys Ser Pro Trp Leu Ile Asp His Ala Val Leu  
 130 135 140  
 Leu Val Gly Tyr Gly Asn Arg Ser Asp Val Pro Phe Trp Ala Ile Lys  
 145 150 155 160  
 Asn Ser Trp Gly Thr Asp Trp Gly Glu Lys Gly Tyr Tyr Tyr Leu His  
 165 170 175  
 Arg Gly Ser Gly Ala Cys Gly Val Asn Thr Met Ala Ser Ser Ala Val  
 180 185 190  
 Val Asp Xaa  
 195

<210> 85  
 <211> 11  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (11)  
 <223> Xaa equals stop translation

<400> 85  
 Asn Thr Met Ile Ala Ala Gly Ser Cys Asp Xaa  
 1 5 10

<210> 86  
 <211> 29  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (29)

<223> Xaa equals stop translation

<400> 86

Gly Asn Pro Lys Lys Leu Trp Arg Arg Met Val Leu Leu Leu Thr Arg  
1 5 10 15

Gln Thr Tyr Leu Pro Leu Ala Leu Leu Cys Gly Lys Xaa  
20 25

<210> 87

<211> 18

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (18)

<223> Xaa equals stop translation

<400> 87

Met Leu Leu Leu Cys Val Phe Leu Phe Val Phe Met Val Phe Gly Ala  
1 5 10 15

Ile Xaa

<210> 88

<211> 19

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (19)

<223> Xaa equals stop translation

<400> 88

Met Thr Cys Leu Leu Ser Gly Cys Leu Phe Cys Ser Arg Glu Gly Ser  
1 5 10 15

Ala Val Xaa

<210> 89

<211> 5

<212> PRT

<213> Homo sapiens



&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (5)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 89

Phe Val Cys Ile Xaa

1 5

&lt;210&gt; 90

&lt;211&gt; 57

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (57)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 90

Met Lys Arg Gly Val Leu Gly Gln Leu Phe Ser Ser Leu His Pro Ile

1 5 10 15

Ser Thr Pro Pro Pro Trp Pro Pro Ala Ser Leu Arg Leu Ile Gln Tyr

20 25 30

Pro Asn Leu Leu Leu Ile Thr Glu Lys Asn Val Lys Lys Glu Glu Lys

35 40 45

Arg Lys Ala Arg Ser Leu Ser Lys Xaa

50 55

&lt;210&gt; 91

&lt;211&gt; 47

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (47)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 91

Gly Ile Ile Gln Ser Val Leu Phe Cys Ala Trp Phe Val Leu Val Asn

1 5 10 15

Ile Ala Ser Gly Ser Phe Ile Ser Val Gln Gly Trp Arg Thr Pro Ala

20 25 30

55

Tyr Lys Pro Asn Leu Val Leu Cys Leu Phe Ser Tyr Gly Leu Xaa  
35 40 45

&lt;210&gt; 92

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (28)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 92

Ala Arg Val Cys Ser Lys Val Thr Leu Leu Leu Phe Trp Thr Leu Leu  
1 5 10 15

Ser Gly Lys Lys Gly Cys Arg Leu Pro Ala Met Xaa  
20 25

&lt;210&gt; 93

&lt;211&gt; 38

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (38)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 93

Met Pro Ser Gln Thr Ala Arg Pro Gly Leu Gln Leu Phe Thr Thr Pro  
1 5 10 15

Cys Ile Leu Gln Leu Leu Trp Cys Phe Ala Pro Pro Val Val Gly Asn  
20 25 30

Phe Cys Thr Thr Leu Xaa  
35

&lt;210&gt; 94

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (25)

56

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; .94

Met Phe Ile Met Ala Phe Ile Leu Leu Ile Ser Phe Tyr Met Leu Ile  
 1 5 10 15

Leu Ile Ser Ser Ser Met Ser Lys Xaa  
 20 25

&lt;210&gt; 95

&lt;211&gt; 118

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (118)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 95

Cys Val Glu Thr Pro Arg Pro Gly Phe Cys Gln Lys Ala Pro Trp Tyr  
 1 5 10 15

Gln Pro Gly Lys Ser Ala Thr Lys Pro Thr Thr Thr Arg Glu Glu Thr  
 20 25 30

Ile Pro Ser Lys Phe Thr Ser Pro Asn Thr Asn Leu Pro Lys Leu Asn  
 35 40 45

Arg Leu Gln Pro Leu Cys Pro Asp Pro Thr Leu Thr Ala Phe Pro Phe  
 50 55 60

Thr Gln Ile Trp Ala Phe Trp Gln Lys Val Leu Arg Leu Trp Gly Lys  
 65 70 75 80

Arg Arg Ala Val Met Ala Leu Arg Trp Val Ser Tyr Ser Pro Glu Glu  
 85 90 95

Ile Gly Leu Phe Tyr Ala Leu Pro Tyr Ile Arg Asn Tyr Ile Gln Asp  
 100 105 110

Ala Ile Leu Arg His Xaa  
 115

&lt;210&gt; 96

&lt;211&gt; 45

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

57

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (45)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 96

Met Ser Cys Arg Cys Ser Gly Phe Leu Arg Arg His Leu His Ser Phe  
1 5 10 15

Leu Ala Phe Phe Ala Gly Glu Gly Phe Gly Pro Leu Ser Leu Arg Glu  
20 25 30

His Arg Gln Arg Lys Pro Gly Arg Ser Arg Leu Gln Xaa  
35 40 45

&lt;210&gt; 97

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (24)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 97

Met Glu Ser Gly His Cys Arg Leu Gly Lys Trp Ser Ser Leu Trp Trp  
1 5 10 15

Cys Cys Ser Cys Gly Leu Leu Xaa  
20

&lt;210&gt; 98

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (24)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 98

His Leu His Val Ser Leu Leu Ser Phe Pro Pro Leu Phe Ile His Ser  
1 5 10 15

Ala Asn Leu Ser Ala Asn Gln Xaa  
20

58

<210> 99  
<211> 35  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (35)  
<223> Xaa equals stop translation

<400> 99  
Met Ala Ala Met Arg His Leu Leu Arg Leu Phe Ser Gly Cys Gly Asp  
1 5 10 15  
Leu Gly Phe Leu Thr Leu Tyr Ile Phe Phe Leu Tyr Ser Lys Gln Asn  
20 25 30  
Asn Phe Xaa  
35

<210> 100  
<211> 34  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (34)  
<223> Xaa equals stop translation

<400> 100  
Leu Pro Arg Leu Gln Ser Ala Leu Leu Leu Leu Pro Leu Pro Pro Thr  
1 5 10 15  
Leu Gln Gly His Val Arg Ala Pro Ile Tyr Pro Pro Pro Ala Cys Arg  
20 25 30  
Ser Xaa

<210> 101  
<211> 22  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (22)

59

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 101

Met Leu Ala Ala Leu Ala Cys Ser Trp Arg Leu Leu Ser Leu Gly Ala  
1 5 10 15

His Ser Gly Arg Ala Xaa  
20

&lt;210&gt; 102

&lt;211&gt; 35

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (35)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 102

Met Lys Asn Leu Thr His Phe Phe Leu Ser Leu Ser Ser Leu Ser Ser  
1 5 10 15

Phe Leu Phe Leu Val Ser Ser Ser Phe Ser Arg Arg Ala Gly Pro Gly  
20 25 30

Gln Gly Xaa  
35

&lt;210&gt; 103

&lt;211&gt; 38

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (38)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 103

Met Pro Ser Arg Thr Pro Pro Ser Ser Leu Leu Trp Leu Gly Trp Thr  
1 5 10 15

Trp Ala Thr Thr Trp Met Trp Leu Pro Cys Pro Ser Pro Cys Trp Ser  
20 25 30

Ala Cys Ala Gly Gly Xaa  
35

60

<210> 104  
<211> 30  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (30)  
<223> Xaa equals stop translation

<400> 104  
Met Gly Ala Arg His Cys Ile Trp Pro Phe Cys Arg Tyr Phe Phe Pro  
1 5 10 15

Leu Ser Leu Ile Val Pro Ile Asp Phe Ser Pro Phe Leu Xaa  
20 25 30

<210> 105  
<211> 27  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (27)  
<223> Xaa equals stop translation

<400> 105  
Met Gly Thr Cys Thr Trp Ala Leu Ser Gly Pro Pro Ser Ser Ala Asp  
1 5 10 15

Ser Ala Ser Arg Leu Phe Ser Pro Pro Arg Xaa  
20 25

<210> 106  
<211> 39  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (39)  
<223> Xaa equals stop translation

<400> 106  
Met Val Asp Pro Leu Ala Ile Ser Cys Gly Val Leu Leu Leu Leu Cys  
1 5 10 15

61

His Phe Ser Met Pro Glu Asp Thr Lys Met Ile Ser Arg Gln Ser Tyr  
                   20                  25                  30

His Ile Ala Ala Ser Leu Xaa  
                   35

<210> 107  
 <211> 124  
 <212> PRT  
 <213> Homo sapiens

<400> 107  
 Asp Glu Ile Ala Lys Ala Gln Val Ala Arg Pro Gly Gly Asp Thr Ile  
   1                  5                  10                  15

Phe Gly Lys Ile Ile Arg Lys Glu Ile Pro Ala Lys Ile Ile Tyr Glu  
                   20                  25                  30

Asp Asp Gln Cys Leu Ala Phe His Asp Ile Ser Pro Gln Ala Pro Thr  
                   35                  40                  45

His Phe Leu Val Ile Pro Lys Lys Tyr Ile Ser Gln Ile Ser Ala Ala  
                   50                  55                  60

Glu Asp Asp Asp Glu Ser Leu Leu Gly His Leu Met Ile Val Gly Lys  
   65                  70                  75                  80

Lys Cys Ala Ala Asp Leu Gly Leu Lys Lys Gly Tyr Arg Met Val Val  
                   85                  90                  95

Asn Glu Gly Ser Asp Gly Gly Gln Ser Val Tyr His Val His Leu His  
                   100                  105                  110

Val Leu Gly Gly Arg Gln Met Asn Trp Pro Pro Gly  
                   115                  120

<210> 108  
 <211> 126  
 <212> PRT  
 <213> Homo sapiens

<400> 108  
 Asn Glu Val Ala Lys Ala Gln Gln Ala Thr Pro Gly Gly Ala Ala Pro  
   1                  5                  10                  15

Thr Ile Phe Ser Arg Ile Leu Asp Lys Ser Leu Pro Ala Asp Ile Leu  
                   20                  25                  30

Tyr Glu Asp Gln Gln Cys Leu Val Phe Arg Asp Val Ala Pro Gln Ala



62

35	40	45
Pro Val His Phe Leu Val Ile Pro Lys Lys Pro Ile Pro Arg Ile Ser		
50	55	60
Gln Ala Glu Glu Glu Asp Gln Gln Leu Leu Gly His Leu Leu Leu Val		
65	70	75
Ala Lys Gln Thr Ala Lys Ala Glu Gly Leu Gly Asp Gly Tyr Arg Leu		
85	90	95
Val Ile Asn Asp Gly Lys Leu Gly Ala Gln Ser Val Tyr His Leu His		
100	105	110
Ile His Val Leu Gly Gly Arg Gln Leu Gln Trp Pro Pro Gly		
115	120	125

<210> 109  
 <211> 89  
 <212> PRT  
 <213> Homo sapiens

<400> 109  
 Phe Ile Leu Pro His Gln Gln Val Asp Lys Gly Ala Ile Lys Phe Ile  
 1 5 10 15  
 Leu Asn Gly Ser Ser Ile Met Cys Pro Gly Leu Thr Ser Pro Gly Ala  
 20 25 30  
 Lys Leu Thr Pro Leu Val Pro Lys Asp Ser Val Val Ala Val Met Ala  
 35 40 45  
 Glu Gly Lys Gln His Ala Leu Ala Ile Gly Leu Met Ser Met Ser Ser  
 50 55 60  
 Glu Glu Ile Gln Ser Val Asn Lys Gly Asn Gly Ile Glu Asn Leu His  
 65 70 75 80  
 Tyr Leu Asn Asp Gly Leu Trp His Leu  
 85

<210> 110  
 <211> 88  
 <212> PRT  
 <213> Homo sapiens

<400> 110  
 Phe Ile Leu Pro His Gln Gln Val Asp Lys Gly Ala Ile Lys Phe Val  
 1 5 10 15

63

Leu Ser Gly Ala Asn Ile Met Cys Pro Gly Leu Thr Ser Pro Gly Ala  
                   20                  25                  30

Lys Leu Tyr Pro Ala Ala Val Asp Thr Ile Val Ala Ile Met Ala Glu  
           35                  40                  45

Gly Lys Gln His Ala Leu Cys Val Gly Val Met Lys Met Ser Ala Glu  
       50                  55                  60

Asp Ile Glu Lys Val Asn Lys Gly Ile Gly Ile Glu Asn Ile His Tyr  
   65                  70                  75                  80

Leu Asn Asp Gly Leu Trp His Met  
                   85

<210> 111

<211> 321

<212> PRT

<213> Homo sapiens

<400> 111

Ile Gly Thr His Ser Gly Lys Phe His Cys Asp Glu Ala Phe Ala Cys  
   1                  5                  10                  15

Phe Met Leu Lys Gln Leu Pro Gln Phe Lys Asp His Ser Ile Leu Arg  
                   20                  25                  30

Thr Arg Asp Ala Ala Gln Leu Glu Lys Cys Asp Ile Ile Val Asp Val  
           35                  40                  45

Gly Gly Ile Phe Asp His Ser Lys Gln Arg Tyr Asp His His Gln Arg  
       50                  55                  60

Gly Phe Thr Asp Thr Met Arg Thr Leu Glu Lys Leu Asn Phe Asp Thr  
   65                  70                  75                  80

Lys Leu Ser Ser Ala Gly Leu Val Tyr Ala His Tyr Gly Arg Glu Val  
                   85                  90                  95

Ile Asn Gln Ile Leu Gly Gly Asn Val Ser Ser Ser Met Ile Asp Leu  
           100                  105                  110

Phe Tyr His Arg Leu Tyr Glu Gln Phe Val Glu Ser Ile Asp Ala Ile  
           115                  120                  125

Asp Asn Gly Ile Ser Gln Tyr Asp Gly Val Pro Arg Tyr His Ser Ser  
       130                  135                  140

Gly Asn Leu Ser Ser Arg Thr Gly Gln Phe Asn Ser His Trp Asn Glu

64

145                      150                      155                      160  
 Pro Glu Asn Asp Ala Asp Glu Arg Phe Gln Gln Ala Met Gln Phe Ile  
                                  165                      170                      175  
 Gly Glu Glu Phe Ser Arg Ser Val Lys Tyr Leu Ala Asn Val Trp Trp  
                                  180                      185                      190  
 Pro Ala Arg Glu Ile Ile Glu Ala Ala Val Asp Lys Arg Phe Glu Ile  
                                  195                      200                      205  
 Asp Ala Ser Gly Arg Ile Ile Leu Ile Glu Asn Gly Gly Cys Pro Trp  
                                  210                      215                      220  
 Lys Glu His Phe Phe Asp Ile Glu Val Glu Lys Asn Ile Ala Asp Asp  
 225                                   230                      235                      240  
 Asn Ile Thr Tyr Ile Leu Phe Ser Asp Ser Thr Asn Ala Ser Trp Arg  
                                  245                      250                      255  
 Val Gln Ala Ile Pro Val Asp Lys Met Ser Ser Phe Glu Asn Arg Met  
                                  260                      265                      270  
 Pro Leu Pro Ala Ala Trp Arg Gly Leu Arg Asp Asp Asp Leu Ser Lys  
                                  275                      280                      285  
 Glu Ser Gly Ile Pro Gly Gly Val Phe Val His Ile Ser Gly Phe Ile  
                                  290                      295                      300  
 Gly Gly Asn Leu Thr Arg Glu Gly Ala Ile Ala Met Ala Arg Lys Ala  
 305                                   310                      315                      320  
 Leu

&lt;210&gt; 112

&lt;211&gt; 88

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 112

Phe Ile Leu Pro His Gln Gln Val Asp Lys Gly Ala Ile Lys Phe Val  
   1                      5                      10                      15  
 Leu Ser Gly Ala Asn Ile Met Cys Pro Gly Leu Thr Ser Pro Gly Ala  
                                  20                      25                      30  
 Lys Leu Tyr Pro Ala Ala Val Asp Thr Ile Val Ala Ile Met Ala Glu  
                                  35                      40                      45

65

Gly Lys Gln His Ala Leu Cys Val Gly Val Met Lys Met Ser Ala Glu  
 50 55 60

Asp Ile Glu Lys Val Asn Lys Gly Ile Gly Ile Glu Asn Ile His Tyr  
 65 70 75 80

Leu Asn Asp Gly Leu Trp His Met  
 85

&lt;210&gt; 113

&lt;211&gt; 396

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 113

Arg Ala Ile Leu Ser Thr Tyr Arg Lys Arg Thr Pro Val Met Glu Gly  
 1 5 10 15

Tyr Val Glu Val Lys Glu Gly Lys Thr Trp Lys Gln Ile Cys Asp Lys  
 20 25 30

His Trp Thr Ala Lys Asn Ser Arg Val Val Cys Gly Met Phe Gly Phe  
 35 40 45

Pro Gly Glu Arg Thr Tyr Asn Thr Lys Val Tyr Lys Met Phe Ala Ser  
 50 55 60

Arg Arg Lys Gln Arg Tyr Trp Pro Phe Ser Met Asp Cys Thr Gly Thr  
 65 70 75 80

Glu Ala His Ile Ser Ser Cys Lys Leu Gly Pro Gln Val Ser Leu Asp  
 85 90 95

Pro Met Lys Asn Val Thr Cys Glu Asn Gly Leu Pro Ala Val Val Ser  
 100 105 110

Cys Val Pro Gly Gln Val Phe Ser Pro Asp Gly Pro Ser Arg Phe Arg  
 115 120 125

Lys Ala Tyr Lys Pro Glu Gln Pro Leu Val Arg Leu Arg Gly Gly Ala  
 130 135 140

Tyr Ile Gly Glu Gly Arg Val Glu Val Leu Lys Asn Gly Glu Trp Gly  
 145 150 155 160

Thr Val Cys Asp Asp Lys Trp Asp Leu Val Ser Ala Ser Val Val Cys  
 165 170 175

Arg Glu Leu Gly Phe Gly Ser Ala Lys Glu Ala Val Thr Gly Ser Arg  
 180 185 190

Leu Gly Gln Gly Ile Gly Pro Ile His Leu Asn Glu Ile Gln Cys Thr  
 195 200 205

Gly Asn Glu Lys Ser Ile Ile Asp Cys Lys Phe Asn Ala Glu Ser Gln  
 210 215 220

Gly Cys Asn His Glu Glu Asp Ala Gly Val Arg Cys Asn Thr Pro Ala  
 225 230 235 240

Met Gly Leu Gln Lys Lys Leu Arg Leu Asn Gly Gly Arg Asn Pro Tyr  
 245 250 255

Glu Gly Arg Val Glu Val Leu Val Glu Arg Asn Gly Ser Leu Val Trp  
 260 265 270

Gly Met Val Cys Gly Gln Asn Trp Gly Ile Val Glu Ala Met Val Val  
 275 280 285

Cys Arg Gln Leu Gly Leu Gly Phe Ala Ser Asn Ala Phe Gln Glu Thr  
 290 295 300

Trp Tyr Trp His Gly Asp Val Asn Ser Asn Lys Val Val Met Ser Gly  
 305 310 315 320

Val Lys Cys Ser Gly Thr Glu Leu Ser Leu Ala His Cys Arg His Asp  
 325 330 335

Gly Glu Asp Val Ala Cys Pro Gln Gly Gly Val Gln Tyr Gly Ala Gly  
 340 345 350

Val Ala Cys Ser Glu Thr Ala Pro Asp Leu Val Leu Asn Ala Glu Met  
 355 360 365

Val Gln Gln Thr Thr Tyr Leu Glu Asp Arg Pro Met Phe Met Leu Gln  
 370 375 380

Cys Ala Met Glu Glu Asn Cys Leu Ser Ala Ser Ala  
 385 390 395

<210> 114

<211> 408

<212> PRT

<213> Homo sapiens

<400> 114

Lys Pro Ile Leu Ala Ser Ala Lys Gln His Ser Pro Val Thr Glu Gly  
 1 5 10 15

Ala Val Glu Val Lys Tyr Glu Gly His Trp Arg Gln Val Cys Asp Gln

67

20					25					30						
Gly	Trp	Thr	Met	Asn	Asn	Ser	Arg	Val	Val	Cys	Gly	Met	Leu	Gly	Phe	
35					40					45						
Pro	Ser	Glu	Val	Pro	Val	Asp	Ser	His	Tyr	Tyr	Arg	Lys	Val	Trp	Asp	
50					55					60						
Leu	Lys	Met	Arg	Asp	Pro	Lys	Ser	Arg	Leu	Lys	Ser	Leu	Thr	Asn	Lys	
65					70					75					80	
Asn	Ser	Phe	Trp	Ile	His	Gln	Val	Thr	Cys	Leu	Gly	Thr	Glu	Pro	His	
85					90					95						
Met	Ala	Asn	Cys	Gln	Val	Gln	Val	Ala	Pro	Ala	Arg	Gly	Lys	Leu	Arg	
100					105					110						
Pro	Ala	Cys	Pro	Gly	Gly	Met	His	Ala	Val	Val	Ser	Cys	Val	Ala	Gly	
115					120					125						
Pro	His	Phe	Arg	Pro	Pro	Lys	Thr	Lys	Pro	Gln	Arg	Lys	Gly	Ser	Trp	
130					135					140						
Ala	Glu	Glu	Pro	Arg	Val	Arg	Leu	Arg	Ser	Gly	Ala	Gln	Val	Gly	Glu	
145					150					155					160	
Gly	Arg	Val	Glu	Val	Leu	Met	Asn	Arg	Gln	Trp	Gly	Thr	Val	Cys	Asp	
165					170					175						
His	Arg	Trp	Asn	Leu	Ile	Ser	Ala	Ser	Val	Val	Cys	Arg	Gln	Leu	Gly	
180					185					190						
Phe	Gly	Ser	Ala	Arg	Glu	Ala	Leu	Phe	Gly	Ala	Arg	Leu	Gly	Gln	Gly	
195					200					205						
Leu	Gly	Pro	Ile	His	Leu	Ser	Glu	Val	Arg	Cys	Arg	Gly	Tyr	Glu	Arg	
210					215					220						
Thr	Leu	Ser	Asp	Cys	Pro	Ala	Leu	Glu	Gly	Ser	Gln	Asn	Gly	Cys	Gln	
225					230					235					240	
His	Glu	Asn	Asp	Ala	Ala	Val	Arg	Cys	Asn	Val	Pro	Asn	Met	Gly	Phe	
245					250					255						
Gln	Asn	Gln	Val	Arg	Leu	Ala	Gly	Gly	Arg	Ile	Pro	Glu	Glu	Gly	Leu	
260					265					270						
Leu	Glu	Val	Gln	Val	Glu	Val	Asn	Gly	Val	Pro	Arg	Trp	Gly	Ser	Val	
275					280					285						
Cys	Ser	Glu	Asn	Trp	Gly	Leu	Thr	Glu	Ala	Met	Val	Ala	Cys	Arg	Gln	

.68

290                      295                      300  
 Leu Gly Leu Gly Phe Ala Ile His Ala Tyr Lys Glu Thr Trp Phe Trp  
 305                      310                      315                      320  
 Ser Gly Thr Pro Arg Ala Gln Glu Val Val Met Ser Gly Val Arg Cys  
                     325                      330                      335  
 Ser Gly Thr Glu Leu Ala Leu Gln Gln Cys Gln Arg His Gly Pro Val  
                     340                      345                      350  
 His Cys Ser His Gly Gly Gly Arg Phe Leu Ala Gly Val Ser Cys Met  
                     355                      360                      365  
 Asp Ser Ala Pro Asp Leu Val Met Asn Ala Gln Leu Val Gln Glu Thr  
                     370                      375                      380  
 Ala Tyr Leu Glu Asp Arg Pro Leu Ser Gln Leu Tyr Cys Ala His Glu  
 385                      390                      395                      400  
 Glu Asn Cys Leu Ser Lys Ser Ala  
                     405

<210> 115  
 <211> 30  
 <212> PRT  
 <213> Homo sapiens

<400> 115  
 Arg Leu Glu Cys Ser Gly Thr Ile Ser Ala His Cys Asn Leu Cys Leu  
   1                      5                      10                      15  
 Pro Gly Ser Ser Asn Ser Pro Ala Ser Ala Ser Arg Val Ala  
                     20                      25                      30

<210> 116  
 <211> 30  
 <212> PRT  
 <213> Homo sapiens

<400> 116  
 Arg Leu Glu Cys Ser Gly Thr Ile Ser Ala His Cys Lys Leu Cys Leu  
   1                      5                      10                      15  
 Pro Gly Ser Gly His Ser Pro Ala Ser Ala Ser Arg Val Ala  
                     20                      25                      30

<210> 117

69

<211> 18  
<212> PRT  
<213> Homo sapiens

<400> 117  
Phe Val Phe Leu Ala Glu Met Gly Phe His His Val Gly Arg Asp Gly  
1 5 10 15

Leu Asp

<210> 118  
<211> 18  
<212> PRT  
<213> Homo sapiens

<400> 118  
Phe Val Phe Leu Val Glu Thr Gly Phe His Arg Val Ser Gln Asp Gly  
1 5 10 15

Leu Asn

<210> 119  
<211> 245  
<212> PRT  
<213> Homo sapiens

<400> 119  
Met Ala Val Arg Ala Ser Phe Glu Asn Asn Cys Glu Ile Gly Cys Phe  
1 5 10 15

Ala Lys Leu Thr Asn Thr Tyr Cys Leu Val Ala Ile Gly Gly Ser Glu  
20 25 30

Asn Phe Tyr Ser Val Phe Glu Gly Glu Leu Ser Asp Thr Ile Pro Val  
35 40 45

Val His Ala Ser Ile Ala Gly Cys Arg Ile Ile Gly Arg Met Cys Val  
50 55 60

Gly Asn Arg His Gly Leu Leu Val Pro Asn Asn Thr Thr Asp Gln Glu  
65 70 75 80

Leu Gln His Ile Arg Asn Ser Leu Pro Asp Thr Val Gln Ile Arg Arg  
85 90 95

Val Glu Glu Arg Leu Ser Ala Leu Gly Asn Val Thr Thr Cys Asn Asp  
100 105 110



Tyr Val Ala Leu Val His Pro Asp Leu Asp Arg Glu Thr Glu Glu Ile  
 115 120 125

Leu Ala Asp Val Leu Lys Val Glu Val Phe Arg Gln Thr Val Ala Asp  
 130 135 140

Gln Val Leu Val Gly Ser Tyr Cys Val Phe Ser Asn Gln Gly Gly Leu  
 145 150 155 160

Val His Pro Lys Thr Ser Ile Glu Asp Gln Asp Glu Leu Ser Ser Leu  
 165 170 175

Leu Gln Val Pro Leu Val Ala Gly Thr Val Asn Arg Gly Ser Glu Val  
 180 185 190

Ile Ala Ala Gly Met Val Val Asn Asp Trp Cys Ala Phe Cys Gly Leu  
 195 200 205

Asp Thr Thr Ser Thr Glu Leu Ser Val Val Glu Ser Val Phe Lys Leu  
 210 215 220

Asn Glu Ala Gln Pro Ser Thr Ile Ala Thr Ser Met Arg Asp Ser Leu  
 225 230 235 240

Ile Asp Ser Leu Thr  
 245

<210> 120

<211> 245

<212> PRT

<213> Homo sapiens

<400> 120

Met Ala Val Arg Ala Ser Phe Glu Asn Asn Cys Glu Ile Gly Cys Phe  
 1 5 10 15

Ala Lys Leu Thr Asn Thr Tyr Cys Leu Val Ala Ile Gly Gly Ser Glu  
 20 25 30

Asn Phe Tyr Ser Val Phe Glu Gly Glu Leu Ser Asp Thr Ile Pro Val  
 35 40 45

Val His Ala Ser Ile Ala Gly Cys Arg Ile Ile Gly Arg Met Cys Val  
 50 55 60

Gly Asn Arg His Gly Leu Leu Val Pro Asn Asn Thr Thr Asp Gln Glu  
 65 70 75 80

Leu Gln His Ile Arg Asn Ser Leu Pro Asp Thr Val Gln Ile Arg Arg

71

[illegible]

```
<210> 121
<211> 37
<212> PRT
<213> Homo sapiens
```

```

<400> 121
Ser Ala Pro Leu Thr Gln Met Gly Gly Arg Arg Val Arg Trp Glu Val
 1             5             10             15
Tyr Ile Ser Arg Ala Arg Leu Val Asn Arg Gln Ile Ala Trp Arg Arg
      20             25             30
His Pro Arg Cys Phe
      35

```

<210> 122  
<211> 37

72

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (22)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 122

Ser Ala Pro Leu Thr Gln Met Gly Gly Arg Arg Val Arg Trp Lys Val

1

5

10

15

Tyr Ile Ser Arg Ala Xaa Leu Val Asn Arg Gln Ile Ala Trp Arg Arg

20

25

30

His Pro Arg Cys Phe

35

&lt;210&gt; 123

&lt;211&gt; 329

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 123

Met Val Gly Tyr His Pro Glu Ala Ile Asn Glu Pro Leu Thr Ser Ala

1

5

10

15

Glu Tyr Ser Glu Ala Gly Leu Ala Ser Gly Ile Val Thr Arg Met Ile

20

25

30

Ile Gln Pro Leu Asp Val Leu Lys Ile Arg Phe Gln Leu Gln Glu Glu

35

40

45

Pro Ile Arg Gly Lys Lys Ser Gly Lys Tyr Lys Gly Val Met Gln Ser

50

55

60

Ile Phe Leu Ile Thr Arg Glu Glu Gly Ala His Ala Phe Trp Lys Gly

65

70

75

80

His Ile Pro Ala Gln Gly Leu Ser Ala Thr Tyr Gly Leu Val Gln Phe

85

90

95

Ser Ser Phe Glu Trp Leu Ser Gln Gln Ala Ala Lys Val Ile Pro Ala

100

105

110

Asp Asn Gln Ser Val Arg Ser Thr Ser Asp Phe Ala Cys Gly Ala Leu

115

120

125

Ser Gly Cys Leu Ala Met Thr Ala Ala Met Pro Leu Asp Val Ile Arg

130

135

140

Thr Arg Leu Val Ala Gln Lys Ala Gly His Ala Val Tyr Thr Gly Thr  
 145 150 155 160  
 Met His Ala Val Lys His Ile Trp Glu Lys Glu Gly Ile Ala Gly Tyr  
 165 170 175  
 Phe Arg Gly Trp Val Pro Ser Val Val Gln Ile Ala Pro Phe Thr Gly  
 180 185 190  
 Met Gln Phe Ala Leu Tyr Asn Cys Phe Met Asp Leu Trp Pro Phe Asn  
 195 200 205  
 Gly Tyr Glu Ser Ala Gly Ala Leu Phe Ser Gly Ala Met Ala Gly Thr  
 210 215 220  
 Val Ala Lys Thr Val Leu Tyr Pro Leu Asp Met Val Arg His Arg Leu  
 225 230 235 240  
 Gln Met Asn Gly Phe Glu Arg Ala Gly Phe Gly Lys Thr Ser Asn Tyr  
 245 250 255  
 Ser Gln Gly Leu Phe Lys Thr Ile Gly Met Val Val Lys Asn Glu Ser  
 260 265 270  
 Trp Tyr Gly Leu Phe Lys Gly Leu Trp Pro Ser Gln Ile Lys Ala Ala  
 275 280 285  
 Ala Asn Ser Gly Trp Arg Ile Val Ser Ile His Ala Ser Ala Phe Thr  
 290 295 300  
 Val Ser Lys Leu Val Phe Gly Thr Ala Ala Asp Arg Thr Ser Asn Ser  
 305 310 315 320  
 Arg Leu Leu Ile Gly Gly Ile Leu Leu  
 325

&lt;210&gt; 124

&lt;211&gt; 335

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (51)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (321)

74

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 124

Met	Val	Gly	Tyr	Asp	Pro	Lys	Pro	Asp	Gly	Arg	Asn	Asn	Thr	Lys	Phe
1				5					10					15	

Gln	Val	Ala	Val	Ala	Gly	Ser	Val	Ser	Gly	Leu	Val	Thr	Arg	Ala	Leu
			20					25					30		

Ile	Ser	Pro	Phe	Asp	Val	Ile	Lys	Ile	Arg	Phe	Gln	Leu	Gln	His	Glu
		35					40					45			

Arg	Leu	Xaa	Arg	Ser	Asp	Pro	Ser	Ala	Lys	Tyr	His	Gly	Ile	Leu	Gln
	50					55					60				

Ala	Ser	Arg	Gln	Ile	Leu	Gln	Glu	Glu	Gly	Pro	Thr	Ala	Phe	Trp	Lys
65					70					75					80

Gly	His	Val	Pro	Ala	Gln	Ile	Leu	Ser	Ile	Gly	Tyr	Gly	Ala	Val	Gln
				85					90					95	

Phe	Leu	Ser	Phe	Glu	Met	Leu	Thr	Glu	Leu	Val	His	Arg	Gly	Ser	Val
			100					105					110		

Tyr	Asp	Ala	Arg	Glu	Phe	Ser	Val	His	Phe	Val	Cys	Gly	Gly	Leu	Ala
		115					120					125			

Ala	Cys	Met	Ala	Thr	Leu	Thr	Val	His	Pro	Val	Asp	Val	Leu	Arg	Thr
	130						135					140			

Arg	Phe	Ala	Ala	Gln	Gly	Glu	Pro	Lys	Val	Tyr	Asn	Thr	Leu	Arg	His
145					150					155				160	

Ala	Val	Gly	Thr	Met	Tyr	Arg	Ser	Glu	Gly	Pro	Gln	Val	Phe	Tyr	Lys
				165					170					175	

Gly	Leu	Ala	Pro	Thr	Leu	Ile	Ala	Ile	Phe	Pro	Tyr	Ala	Gly	Leu	Gln
			180					185					190		

Phe	Ser	Cys	Tyr	Ser	Ser	Leu	Lys	His	Leu	Tyr	Lys	Trp	Ala	Ile	Pro
		195					200					205			

Ala	Glu	Gly	Lys	Lys	Asn	Glu	Asn	Leu	Gln	Asn	Leu	Leu	Cys	Gly	Ser
	210					215					220				

Gly	Ala	Gly	Val	Ile	Ser	Lys	Thr	Leu	Thr	Tyr	Pro	Leu	Asp	Leu	Phe
225					230					235				240	

Lys	Lys	Arg	Leu	Gln	Val	Gly	Gly	Phe	Glu	His	Ala	Arg	Ala	Ala	Phe
				245					250					255	

75

Gly Gln Val Arg Arg Tyr Lys Gly Leu Met Asp Cys Ala Lys Gln Val  
 260 265 270

Leu Gln Lys Glu Gly Ala Leu Gly Phe Phe Lys Gly Leu Ser Pro Ser  
 275 280 285

Leu Leu Lys Ala Ala Leu Ser Thr Gly Phe Met Phe Phe Ser Tyr Glu  
 290 295 300

Phe Phe Cys Asn Val Phe His Cys Met Asn Arg Thr Ala Ser Gln Arg  
 305 310 315 320

Xaa Ala Gln Glu Gly Pro Gln Val Phe Pro Gly Gly Ser Leu Leu  
 325 330 335

&lt;210&gt; 125

&lt;211&gt; 71

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 125

Ser Phe Leu Phe Phe Phe Phe Glu Thr Gln Ser His Ser Val Thr Arg  
 1 5 10 15

Leu Glu Cys Ser Gly Thr Ile Ser Ala His Cys Asn Leu Cys Leu Pro  
 20 25 30

Gly Ser Ser Asn Ser Pro Ala Ser Ala Ser Arg Val Ala Gly Thr Ala  
 35 40 45

Gly Thr Cys Arg Arg Ala Gln Leu Ile Phe Val Phe Leu Ala Glu Met  
 50 55 60

Gly Phe His His Val Gly Arg  
 65 70

&lt;210&gt; 126

&lt;211&gt; 71

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (52)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (61)

76

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 126

Asn Phe Phe Phe Pro Leu Leu Arg Gln Ser Leu Ala Leu Leu Pro Arg  
1 5 10 15

Leu Glu Cys Ser Gly Met Ile Gln Ala His Arg Asn Leu Arg Leu Pro  
20 25 30

Gly Ser Ser Asn Ser His Ala Ser Ala Ser Arg Val Ala Gly Ile Thr  
35 40 45

Gly Ala Cys Xaa His Gly Trp Leu Leu Phe Val Phe Xaa Val Glu Thr  
50 55 60

Gly Phe His His Val Gly Gln  
65 70

<210> 127

<211> 49

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (31)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 127

Ile Gly Ala Trp Ser Val Trp Ala Met Gln Ser Arg Gly Phe Ser Ser  
1 5 10 15

Asp Thr Pro Glu Gly Val Arg Ser Gly Ala Gly Ala Val Arg Xaa Ala  
20 25 30

Gly Gly Ala Phe Gly Lys Lys Glu Gln Ala Asp Glu Glu Arg Tyr Phe  
35 40 45

Arg

<210> 128

<211> 49

<212> PRT

<213> Homo sapiens

<400> 128

Leu Gly Val Trp Gly Val Arg Thr Met Gln Ala Arg Gly Phe Gly Ser  
1 5 10 15

77

Asp Gln Ser Glu Asn Val Asp Arg Gly Ala Gly Ser Ile Arg Glu Ala  
20 25 30

Gly Gly Ala Phe Gly Lys Arg Glu Gln Ala Glu Glu Glu Arg Tyr Phe  
35 40 45

Arg

<210> 129

<211> 47

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (18)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 129

Arg Ala Arg Ala Arg Glu Gln Leu Ala Ala Leu Lys Lys His His Glu  
1 5 10 15

Asn Xaa Ile Ser His His Val Lys Glu Ile Glu Arg Leu Gln Lys Glu  
20 25 30

Ile Glu Arg His Lys Gln Ser Ile Lys Lys Leu Lys Asn Asp Asp  
35 40 45

<210> 130

<211> 47

<212> PRT

<213> Homo sapiens

<400> 130

Arg Ala Gln Ser Arg Glu Gln Leu Ala Ala Leu Lys Lys His His Glu  
1 5 10 15

Glu Glu Ile Val His His Lys Lys Glu Ile Glu Arg Leu Gln Lys Glu  
20 25 30

Ile Glu Arg His Lys Gln Lys Ile Lys Met Leu Lys His Asp Asp  
35 40 45

<210> 131

<211> 234

<212> PRT



&lt;213&gt; Homo sapiens

&lt;400&gt; 131

Thr Leu Leu Arg Lys Glu Pro Gly Asn Lys Met Lys Gln Ala Lys Ser  
 1 5 10 15

Val Gly Asp Leu Ala Pro Pro Glu Trp Asp Trp Arg Ser Lys Gly Ala  
 20 25 30

Val Thr Lys Val Lys Asp Gln Gly Met Cys Gly Ser Cys Trp Ala Phe  
 35 40 45

Ser Val Thr Gly Asn Val Glu Gly Gln Trp Phe Leu Asn Gln Gly Thr  
 50 55 60

Leu Leu Ser Leu Ser Glu Gln Glu Leu Leu Asp Cys Asp Lys Met Asp  
 65 70 75 80

Lys Ala Cys Met Gly Gly Leu Pro Ser Asn Ala Tyr Ser Ala Ile Lys  
 85 90 95

Asn Leu Gly Gly Leu Glu Thr Glu Asp Asp Tyr Ser Tyr Gln Gly His  
 100 105 110

Met Gln Ser Cys Asn Phe Ser Ala Glu Lys Ala Lys Val Tyr Ile Asn  
 115 120 125

Asp Ser Val Glu Leu Ser Gln Asn Glu Gln Lys Leu Ala Ala Trp Leu  
 130 135 140

Ala Lys Arg Gly Pro Ile Ser Val Ala Ile Asn Ala Phe Gly Met Gln  
 145 150 155 160

Phe Tyr Arg His Gly Ile Ser Arg Pro Leu Arg Pro Leu Cys Ser Pro  
 165 170 175

Trp Leu Ile Asp His Ala Val Leu Leu Val Gly Tyr Gly Asn Arg Ser  
 180 185 190

Asp Val Pro Phe Trp Ala Ile Lys Asn Ser Trp Gly Thr Asp Trp Gly  
 195 200 205

Glu Lys Gly Tyr Tyr Tyr Leu His Arg Gly Ser Gly Ala Cys Gly Val  
 210 215 220

Asn Thr Met Ala Ser Ser Ala Val Val Asp  
 225 230

&lt;210&gt; 132

&lt;211&gt; 234

79

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 132

Thr Glu Val Arg Lys Glu Pro Gly Asn Lys Met Lys Gln Ala Lys Ser  
 1 5 10 15

Val Gly Asp Leu Ala Pro Pro Glu Trp Asp Trp Arg Ser Lys Gly Ala  
 20 25 30

Val Thr Lys Val Lys Asp Gln Gly Met Cys Gly Ser Cys Trp Ala Phe  
 35 40 45

Ser Val Thr Gly Asn Val Glu Gly Gln Trp Phe Leu Asn Gln Gly Thr  
 50 55 60

Leu Leu Ser Leu Ser Glu Gln Glu Leu Leu Asp Cys Asp Lys Met Asp  
 65 70 75 80

Lys Ala Cys Met Gly Gly Leu Pro Ser Asn Ala Tyr Ser Ala Ile Lys  
 85 90 95

Asn Leu Gly Gly Leu Glu Thr Glu Asp Asp Tyr Ser Tyr Gln Gly His  
 100 105 110

Met Gln Ser Cys Asn Phe Ser Ala Glu Lys Ala Lys Val Tyr Ile Asn  
 115 120 125

Asp Ser Val Glu Leu Ser Gln Asn Glu Gln Lys Leu Ala Ala Trp Leu  
 130 135 140

Ala Lys Arg Gly Pro Ile Ser Val Ala Ile Asn Ala Phe Gly Met Gln  
 145 150 155 160

Phe Tyr Arg His Gly Ile Ser Arg Pro Leu Arg Pro Leu Cys Ser Pro  
 165 170 175

Trp Leu Ile Asp His Ala Val Leu Leu Val Gly Tyr Gly Asn Arg Ser  
 180 185 190

Asp Val Pro Phe Trp Ala Ile Lys Asn Ser Trp Gly Thr Asp Trp Gly  
 195 200 205

Glu Lys Gly Tyr Tyr Tyr Leu His Arg Gly Ser Gly Ala Cys Gly Val  
 210 215 220

Asn Thr Met Ala Ser Ser Ala Val Val Asp  
 225 230

&lt;210&gt; 133

80

&lt;211&gt; 83

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 133

Ala Lys Pro Ser Thr Met Val Gln Lys Met Gln Asn Ile Lys Lys Leu  
1 5 10 15

Arg Gly His Arg Asn Ala Val Tyr Cys Ala Ile Phe Asp Arg Ser Gly  
20 25 30

Arg Tyr Val Ile Thr Gly Ser Asp Asp Arg Leu Val Lys Ile Trp Ser  
35 40 45

Met Glu Thr Ala Leu Cys Leu Ala Ser Cys Arg Gly His Glu Gly Asp  
50 55 60

Ile Thr Asp Leu Ala Val Ser Ser Asn Asn Ala Leu Val Ala Ser Ala  
65 70 75 80

Ser Asn Asp

&lt;210&gt; 134

&lt;211&gt; 83

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 134

Ala Phe Pro Gly Thr Met Tyr Gln His Ile Lys Met His Arg Arg Ile  
1 5 10 15

Leu Gly His Leu Ser Ala Val Tyr Cys Val Ala Phe Asp Arg Thr Gly  
20 25 30

His Arg Ile Phe Thr Gly Ser Asp Asp Cys Leu Val Lys Ile Trp Ser  
35 40 45

Thr His Asn Gly Arg Leu Leu Ser Thr Leu Arg Gly His Ser Ala Glu  
50 55 60

Ile Ser Asp Met Ala Val Asn Tyr Glu Asn Thr Met Ile Ala Ala Gly  
65 70 75 80

Ser Cys Asp

&lt;210&gt; 135

&lt;211&gt; 26

81

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 135

Val	Ile	Arg	Val	Trp	Arg	Leu	Pro	Asp	Gly	Met	Pro	Ile	Ser	Val	Leu
1				5					10					15	

Arg	Gly	His	Thr	Gly	Ala	Val	Thr	Ala	Ile
			20					25	

&lt;210&gt; 136

&lt;211&gt; 26

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 136

Ile	Ile	Arg	Val	Trp	Cys	Leu	Arg	Thr	Cys	Ala	Pro	Val	Ala	Val	Leu
1				5					10					15	

Gln	Gly	His	Thr	Gly	Ser	Ile	Thr	Ser	Leu
			20					25	

&lt;210&gt; 137

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 137

Leu	Ile	His	Glu	Arg	Leu	Glu	Asn	Gln	Tyr	Tyr	Arg	Ser	Ile	Glu	Ser
1				5					10					15	

Phe	Lys	His	Asp
			20

&lt;210&gt; 138

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 138

Val	Leu	Ser	Lys	Arg	Ser	Asp	Asn	His	Ser	Tyr	Lys	Ser	Tyr	Lys	Ser
1				5					10					15	

Trp	Lys	Ala	Asp
			20

&lt;210&gt; 139

82

&lt;211&gt; 224

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 139

Glu Glu Leu Lys Ser Ile Leu Gly Glu Arg Glu Tyr Ile Ile Asp Ile  
 1 5 10 15

Asn Asp Ile Gln Phe Ile Gln Lys Val Gly Glu Gly Ala Phe Ser Glu  
 20 25 30

Val Trp Glu Gly Trp Trp Lys Gly Ile His Val Ala Ile Lys Lys Leu  
 35 40 45

Lys Ile Ile Gly Asp Glu Glu Gln Phe Lys Glu Arg Phe Ile Arg Glu  
 50 55 60

Val Gln Asn Leu Lys Lys Gly Asn His Gln Asn Ile Val Met Phe Ile  
 65 70 75 80

Gly Ala Cys Tyr Lys Pro Ala Cys Ile Ile Thr Glu Tyr Met Ala Gly  
 85 90 95

Gly Ser Leu Tyr Asn Ile Leu His Asn Pro Asn Ser Ser Thr Pro Lys  
 100 105 110

Val Lys Tyr Ser Phe Pro Leu Val Leu Lys Met Ala Thr Asp Met Ala  
 115 120 125

Leu Gly Leu Leu His Leu His Ser Ile Thr Ile Val His Arg Asp Leu  
 130 135 140

Thr Ser Gln Asn Ile Leu Leu Asp Glu Leu Gly Asn Ile Lys Ile Ser  
 145 150 155 160

Asp Phe Gly Leu Ser Ala Glu Lys Ser Arg Glu Gly Ser Met Thr Met  
 165 170 175

Thr Asn Gly Gly Ile Cys Asn Pro Arg Trp Arg Pro Pro Glu Leu Thr  
 180 185 190

Lys Asn Leu Gly His Tyr Ser Glu Lys Val Asp Val Tyr Cys Phe Ser  
 195 200 205

Leu Val Val Trp Glu Ile Leu Thr Gly Glu Ile Pro Phe Ser Asp Leu  
 210 215 220

83

<210> 140  
 <211> 236  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (65)  
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 140  
 Glu Lys Lys Lys Ser Val Leu Cys Ser Thr Pro Thr Ile Asn Ile Pro  
   1                  5                  10                  15  
 Ala Ser Pro Phe Met Gln Lys Leu Gly Phe Gly Thr Gly Val Asn Val  
                   20                  25                  30  
 Tyr Leu Met Lys Arg Ser Pro Arg Gly Leu Ser His Ser Pro Trp Ala  
           35                  40                  45  
 Val Lys Lys Ile Asn Pro Ile Cys Asn Asp His Tyr Arg Ser Val Tyr  
   50                  55                  60  
 Xaa Lys Arg Leu Met Asp Glu Ala Lys Ile Leu Lys Ser Leu His His  
   65                  70                  75                  80  
 Pro Asn Ile Val Gly Tyr Arg Ala Phe Thr Glu Ala Ser Asp Gly Ser  
                   85                  90                  95  
 Leu Cys Leu Ala Met Glu Tyr Gly Gly Glu Lys Ser Leu Asn Asp Leu  
           100                  105                  110  
 Ile Glu Glu Arg Tyr Lys Ala Ser Gln Asp Pro Phe Pro Ala Ala Ile  
   115                  120                  125  
 Ile Leu Lys Val Ala Leu Asn Met Ala Arg Gly Leu Lys Tyr Leu His  
   130                  135                  140  
 Gln Glu Lys Lys Leu Leu His Gly Asp Ile Lys Ser Ser Asn Val Val  
 145                  150                  155                  160  
 Ile Lys Gly Asp Phe Glu Thr Ile Lys Ile Cys Asp Val Gly Val Ser  
           165                  170                  175  
 Leu Pro Leu Asp Glu Asn Met Thr Val Thr Asp Pro Glu Ala Cys Tyr  
           180                  185                  190  
 Ile Gly Thr Glu Pro Trp Lys Pro Lys Glu Ala Val Glu Glu Asn Gly  
   195                  200                  205  
 Val Ile Thr Asp Lys Ala Asp Ile Phe Ala Phe Gly Leu Thr Leu Trp

84

210 215 220

Glu Met Met Thr Leu Ser Ile Pro His Ile Asn Leu  
225 230 235

<210> 141  
<211> 68  
<212> PRT  
<213> Homo sapiens

<400> 141  
Ala Phe Leu Ser Ala Lys Ala Ala Ala Ser Asn Ser Ser Gln Met Gly  
1 5 10 15

Ser Gln Pro Pro Leu Leu Ser Arg Pro Leu Pro Leu Gly Ser Met Pro  
20 25 30

Ala Ala Leu Leu Thr Ser Pro Pro Thr Phe Pro Ala Thr Leu His Ala  
35 40 45

His Gln Ala Leu Pro Val Leu Gln Ala Gln Pro Leu Ser Leu Val Thr  
50 55 60

Lys Ser Ala His  
65

<210> 142  
<211> 236  
<212> PRT  
<213> Homo sapiens

<220>  
<221> SITE  
<222> (65)  
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 142  
Glu Lys Lys Lys Ser Val Leu Cys Ser Thr Pro Thr Ile Asn Ile Pro  
1 5 10 15

Ala Ser Pro Phe Met Gln Lys Leu Gly Phe Gly Thr Gly Val Asn Val  
20 25 30

Tyr Leu Met Lys Arg Ser Pro Arg Gly Leu Ser His Ser Pro Trp Ala  
35 40 45

Val Lys Lys Ile Asn Pro Ile Cys Asn Asp His Tyr Arg Ser Val Tyr  
50 55 60

85

Xaa Lys Arg Leu Met Asp Glu Ala Lys Ile Leu Lys Ser Leu His His  
65 70 75 80

Pro Asn Ile Val Gly Tyr Arg Ala Phe Thr Glu Ala Ser Asp Gly Ser  
85 90 95

Leu Cys Leu Ala Met Glu Tyr Gly Gly Glu Lys Ser Leu Asn Asp Leu  
100 105 110

Ile Glu Glu Arg Tyr Lys Ala Ser Gln Asp Pro Phe Pro Ala Ala Ile  
115 120 125

Ile Leu Lys Val Ala Leu Asn Met Ala Arg Gly Leu Lys Tyr Leu His  
130 135 140

Gln Glu Lys Lys Leu Leu His Gly Asp Ile Lys Ser Ser Asn Val Val  
145 150 155 160

Ile Lys Gly Asp Phe Glu Thr Ile Lys Ile Cys Asp Val Gly Val Ser  
165 170 175

Leu Pro Leu Asp Glu Asn Met Thr Val Thr Asp Pro Glu Ala Cys Tyr  
180 185 190

Ile Gly Thr Glu Pro Trp Lys Pro Lys Glu Ala Val Glu Glu Asn Gly  
195 200 205

Val Ile Thr Asp Lys Ala Asp Ile Phe Ala Phe Gly Leu Thr Leu Trp  
210 215 220

Glu Met Met Thr Leu Ser Ile Pro His Ile Asn Leu  
225 230 235

&lt;210&gt; 143

&lt;211&gt; 46

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 143

Gln Ala Gln Pro Leu Ser Leu Thr Thr Lys Pro Glu Ala Arg Ala Gln  
1 5 10 15

Leu Ala Leu His Ser Ala Ala Phe Leu Ser Ala Lys Ala Ala Ser  
20 25 30

Asn Ser Ser Gln Met Gly Ser Gln Pro Pro Leu Leu Ser Arg  
35 40 45

&lt;210&gt; 144



86

&lt;211&gt; 36

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (33)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 144

Glu Ala Gln Pro Leu Ser Leu Thr Thr Lys Pro Glu Thr Arg Ala Gln  
 1 5 10 15

Leu Ala Leu His Ser Ala Pro Ser Cys Arg Leu Arg Leu Gln Pro Pro  
 20 25 30

Xaa Leu Gly Arg  
 35

&lt;210&gt; 145

&lt;211&gt; 196

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 145

Lys Leu Gln Gln Cys Lys Ala Glu Leu Asn Ser Thr Thr Glu Glu Leu  
 1 5 10 15

His Lys Tyr Gln Lys Met Leu Glu Pro Pro Pro Ser Ala Lys Pro Phe  
 20 25 30

Thr Ile Asp Val Asp Lys Lys Leu Glu Glu Gly Gln Lys Asn Ile Arg  
 35 40 45

Leu Leu Arg Thr Glu Leu Gln Lys Leu Gly Glu Ser Leu Gln Ser Ala  
 50 55 60

Glu Arg Ala Cys Cys His Ser Thr Gly Ala Gly Lys Leu Arg Gln Ala  
 65 70 75 80

Leu Thr Thr Cys Asp Asp Ile Leu Ile Lys Gln Asp Gln Thr Leu Ala  
 85 90 95

Glu Leu Gln Asn Asn Met Val Leu Val Lys Leu Asp Leu Arg Lys Lys  
 100 105 110

Ala Ala Cys Ile Ala Glu Gln Tyr His Thr Val Leu Lys Leu Gln Gly  
 115 120 125

Gln Val Ser Ala Lys Lys Arg Leu Gly Thr Asn Gln Glu Asn Gln Gln

87

130                      135                      140  
 Pro Asn Gln Gln Pro Pro Gly Lys Lys Pro Phe Leu Arg Asn Leu Leu  
 145                      150                      155                      160  
 Pro Arg Thr Pro Thr Cys Gln Ser Ser Thr Asp Cys Ser Pro Tyr Ala  
                     165                      170                      175  
 Arg Ile Leu Arg Ser Arg Arg Ser Pro Leu Leu Lys Ser Gly Pro Phe  
                     180                      185                      190  
 Gly Lys Lys Tyr  
                     195  
  
 <210> 146  
 <211> 196  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 146  
 Lys Leu Gln Gln Cys Lys Ala Glu Leu Asn Ser Thr Thr Glu Glu Leu  
   1                      5                      10                      15  
 His Lys Tyr Gln Lys Met Leu Glu Pro Pro Pro Ser Ala Lys Pro Phe  
                     20                      25                      30  
 Thr Ile Asp Val Asp Lys Lys Leu Glu Glu Gly Gln Lys Asn Ile Arg  
                     35                      40                      45  
 Leu Leu Arg Thr Glu Leu Gln Lys Leu Gly Glu Ser Leu Gln Ser Ala  
                     50                      55                      60  
 Glu Arg Ala Cys Cys His Ser Thr Gly Ala Gly Lys Leu Arg Gln Ala  
                     65                      70                      75                      80  
 Leu Thr Thr Cys Asp Asp Ile Leu Ile Lys Gln Asp Gln Thr Leu Ala  
                     85                      90                      95  
 Glu Leu Gln Asn Asn Met Val Leu Val Lys Leu Asp Leu Arg Lys Lys  
                     100                      105                      110  
 Ala Ala Cys Ile Ala Glu Gln Tyr His Thr Val Leu Lys Leu Gln Gly  
                     115                      120                      125  
 Gln Val Ser Ala Lys Lys Arg Leu Gly Thr Asn Gln Glu Asn Gln Gln  
                     130                      135                      140  
 Pro Asn Gln Gln Pro Pro Gly Lys Lys Pro Phe Leu Arg Asn Leu Leu  
 145                      150                      155                      160

88

Pro Arg Thr Pro Thr Cys Gln Ser Ser Thr Asp Cys Ser Pro Tyr Ala  
                   165                  170                  175

Arg Ile Leu Arg Ser Arg Arg Ser Pro Leu Leu Lys Ser Gly Pro Phe  
                   180                  185                  190

Gly Lys Lys Tyr  
                   195

&lt;210&gt; 147

&lt;211&gt; 162

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 147

Pro Ala Arg Arg Pro Thr Glu Pro Pro Lys Ala Thr Glu Gly Gln Ser  
   1                  5                  10                  15

Lys Pro Arg Ala Gln Thr Glu Ser Lys Ala Lys Val Val Asp Leu Met  
                   20                  25                  30

Ser Ile Thr Glu Gln Lys Arg Glu Glu Arg Lys Val Asn Ser Asn Asn  
                   35                  40                  45

Asn Asn Lys Lys Gln Leu Asn His Ile Lys Asp Glu Lys Ser Asn Pro  
                   50                  55                  60

Thr Pro Met Glu Pro Thr Ser Pro Gly Glu His Gln Gln Asn Ser Lys  
   65                  70                  75                  80

Leu Val Leu Ala Glu Ser Pro Gln Pro Lys Gly Lys Asn Lys Lys Asn  
                   85                  90                  95

Lys Lys Lys Lys Gly Asp Arg Val Asn Asn Ser Ile Asp Asp Val Phe  
                   100                  105                  110

Leu Pro Lys Asp Ile Asp Leu Asp Ser Val Asp Met Asp Glu Thr Glu  
                   115                  120                  125

Arg Glu Val Glu Tyr Phe Lys Arg Phe Cys Leu Asp Ser Ala Arg Gln  
                   130                  135                  140

Thr Arg Gln Arg Leu Ser Ile Asn Trp Ser Asn Phe Ser Leu Lys Lys  
   145                  150                  155                  160

Ala Thr

&lt;210&gt; 148

89

&lt;211&gt; 153

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (22)

&lt;223&gt; Xaa equals stop translation

&lt;400&gt; 148

Pro Gly Arg Trp Pro Gln Ala Ala Arg Gln Gly Pro Arg Ala Ser Gln  
 1 5 10 15

Ser Arg Gln Leu Cys Xaa Gly Leu Glu Glu Gly Lys Pro Gly Glu Ala  
 20 25 30

Gly Gln Asp Gln Val Gly Leu Ala Val Pro Lys Leu Arg Arg Arg Arg  
 35 40 45

Ala Ala Pro Gly Glu Thr Gly Gln Ala Arg Pro Arg His Gly Pro Gln  
 50 55 60

Glu Gln Glu Ser Val Gln Pro Pro Gly Pro Ala Arg Pro Gln Ser Leu  
 65 70 75 80

Pro Gln Gly Lys Gly Arg Ser Arg Arg Ser Arg Asn Lys Gln Glu Lys  
 85 90 95

Pro Ala Ser Ser Leu Asp Asp Val Phe Leu Pro Lys Asp Met Asp Gly  
 100 105 110

Val Glu Met Asp Glu Thr Asp Arg Glu Val Glu Tyr Phe Lys Arg Phe  
 115 120 125

Cys Leu Asp Ser Ala Lys Gln Thr Arg Gln Lys Val Ala Val Asn Trp  
 130 135 140

Thr Asn Phe Ser Leu Lys Lys Thr Thr  
 145 150

&lt;210&gt; 149

&lt;211&gt; 68

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 149

Glu Thr Gln Ser His Ser Val Thr Arg Leu Glu Cys Ser Gly Thr Ile  
 1 5 10 15

Ser Ala His Cys Asn Leu Cys Leu Pro Gly Ser Ser Asn Ser Pro Ala

90

20

25

30

Ser Ala Ser Arg Val Ala Gly Thr Ala Gly Thr Cys Arg Arg Ala Gln  
35 40 45

Leu Ile Phe Val Phe Leu Ala Glu Met Gly Phe His His Val Gly Arg  
50 55 60

Asp Gly Leu Asp  
65

<210> 150  
<211> 68  
<212> PRT  
<213> Homo sapiens

<400> 150  
Glu Met Glu Ser Arg Cys Ile Asn Arg Leu Glu Cys Ser Gly Ala Ile  
1 5 10 15

Ser Thr His Cys Asn Leu His Leu Leu Gly Leu Ser Asn Ser Pro Ala  
20 25 30

Ser Ala Ser Arg Val Ala Gly Thr Thr Gly Ala Arg His His Ala Gln  
35 40 45

Pro Thr Leu Val Ser Leu Ala Glu Thr Gly Phe His His Val Gly Gln  
50 55 60

Ala Gly Leu Glu  
65

<210> 151  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 151  
Val Ile His Pro Pro Arg Ser Pro Lys Ala Leu Gly Leu Gln Ala  
1 5 10 15

<210> 152  
<211> 15  
<212> PRT  
<213> Homo sapiens

<400> 152  
Val Ile His Gln Pro Arg Pro Pro Lys Val Leu Gly Leu Gln Ala

91

1

5

10

15

&lt;210&gt; 153

&lt;211&gt; 116

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 153

Pro Gly Leu Pro Asp Asn Ile Arg Ser Ser Gly Arg Gly Thr Tyr Trp

1

5

10

15

Val Gly Leu Thr Ala Thr Arg Ser Ala Thr His Pro Ser Leu Leu Asp

20

25

30

Arg Leu Gly Ser Leu Pro Gly Ile Arg Gln Phe Leu Val Asp Ile Val

35

40

45

Pro Gly Pro Tyr Trp Lys Pro Leu Leu Gly Leu Phe Lys Asn Pro His

50

55

60

Ser Ile Ile Ile Glu Leu Asp Ser Val Gly Lys Ile Val Arg Ser Leu

65

70

75

80

His Asp Val Thr Gly Lys His Val Gly Asp Ala Ser Gln Val Thr Glu

85

90

95

His Asn Gly His Leu Tyr Ile Gly Ser Phe Ala Asp His Tyr Ile Ala

100

105

110

Lys Val Lys Leu

115

&lt;210&gt; 154

&lt;211&gt; 112

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 154

Pro Arg Val Arg Asp Asn Ile Arg Pro Ser Ser Ser Gly Gly Tyr Trp

1

5

10

15

Val Gly Met Ser Thr Ile Arg Pro Asn Pro Gly Phe Ser Met Leu Asp

20

25

30

Phe Leu Ser Glu Arg Pro Trp Ile Lys Arg Met Ile Phe Lys Leu Phe

35

40

45

Ser Gln Glu Thr Val Met Lys Phe Val Pro Arg Tyr Ser Leu Val Leu

50

55

60

Glu Leu Ser Asp Ser Gly Ala Phe Arg Arg Ser Leu His Asp Pro Asp  
65 70 75 80

Gly Leu Val Ala Thr Tyr Ile Ser Glu Val His Glu His Asp Gly His  
85 90 95

Leu Tyr Leu Gly Ser Phe Arg Ser Pro Phe Leu Cys Arg Leu Ser Leu  
100 105 110

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/08981

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) :C07K 14/47; C12N 5/10, 5/16, 15/63, 15/64

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 536/23.1, 23.5, 24.3, 24.31; 435/69.1, 71.1, 71.2, 471, 325, 252.3, 254.11, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
WEST, CAS ONLINE, MEDLINE**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — A	WO 94/00578 A1 (COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION) 06 January 1994 (06.01.94), see entire document, especially pages 15-17.	1-3, 7-11, 14-16 ----- 4-6, 12, 21

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

09 JUNE 2000

Date of mailing of the international search report

28 JUL 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PREMA MERTZ

Telephone No. (703) 308-0196



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/08981

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-12, 14-16, 21 (SEQ ID NO:11, 59)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**A. CLASSIFICATION OF SUBJECT MATTER:**

US CL :

530/350; 536/23.1, 23.5, 24.3, 24.31; 435/69.1, 71.1, 71.2, 471, 325, 252.3, 254.11, 320.1

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-12, 14-16, 21, drawn to a nucleic acid of SEQ ID NO:11 encoding a protein of SEQ ID NO:59, a vector, a host cell, a method of making the protein and the protein of SEQ ID NO:59.

Group II, claim 13, drawn to an antibody that binds the protein of SEQ ID NO:59.

Group III, claim 17, drawn to a method of treating a condition comprising administering the protein of SEQ ID NO:59.

Group IV, claim 18, drawn to a method of diagnosing a pathological condition using the polynucleotide encoding a protein of SEQ ID NO:59.

Group V, claim 19, drawn to a method of diagnosing a pathological condition by determining the amount of protein of SEQ ID NO:59.

Group VI, claim 20, drawn to a method of identifying a binding partner of the protein of SEQ ID NO:59.

Group VII, claims 22-23, drawn to a method of identifying an activity in a biological assay.

Group VIII, claim 17, drawn to a method for treating a condition comprising administering the nucleic acid of SEQ ID NO:11.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product, a nucleic acid encoding a protein of SEQ ID NO:59, a vector, a host cell, a method of making the protein of SEQ ID NO:59, and the protein of SEQ ID NO:59. Further pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

the polynucleotides set forth in SEQ ID NO:11-58 encoding the polypeptides set forth in SEQ ID NO:59-106.